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Resumé 
Tyrosin sulfatering er en post-translationel modifikation af peptider og proteiner, som finder sted i 
trans-Golgi netværket og katalyseres af to membran bundne enzymer TPST-1 and TPST-2. Indenfor de 
senere år er tyrosinsulfat fundet i G protein-koblede receptorer (GPCRs). I dette studie blev Pituitary 
Adenylate Cyclase Activating Polypeptide type 1 (PAC1) receptoren undersøgt, idet den indeholder fire 
tyrosiner i den N-terminale ekstracellulære del af receptoren der kunne være mål for sulfatering. De fire 
tyrosiner blev muteret ved site-dirigeret mutagenese og mutationernes effekter på ligand binding og 
signaltransduktion blev bestemt. Resultaterne viste en cirka 3-fold øget bindings affinitet af PAC1 
receptoren for den naturlige ligand PACAP-27, når de fire tyrosiner var muteret til phenylalaniner, 
sammenlignet med vildtype receptoren. Det samme blev observeret ved signaltransduktion, hvor den 
muterede receptor havde cirka 3-fold højere cAMP niveau, i respons på PACAP-27 stimulation, hvilket 
indikerer at disse tyrosiner har en rolle i ligand binding eller i korrekt foldning af receptoren. 
Identifikation af sulfaterede tyrosiner via oprensning af det rekombinante receptor protein efterfulgt af 
massespektrometrisk analyse lykkedes ikke og et bevis for tyrosin sulfatering kunne ikke findes. 
Når peptider og proteiner sekvenseres, er det sjældent at sulfaterede tyrosiner observeres, idet 
sulfatesteren er meget syrelabil, hvilket vil sige at tyrosinsulfat hurtigt hydrolyserer til tyrosin i stærkt 
sure opløsninger (pH < 1). Hydrolysen er ubeskrevet i mildere syreopløsninger, som anvendes i 
forskellige proteinoprensnings- og analyseprocedurer (pH 1 to 4). I dette studie blev sulfateret gastrin-
17 brugt som model peptid til at undersøge syre-labiliteten af tyrosinsulfat i pH området 1 til 3, samt i 
en række forskellige syrekoncentrationer, temperaturer, inkubations tider og i forskellige syrer. 
Resultaterne viste at tyrosinsulfat var relativ stabil ved pH 1 til 3, inkuberet ved stuetemperatur eller 
lavere. Syrehydrolysen var en pseudo første-ordens reaktion, hvor hastighedskonstanterne bestemt ved 
forskellige temperaturinkubationer fulgte Arrhenius ligning. Arrhenius A faktoren blev bestemt for 
hydrolysereaktionen og lå indenfor de værdier der observeres for unimolekylære reaktioner. Derudover 
blev reaktionens aktivering energi (Ea) beregnet, hvilket indikerede at S-O bindingen mellem sulfuryl 
gruppen og phenolen var svækket, sammenlignet med standard S-O bindings energier. Syrehydrolysen 
af sulfateret gastrin-17 blev sammenlignet med hydrolysen af to andre tyrosin sulfaterede peptider, 
drosulfokinin og caerulein, og det blev vist at hydrolyse-hastigheden afhang af den primære aminosyre 
sammensætning af peptidet. 
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Abstract 
Tyrosine sulfation is a post-translational modification of proteins and peptides, which takes place in the 
trans-Golgi network and is catalyzed by two membrane-bound enzymes TPST-1 and TPST-2. In recent 
years several G protein-couples receptors (GPCRs) have been found to contain tyrosine sulfate. In this 
study the Pituitary Adenylate Cyclase Activating Polypeptide type 1 (PAC1) receptor was investigated, 
since the receptor contains four tyrosine sites in the N-terminal extracellular region that might be 
targets for sulfation. The four tyrosines were mutated through site-directed mutagenesis and the effect 
of these receptor mutations on ligand binding and signal transduction were determined. The results 
showed an approximately 3-fold increase in PAC1 receptor binding affinity towards the natural ligand 
PACAP-27, when the four tyrosines were mutated to phenylalanines, compared to the wild-type 
receptor. The same was observed in the signal transduction where the mutant receptor showed an 
approximately 3-fold increase in cAMP levels in response to PACAP-27 stimulation, indicating a role of 
these tyrosines in ligand binding or in correct receptor folding. Identification of sulfated tyrosines by 
purification of the recombinant receptor protein followed by mass spectrometry analysis was 
unsuccessful and evidence for tyrosine sulfation could not be determined. 
Sulfated tyrosines are not identified during Edmann sequencing of peptides and proteins, because the 
sulfate ester is very acid labile and rapidly hydrolyses to tyrosine in strong acidic solutions (pH < 1). 
Little is known about the hydrolysis at mildly acidic solutions, which are used in several protein 
purification and analysis procedures (pH 1 to 4). In the present study sulfated gastrin-17 was used as a 
model tyrosine sulfated peptide, where the acid lability was investigated in the pH range 1 to 3 and at 
different temperatures, incubation times and with different acids. The results indicated that the tyrosine 
sulfate was fairly stable at the pH range 1 to 3 at room temperature and lower, only showing marginal 
hydrolysis. The acid hydrolysis was a pseudo first-order reaction and the rate constants measured at 
different temperatures followed the Arrhenius equation. The Arrhenius A factor of the hydrolysis 
reaction was determined which was within the range observed for unimolecular reactions. In addition 
the activation energy (Ea) of the reaction was calculated and showed a weakened S-O bond between the 
sulfuryl group and the phenol. The acid hydrolysis of sulfated gastrin-17 was compared to the 
hydrolysis of two other tyrosine sulfated peptides, drosulfokinin and caerulein, and it was shown that 
hydrolysis rate depended on the primary amino acid composition of the protein/peptide. 
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MALDI - Matrix-assisted laser desorption ionization 
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PACAP  - Pituitary adenylate cyclase activating polypeptide 
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1 Aim of study 
Tyrosine sulfation is a post-translational modification within peptides and proteins. The reaction takes 
place in the trans-Golgi network by two enzymes that catalyze the transfer of sulfur trioxide to the 
phenolic oxygen on tyrosine. Approximately 70 peptides and proteins have been found to contain 
sulfated tyrosines and the biological importance of tyrosine sulfation is within protein-protein 
interactions. Within recent years a growing number of G protein-coupled receptors (GPCRs) have been 
found to contain tyrosine sulfate, which makes it more likely that this modification is present in other 
GPCRs. When identifying sulfated tyrosines in peptides and proteins it is necessary to avoid high acid 
concentrations (pH < 1), because the tyrosine sulfate ester has been described as very acid labile, 
quickly hydrolyzing to tyrosine. Many protein purification and preparation procedures involve acidic 
solutions at higher pH values, but little is known about the hydrolysis rate at these acid concentrations. 
It might be difficult to conclude whether or not a protein is tyrosine sulfated if the sulfate group is lost 
during the preliminary analysis. 
 
Because this master thesis is a combination of the two subject’s chemistry and molecular biology, the 
aim is to elucidate two problems described below. 
Chemistry 
Aim: Evaluating the acid hydrolysis of tyrosine sulfate in the pH 1 to 3 range, at various physical 
parameters including different temperatures, incubation times, in different acids and in 
addition the effect of primary amino acid sequence on the hydrolysis rate. 
None of these parameters have previously been investigated with tyrosine sulfated peptides, but are 
very relevant in the identification of sulfated tyrosines in peptides and proteins. 
Molecular biology 
Aim: Search for new GPCRs that are targets for tyrosine sulfation, and determine what effect the 
sulfated tyrosines might have on ligand binding and signal transduction.  
The Pituitery Adenylate Cyclase Activating Polypeptide type 1 Receptor (PAC1 receptor) was selected. 
If the PAC1 receptor is sulfated and the sulfated tyrosine(s) are involved in ligand binding it might hold 
therapeutic possibilities, since the PAC1 receptor and its ligands are involved in a variety of deceases 
including cancer. 
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2 Introduction 
2.1 Tyrosine sulfation 
Tyrosine sulfation was first discovered in 1954 in a peptide from fibrinogen1, which had the chemical 
characteristics of an aryl sulfate, i.e. lability to acid and stability to alkali. Occurrence of tyrosine sulfate 
as an amino acid residue (fig. 1) in proteins was considered to be very rare, limited to fibrinogen and a 
few other proteins, until 1982, when Huttner2 reported evidence of every tissue in rats contain a 
number of proteins with tyrosine sulfate. Subsequent studies by Huttner demonstrated further that 
sulfation of tyrosine residues in proteins occurs in a diverse range of organisms3.  
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Figure 1: A: The amino acid tyrosine displayed as a residue in a peptide chain. B: The same tyrosine residue presented with 
the para-sulfate ester. At physiological pH the sulfate group will not be protonated. C: Ball and stick model of the free form 
of tyrosine sulfate. 
 
Until mid-eighties it was believed that tyrosine sulfation occurred only on secretory peptides and 
proteins but in resent years membrane proteins4-7 and antibodies8,9 are also found to contain this 
modification. For any given animal species tyrosine sulfated proteins have been found in all tissues, 
primary cell cultures and cell lines examined2,10,11. When examining the fruit fly (Drosophila melanogaster) it 
was found that on average 1.0% and 0.4% of all tyrosine residues were sulfated in female and male fly 
protein, respectively12. Whether these percentages represents other species remains to be examined, but 
this could imply that we have so far only seen a marginal amount of the tyrosine-sulfated proteins. 
Table 1 shows some of the known tyrosine sulfated peptides and proteins identified so far. 
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Table 1: Examples of sulfated proteins most have been included on the basis of known effect of sulfated tyrosine.  
 
Class Peptide/protein Species Functional role of sulfated Tyrosine Reference
Adhesion 
molecules 
Glycoprotein Ibα 
PSGL-1 
Hs 
Hs 
Thrombin/vWF binding 
P- and L-selectin binding 
5,13-15 
6,16-18 
Coagulation factors Factor V 
Factor VIII 
Hs 
Hs 
Thrombin cleavage 
Thrombin cleavage, vWF binding 
19,20 
21 
Matrix proteins Fibronectin 
Procollagen Type III 
Vitronectin 
Hs,Rn 
Hs 
Hs 
Fibrin binding 
Unknown 
Unknown 
22,23 
24 
25 
Serpins α2-antiplasmin 
Heparin cofactor II 
Hs 
Hs 
Plasmin binding? /processing? 
Thrombin inhibition, Heparin binding 
26 
27,28 
G-protein coupled 
receptors 
CCR5 
CCR8 
CCR2B 
CXCR4 
CX3CR1 
C5a receptor 
TSH receptor 
S1P1 
Hs 
Mm 
Hs 
Hs 
Hs 
Hs 
Hs 
Hs 
MIP-1α/MIP-1β/gp120/CD4 binding 
CCL1 binding 
MCP-1 binding 
SDF-1α binding 
Fractaline binding 
C5a binding 
TSH binding 
S1P binding 
7 
29 
30 
31 
32 
33 
34 
35 
Gastrin/CCK 
family 
Gastrin 
Cholecystokinin 
Caerulein 
Cionin 
Sulfakinins 
Various species 
Various species 
Lc 
Ci 
Various insects 
and crustacea 
Progastrin processing 
CCK-A receptor binding 
CCK/Gastrin-like activity 
Unknown 
DSK receptor-1 binding (Dm) 
Myotrophic activity (Lm) 
36 
37,38 
39,40 
41 
42-44  
Enzymes Aminopeptidase N 
PAM-3 
Ss 
Rn 
Unknown 
Unknown 
4 
45 
Other C4 α chain 
Hirudin 
Vitellogenin II 
IgM µ-chain 
Hs 
Hm 
Dm 
Mm, Rn 
Cleavage by C1s 
Thrombin inhibition 
Enhanced secretion rate 
Unknown 
46,47 
48-50 
12,51 
52 
Abbreviations see page 4.  
 
2.1.1 The tyrosine sulfation pathway 
The sulfation of tyrosine is catalyzed by the specific enzymes tyrosylprotein sulfotransferase-153,54 and 
tyrosylprotein sulfotransferase-255,56 (TPST-1 and TPST-2, respectively). TPST activity have been 
identified in many tissues and species (for review se Moore 200357), and even a plant tyrosylprotein 
sulfotransferase has been found58. No tyrosine sulfated proteins, TPST activity or putative TPST 
orthologs have been described in yeast or in prokaryotes57. TPST-1 and TPST-2 seems to be 
coexpressed in many if not all mammalian cells55. Each TPST gene encodes a protein with a short N-
terminal cytoplasmic domain, a single approximately 17 amino acid residue transmembrane domain and 
a luminal catalytic domain (fig. 2). 
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Figure 2: Domaine structure of tyrosylprotein sulfotransferases. Human TPST-1 and TPST-2 are transmembrane 
proteins of similar size (370-377 residues). Each have a short 8-residue N-terminal cytoplasmic domain, a single ~17-residue 
transmembrane domain (TM), a putative ~40-residue stem region, a luminal catalytic domain, and two N-glycosylation sites. 
Four luminal cysteine residues are shown, as are the 5’PSB and 3’PB motifs that are involved in binding of the 5’- and 3’-
phosphate groups of the reaction product 3’,5’-ADP, respectively. Figure and text from Moore 200357. 
 
The enzymes catalyze the transfer of sulfate from adenosine 3’-phosphate 5’-phosphosulfate (PAPS)59, 
the universal sulfate donor52, to the hydroxyl group of the tyrosine residue forming a tyrosine sulfate 
ester and 3’5’-ADP (fig. 3). PAPS is transported into the lumen of the trans-Golgi via PAPS 
translocase/PAPS transporters residing in the trans-Golgi membranes60,61. 
 
 
Figure 3:  The tyrosine sulfation reaction. TPST-1 and TPST-2 catalyze the transfer of sulfate from PAPS to the 
hydroxyl group of a protein tyrosine residue, forming tyrosine-O4-sulfate and 3’,5’-ADP. Figure adapted from Moore 200357. 
 
The reaction takes place on the luminal side of the trans-Golgi network and maybe in the trans-Golgi 
cisternae52,62(fig. 4). The luminal active site orientation of TPST-1 and TPST-254,63 predict that tyrosine 
sulfation occurs only on peptides and proteins that transit the trans-Golgi network, i.e. secretory  and 
membrane proteins.  
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Figure 4: The Tyrosin sulfation pathway. Inorganic sulfate enters the cell via of one of several sulfate transporters. In the 
cytosol, sulfate is then coupled to the ATP molecule in a couple of steps by the action of one of two PAPS synthases 
(PAPSS1 or PAPSS2). PAPS is then transported into the Golgi lumen by a PAPS translocase. Once inside the Golgi lumen 
PAPS acts as the sulfate donor for TPSTs and all other carbohydrate sulfotransferases, and the sulfated products are either 
secreted or retained in the membrane of lysosomes, secretory vesicles, and/or the plasma membrane. TGN, trans-Golgi 
network. Figure adapted from Moor e 200357.  
 
The highest levels of TPST have been found in liver and submandibular salivary glands as compared to 
levels in the stomach, cerebellum, thalamus and pituitary64, but the relative abundance of the two TPST 
enzymes at the protein level in tissues and cells are not very well characterized. In addition, only limited 
data exists on differences in specificity of TPST-1 and -2. Studies with leech and bovine TPSTs showed 
a difference in catalytic properties towards the same recombinant peptide, hirudin, indicating that there 
might be differential substrate specificities of the TPSTs between species65.  
2.1.2 Regulation of TPST and tyrosine sulfation 
Evidence that the TPST-1 and TPST-2 genes are subject to transcriptional regulation is very limited. 
Goettsch et al. 200266 showed that biomechanical forces such as shear stress affect the expression of 
TPSTs in endothelial cells. Although the changes were modest, the cells response to continuous shear 
stress was time dependant. TPST-1 was found to be a more long termed responder, in contrast to 
TPST-266.  
Unlike protein phosphorylation, the evidence available indicates that tyrosine sulfation is almost 
irreversible67,68. Pulse-chase experiments with various secretory proteins have shown that no significant 
protein desulfation occurs during transport to the cell surface or in secretory granules. Either there is 
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no sulfotyrosylprotein sulfatase or, if present, it is very different from known arylsulfatases or it does 
not have the tyrosine sulfated proteins identified so far as substrates11. Degradation of tyrosine sulfated 
proteins yields, at least in part, free tyrosine sulfate to be excreted in the urine69-71.  
 
The number of sulfated tyrosines found in one single protein ranges from one to six. The recombinant 
human coagulation factor VIII has six sulfated tyrosines20 and the chemokine receptor CCR5 contains 
3 to 4 sulfation sites. Research on the CCR5 receptor showed a discrete sulfation pattern where 
sulfation of one specific tyrosine lead to the sulfation of another72, sort of a sulfation cascade. Whether 
this cascade event is a general feature of the TPSTs remains to be investigated. Little is known about 
the kinetics of these two enzymes. 
2.2 Chemical properties of tyrosine sulfation 
Tyrosine belongs to the aromatic amino acids, which are relatively nonpolar. The hydroxyl group of 
tyrosine has the ability to form hydrogen bonds, but the large phenyl group is hydrophobic. The pKa 
value of the phenolic group in tyrosine is 10.07, but when tyrosine is sulfated the pKa of the functional 
group is ≈ -4 (pKa = -3.88 for phenyl sulfate73). At the same time sulfation quadruples the amount of 
possible hydrogen binding sites for the tyrosine. 
2.2.1 Hydrolysis of tyrosine sulfate 
Tyrosine sulfate is often not discovered in peptides and proteins because it is very acid labile, i.e. 
tyrosine sulfate residues tend to desulfate/hydrolyze to tyrosine under acidic conditions. 
 
Tyrosine-O-SO3-   +    H+        Tyrosine  +   SO3  
 
According to Huttner 1984 more than 95% of the ester was hydrolyzed after 5 minutes in 1M HCl at 
100°C, making it impossible to detect tyrosine sulfate after acid hydrolysis of proteins3. This eliminates 
observing tyrosine sulfate when sequencing amino acids by traditional analytical methods such as amino 
acid analysis of the acid hydrolysate, or Edman degradation since the sulfate ester bond is quickly 
hydrolyzed to unsulfated tyrosine during the first cycle of acidic cleavage74. These methods use very 
high concentrations of strong acids (>1 M) but many experiments involving purification and 
identification of peptides and proteins often involve milder acidic solutions.  
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To mention a few:  
? Trifluoroacetic acid (TFA, from 0.1%-90%) is used for purification and reverse-phase HPLC. 
? Formic acid (FA, ~0.2%) is used in reverse-phase HPLC and mass spectrometry. 
? Trichloroacetic acid (TCA) is used for quantitative protein precipitation, electrophoresis, 
decalcifier, and fixative in microscopy. 
To date little is known about the acid hydrolysis in these milder acid concentrations. Research by 
Yagami et al. 2000 showed stabilization of tyrosine sulfate when forming a conjugate acid-base pair with 
a cationic functional group74 (fig. 5). They investigated the stability of tyrosine sulfate in various lengths 
of the peptides, gastrin and cholecystokinin (CCK), when subjected to 5% TFA incubated at 37°C for 1 
to 5 hours. The conclusions were that the gastrin peptides were more prone to hydrolysis than the 
CCK peptides, and that both longer peptide chains and the presence of basic amino acids increased the 
stability of the sulfate group. Especially the basic amino acid, arginine (highest proton affinity among 
the 20 amino acids75) within the CCK peptides, was effective in forming conjugate acid-base pair with 
the sulfate group, thereby stabilizing the sulfate group74. The smallest CCK peptide showing a 
protective effect was CCK8, which has one arginine situated at position -2 from the tyrosine.  
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Figure 5: The possible reaction mechanism for stabilization of the sulfated tyrosine residue by the counter-ion, X+,74. 
 
Larger peptides and proteins with secondary structures might have basic amino acids situated far from 
the tyrosine in the peptide chain, which could be brought close enough to the sulfated tyrosine to form 
a conjugate acid-base pair because of protein folding. 
The stabilization afforded by the length of the peptide is expected to be a result from conjugate acid-
base pairs between the sulfated tyrosine and the amino groups within the peptide backbone and 
sidechains74. The stabilization can be explained by assuming that a higher energy barrier would have to 
be overcome in order to form the intermediate ions during the course of the hydrolysis reaction (se 
next section).
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2.2.2 Hydrolysis reaction mechanism 
To elucidate the mechanisms involved in the hydrolysis of tyrosine sulfate it can be useful to refer to 
studies performed with aryl sulfate esters76-78 Although sulfate ester chemistry has been the subject of 
rather few studies, data exists on pH profiles, dissociation constants and reaction mechanisms. From 
what is known to date, the chemistry of the sulfate esters is mechanistically similar to that of phosphate 
esters76.  
Data on the pH-rate profile for the hydrolysis of ortho-nitrophenyl sulfate involves three stages (fig. 6). 
First stage is between pH 0 to 4 where the first-order rate constants falls drastically, from there it 
reaches a plateau between pH 4 to 12 where the rate constant is virtually unaffected, and finally 
followed by an exponential rise towards pH 14, due to the incursion of base catalysis79,80. 
 
Figure 6: Variation of Ko with pH for ortho-nitrophenyl sulfate at 100°C. Sulfate ester hydrolysis is accelerated under 
strongly acidic and strongly basic conditions, with a broad pH-independent range between pH 4 and 12. Diagram from 
Fendler and Fendler 196879. 
 
The hydrolysis of tyrosine sulfate shows resemblance to the diagram in figure 6, being labile in strong 
acid and stabile in neutral to basic solutions. Tyrosine sulfate can actually withstand alkaline hydrolysis 
(90% of the sulfate ester remains after 24 hours in 0.2M Ba(OH)2 at 110°C3), a method employed for 
peptide degradation prior to thin layer electrophoresis/ chromatography (TLE/TLC) and detection of 
tyrosine sulfate.  
Sulfate monoesters, including tyrosine sulfate, may exist in either of two protonation states, the anion 
and the neutral species. There is evidence that these species induce different reaction mechanisms; the 
hydrolysis of the anionic compound and the hydrolysis of the neutral compound (fig. 7).  
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Figure 7: The possible reaction mechanisms for the hydrolysis of aryl sulfate esters. A: The reaction in the broad pH 
range of 4-12. B: The reaction mechanism proposed for very strong acidic solutions, where the neutral species is a 
zwitterion. C: The proposed reaction under acidic conditions where more than one water molecule may be involved in 
facilitating the proton transfer in the reaction. 
 
Reaction A: In the pH-independent region between pH 4 to 12 the reactive species is the aryl sulfate 
anion. Tracer studies with 18O, have shown that para-nitrophenyl sulfate (pNPS) undergo hydrolysis 
predominantly by S-O bond fission79,80 .  
The S-O bond fission can be explained by charge delocalization in the molecule. In the starting aryl 
sulfate anion, the -SO3- can act as a strong electron-withdrawing group when adjacent to a reaction site. 
This is due to the presence of a large positive charge on sulfur as a result of the contribution of 
structure I (fig. 8), which will decrease the electron density on the phenolic oxygen in ArOSO3- 78.  
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Figure 8: The charge delocalization in the sulfuryl group. 
 
In the transition state the electron density on the phenolic oxygen is slightly higher and kinetic isotope 
effects suggests a transition state like the one shown in figure 7A. The S-O bond to the phenol is 
largely broken in the transition state, and the phenolic oxygen bears essentially a full negative charge. 
The sulfuryl group resembles sulfur trioxide77. 
Through deuterium isotope effect studies for pNPS the reaction was proposed to be unimolecular since 
very little bond formation occurred between the solvent and the substrate in the transition state80.  
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Contrary, observed entropies of activation (∆S*) for the pH-independent hydrolysis of nitrophenyl and 
dinitrophenyl sulfates were more negative than those generally associated with a unimolecular reaction 
mechanism77,79,80. Unimolecular reactions generally have small, slightly positive entropies, but some with 
small negative ∆S* also exists80. Hence it is difficult to rationalize the negative entropy term as evidence 
for other than a bimolecular reaction.  
Thus results does not clearly define a particular hydrolysis mechanism, but if viewed as involving 
participation of water as a nucleophilic species, a degree of bond formation between the solvent and 
the ester might occur77,79,80. 
 
Reaction B: In the acidic hydrolysis of sulfate esters, the reactive species is the neutral molecule, and 
this form is much more reactive than the anion. The proposed mechanism for the hydrolysis of the 
neutral species proceeds via a two-step pathway involving equilibrium proton transfer to the phenolic 
oxygen atom creating an intermediate zwitterions and then followed by S-O bond cleavage leading to 
the dissociation of the zwitterion to phenol and SO376,78,79. The intermediacy of free SO3 in the acid 
hydrolysis is often assumed but has never been proven77, most likely because it will react very rapidly 
with water forming sulfuric acid eliminating any possible reverse reaction. 
As with the pH-independent hydrolysis, observed kinetic isotope effects for the transition state in the 
acid hydrolysis showed a S-O bond, which was largely broken, and in addition that protonation of the 
phenolic oxygen was essentially complete77. 
The acid catalyzed hydrolysis bears more resemblance to a unimolecular reaction. Contrary to the pH-
independent hydrolysis, the ∆S* values were higher for the acid-catalyzed hydrolysis of pNPS but still 
negative79. In addition, the acid catalyzed hydrolysis of sodium phenyl sulfate showed a solvent isotope 
effect corresponding to a unimolecular reaction, and at the same time there seemed to be considerably 
less involvement of water in the transition state78. 
An argument favoring reaction B is, given the very low pKa of the sulfuryl group of pNPS (pKa =          
-4.8673), pKa of the phenolic oxygen might not be lower, and thus protonation might not occur on the 
sulfuryl group at all in the hydrolysis reaction. The phenolic oxygen is protonated directly by the 
hydronium ion to give the zwitterion77. Hoff et al. 200177 found that this was not the case and proposed 
another mechanism (reaction C). 
 
Reaction C: The mechanism for the acidic hydrolysis proposed by Hoff et al. 200177. Observed kinetic 
isotope effects indicates that the sulfuryl-protonated species is the reactive form, not the zwitterions, 
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which then transfers the proton to the phenolic oxygen, probably via one or more water molecules in 
the same step as the sulfuryl transfer76,77.  
Tyrosine sulfate differs from pNPS having a CH2 group as para-substituent, which is not an electron-
withdrawing group. Para-substituents such as NO2 (in pNPS) stabilize the phenol by resonance 
interactions, interactions not likely to be observed in the starting aryl sulfate (fig. 9).  
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Figure 9: A: Stabilization of the para-nitrophenol by resonance interactions. B: In the pNPS resonance interactions are 
unfavorable, because of adjacent positive charges on the phenolic oxygen and sulfur. C: No resonance interactions are 
possible in tyrosine or sulfated tyrosine. A and B are adapted from Kice and Anderson 196678. 
 
The para-NO2 group in pNPS will cause the activation energy (Ea) for the hydrolysis to be somewhat 
less than it would for unsubstituted aryl sulfate78. The phenol in tyrosine will not have the same 
resonance stabilizing effect and the Ea for the hydrolysis of tyrosine sulfate should therefore be 
somewhat larger than for pNPS, but this has not yet been examined. 
2.2.3 Factors influencing hydrolysis rate 
A factor that has been shown to influence the hydrolysis of aryl sulfates is the nature of the acid itself. 
Hydrolysis research with nitrophenyl and dinitrophenyl sulfates has showed that the catalytic power of 
the three acids, H2SO4, HClO4 and HCl was in the order H2SO4 > HClO4 > HCl79. It is unlikely that 
this order is dependent on the nucleophilicity of the anions since sodium chloride and sodium sulfate 
had little effect, whereas sodium perchlorate ions markedly decreased the rate of spontaneous 
hydrolysis. Therefore these acids not only affect the reaction rate by their proton-donating power but 
also by their electrolyte effects which are specific and possibly equal to those of the anions of their 
sodium salts79.  
 
 
Summer 2006 
Introduction  Roskilde University Center 
 19
The sulfate ester hydrolysis reaction is also influenced by the medium. The hydrolysis reaction of para-
nitrophenyl sulfate (pNPS) or 2,4-dinitrophenyl sulfate was accelerated when reducing the 
concentration of water in DMSO77,79,81, DMF79,81 or dioxane78,79,81. The rate acceleration is probably due 
to the dissociation constant (ka) of any neutral acid HA decreases markedly with increasing content of 
nonpolar solutes. This means that the amount of free protons is reduced and that the fraction of 
protons bound to aryl sulfate ions (III and IV) increases markedly78.  
 
ArO SO3- ArOSO3
-  +  H+ ArOSO3H
H
+
III IV  
Contrary, the hydrolysis rate decreases with increasing amounts of non-nucleophilic species in the 
solvent. Changing the medium to aqueous acetonitril79,80 or tert-amyl alcohol77 decreases the hydrolysis 
rate. The effects of electrolytes and solvents on the hydrolysis are likely to originate from their ability to 
alter the structure of liquid water, and thereby the degree of solvation of the ground- and transition 
state of the aryl sulfate79.  
In conclusion, when handling sulfated peptides, it is necessary not only be aware of the pH of the 
solution, but also of electrolyte and medium effects to limit the risk of hydrolysis. 
2.3 The biological role of tyrosine sulfation 
To date, approximately 70 tyrosine-sulfated proteins have been identified and for many of these, the 
biological function has not been elucidated. In most cases tyrosine sulfation does not alter the level of 
expression of the protein. For those with a known biological role(s), the sulfated tyrosine is involved in 
protein-protein interactions10, be it between:  
? Two secretory proteins 21,23,46,49.  
? A secretory protein and its cell surface receptor38. 
? Two plasma membrane proteins6,17,18. 
? A membrane receptor and its ligand7,29-34.  
 
In addition, sulfation has been reported to modulate proteolytic processing36,46, secretion rates82-84 and 
enhance the activity46 of secretory proteins. Tyrosine sulfation could affect protein function in at least 
two ways; the sulfates could simply serve as an additional means of providing negative charges for 
electrostatic interactions or they could provide a specific structure for intra- or interpolypeptide 
interactions.  
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It has also been shown that viral proteins undergo tyrosine sulfation, with the possible function of 
enhance target cell recognition, attachment, and entry by viruses85,86. There may be a link between 
tyrosine sulfation and viral disease mechanisms87.  
2.3.1 Significance of tyrosine sulfation - Tpst null mice 
To address the role of tyrosine sulfation in vivo, TPST-1 or TPST-2 knockout mice models have been 
made88,89 (Our research lab, unpublished data). Disruption of one Tpst gene has no detectable effect on 
the expression of the other Tpst gene in the tissues examined88. Heterozygous Tpst1+/- and Tpst2 +/- mice 
appear normal; have normal fertility and normal growth curves, indicating no intermediary phenotypes. 
The homozygous Tpst1 -/- and   Tpst2 -/- mice on the contrary have distinct phenotypes57. 
Tpst1 -/- mice appear normal but have a approximately 5% lower average bodyweight in both male and 
female. Fertility in both males and females are normal, although the females have lower litter sizes 
(approximately 35% reduction) compared to wild type females. The smaller litter sizes are due to post 
implantation fetal loss, and appear to be exclusively from maternal TPST-1 deficiency. Fetal loss 
appears between 8.5 and 15.5 days postcoitum88. To date there are no proteins involved in female 
reproductive physiology that are known to be tyrosine-sulfated or to require tyrosine sulfation for 
optimal function. 
Tpst2 -/- mice, both male and female, have severely reduced bodyweights at birth with an average of 
20% below wild type littermates, however the Tpst2 -/- mice attained normal body weight after 10 
weeks. The Tpst2 -/- male reproductive performance was severely defective and experiments suggest that 
the sterility was due to abnormalities in sperm transport, sperm capacitation and/or fertilization per se89. 
Attempts have been made to construct Tpst1/Tpst2 double knockouts, but these mice are not viable, 
dying within a few days postnatal (Kevin Moore, unpublished data). This distinct phenotype 
underscores the importance of tyrosine sulfation in general. 
 
Currently there is no link between the phenotypic effects of TPST-1 and TPST-2 deficiency and the 
defective sulfation of any known TPST substrates. In corporation with Kevin Moore, our research lab 
are trying to elucidate the sterility of the tpst2 -/- males through 2D gels and gene-chip analysis, but no 
distinct differences have yet been found between tpst2 -/- mice and wild type mice. The phenotypes may 
reflect differences in substrate specificity of TPST-1 and TPST-2. Another explanation might be that 
TPST-1 and TPST-2 have redundant substrate specificities, but that the local level of expression of the 
remaining TPST is simply insufficient to compensate for the other88.  
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2.3.2 Protein consensus features for tyrosine sulfation 
To determine if a protein might be sulfated, it is necessary to know the structural features of the 
protein needed for it to be a substrate of the TPSTs. Currently there is no consensus sequence for 
tyrosine sulfation, but there are some guidelines for the primary amino acid sequence that may indicate 
that a tyrosine is sulfated90-92.  
Characteritic features for tyrosine sulfation: 
? Acidic residues are the major requirements for tyrosine sulfation. Both adjacent and distant 
(+/-5 aa) acidic amino acids contribute to the sulfation of peptides, but position -1 seems to be 
the most important, and neighboring residues contribute only moderately to sulfation.  
? Several tyrosines within close range or tandem repeated tyrosines7,41. 
? Absence of amino acids (cysteine and aspargine residues) that induce steric hindrances such as 
disulfide bridges and glycosylations11 near the tyrosine residue. 
? The presence of turn-inducing residues, proline or glycine may contribute to sulfation11. 
Although this may be a minor requirement for sulfation, only necessary for proteins in which 
their absence otherwise would impose secondary structures that inhibit sulfation, i.e. presence 
of turn inducing residues may promote sulfation in proteins, but not in peptides. The latter are 
less restrained in adopting a conformation for recognition by TPSTs. 
? Absence of basic and hydrophobic residues within five residues of the tyrosine. This again 
being a minor requirement for sulfation. 
 
As the number of proteins with sulfated tyrosines has grown, so has the number of sulfation sites that 
do not conform to these established consensus features90,91. Complete conservation exists at no 
position within the sulfation site, and it has therefore been suggested that the secondary structure also 
plays a role92. 
Many of the proteins known to be sulfated do not contain acidic amino acids features considered to be 
the major sulfation requirement. Cionin for example (NsYsYGWMDF-NH2), is completely sulfated in 
two neighboring tyrosines, despite considerable deviations from the proposed consensus sequence41. 
Likewise gastrin, one of the most investigated tyrosine sulfated secretory peptides, contains a neutral 
residue, alanine in position -1, but immediately N-terminal to this, gastrin has a stretch of 5 acidic 
amino acids pEGPWLEEEEEAsYGWMDF-NH2. Intriguingly, the wild-type gastrin is only 
approximately 72% sulfated, but when the neutral residue alanine at position -1 is changed to aspartate, 
gastrin is 100% sulfated36. In addition, the sulfation pattern of gastrin is complex, showing both tissue 
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and species variation93. Whether this is limited to gastrin or is the case for other sulfated peptides and 
proteins is not known. The differences in sulfation pattern might be connected to possible substrate 
differences and expression levels of the two isoforms of the TPST enzymes but this remains to be 
examined. Levels of sulfation may be a combination of both consensus sequence, tertiary structure and 
TPST activity in cells and tissues94,95. 
Although no consensus sequence has been established, a software tool, the ”Sulfinator” has been made 
by Monigatti et al. in 200296, to predict tyrosine sites in a protein sequence that might be sulfated. Using 
the sulfinator tool to scan the proteome, one third of the proteins that enter the secretory pathway may 
contain on average two tyrosine sulfation sites per protein. The predictive value of this software is 
rather uncertain, since it is based on the few known sulfated proteins, which have very large variations 
in the sulfation site sequence. Even if it is possible to predict a possible tyrosine sulfation site in a 
protein, it might not be sulfated in the cells in which these proteins are naturally present, because of a 
possible variation in TPST activity. 
2.4 Sulfation of G-protein coupled receptors 
G protein-coupled, seven-transmembrane segment receptors (GPCRs or 7TM receptors) comprise the 
largest superfamily of proteins in the body. The chemical diversity among the endogenous ligands is 
exceptional. They include biogenic amines, peptides, glycoproteins, lipids, nucleotides, ions, and 
proteases. Moreover, the sensation of exogenous stimuli, such as light, odors, and taste, is mediated 
through this class of receptors97. As noted earlier tyrosine sulfation have been identified in several 
GPCRs in recent years. Sulfated tyrosines have been found in chemokine receptors CCR57, CCR829, 
CCR2B30, CXCR431, CX3CR132, C5a33, in the glyoprotein hormone receptors TSH, FSH and LH34 and 
in the lymphocyte sphingosine receptor S1P135. The most well known is probably the CCR5 receptor of 
which the sulfated tyrosines is involved in HIV-1 entry into target cells7.  
In all the tyrosine sulfated GPCRs, the function of the sulfated tyrosine is within the interaction 
between the receptor and the ligand, in all cases enhancing the binding and response signal7,29-35. This 
underscores that this posttranslational modification plays a wider role in receptor-mediated biological 
processes than previously appreciated.  
2.5 Pituritary adenylate cyclase activating polypeptide type 1 receptor 
The PAC1 receptor (name according to the International Union of Pharmacology98) is a member of the 
glucagon/calcitonin/ secretin/vasointestinal peptide (VIP) receptor family, which are characterized by 
a large (approximately 100 residues) extracellular amino terminus containing several cysteines97 
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(alignment see supplement 13.1). It was first identified in bovine brain membrane by Ohtaki et al. in 
199099 and the human PAC1 receptor was cloned in 1993 by Ogi et al. 100. The amino acid sequence was 
corrected by Pantaloni et al. in 1996101. The PAC1 receptor belongs to a smaller group of three 
receptors: PAC1, VPAC1 and VPAC2, characterized by their different affinities for their ligands pituitary 
adenylate cyclase activating polypeptide (PACAP) and vasointestinal peptide (VIP); PAC1 receptor 
binding PACAP with high affinity and VIP with a much lower affinity102, and VPAC1 and VPAC2 
receptors, which bind PACAP and VIP with similar affinities103 (104,105 for reviews). 
The structure of PAC1 receptor consists of seven trans-membrane spanning α-helical segments 
connected by alternating intracellular and extracellular loops, with the amino terminus located on the 
extracellular side and the carboxy terminus on the intracellular side (fig. 10). 
 
 
 
Figure 10: Amino acid structure of the human PAC1 receptor. Model of the predicted amino acid sequence for the 
human PAC1 receptor (the null splice variant) showing the seven transmembrane-spanning regions, a 20 amino acid signal 
peptide (light blue amino acids), the five potential sites for N-linked glycosylation (green amino acids), five highly conserved 
cysteine residues (yellow amino acids), the four possible sulfated tyrosines (red amino acids), and the sites of alternative splicing 
(short, very-short, SV-1, SV-2 and SV-3) (arrows)101,106-108. Figure modified from Chatterjee et al. 1997109. 
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The receptor sequence is highly conserved among species (full alignment see supplement 13.2). Most 
important for this study is the conservation of the amino acids surrounding the tyrosines in the N-
terminal extracellular domain, giving an indication that this region is of great importance (fig. 11). 
 
 
 
 
Figure 11: Alignment of part of the N-terminal extracellular sequences of PAC1 receptor in human, mouse, rat and 
bovine. The sequence is highly conserved and contains many acidic amino acids (amino acids in bold) and multiple subsequent 
tyrosines (red amino acids), two of the major requirements for sulfation. 
 
To this date, little is known about the sites of ligand bindig and conformation of the PAC1 receptor. 
Most importantly, it is demonstrated that the N-terminal extracellular domain of the PAC1 receptor 
contains the major binding site for its ligands110,111, and that residues 53-88 within the N-terminal 
domain of PAC1 are important for high affinity ligand binding, whereas residues 89-109 determine the 
receptor’s ligand selectivity101,106. 
The extracellular domains of PAC1 receptor contain six cysteine residues, which are highly conserved 
among VPAC1, VPAC2, secretin, and glucagon receptors (see supplement 13.1). These may form 
disulfide bonds necessary for conformation and agonist binding112 as is seen with the VPAC1 
receptor113. It has been shown that the PAC1 receptor is glycosylated114 and that the  receptor possesses 
five potential glycosylation sites in the extracellular domains115-117 (fig. 10, green amino acids), however 
the exact sites of glycosylation are not known. 
Besides the posttranslational modifications, the receptor exists in many isoforms resulting from 
alternatively spliced mRNA. Most studies have been performed on the rat and human receptors, which 
exhibits a nucleotide sequence identity of 93%. To date nine variant forms of the rat PAC1 receptor 
have been identified, making it one of the most extensively spliced GPCR mRNAs. The human PAC1 
receptor has only been identified in six isoforms: one isoform, the human PAC1 null, encoding a 486 
amino acid protein showing 93% homology with the rat PAC1 short/normal form. Three isoforms results 
from amino acid inserts in the third intracellular loop: the human PAC1-SV-1, a 28-amino acid insert 
(similar to rat PAC1-hip differing by two amino acids); the human PAC1-SV-2, a different 28-amino acid 
insert (identical to rat PAC1-hop-1 isoform); and human PAC1-SV-3, a 56-amino acid insert 
(combination of both the 28-amino acid inserts, similar to rat PAC1-hip-hop-1 isoform)112. In addition 
the human PAC1 exists in two shorter forms, short and very short, characterized by a 21 or 57 amino acid 
deletion in the N-terminal extracellular domain, respectively101,106 (the short version is the homologue to 
HUMAN PAC1  NSLDLSDMGVVSRNCTEDGWSEPFPHYFDACGFDEYESETGDQDYYYLSVKALYTVGYST 163  
MOUSE PAC1  NSLEITDMGVVGRNCTEDGWSEPFPHYFDACGFDDYEPESGDQDYYYLSVKALYTVGYST 163  
RAT PAC1 NSLEITDMGVVGRNCTEDGWSEPFPHYFDACGFDDYEPESGDQDYYYLSVKALYTVGYST 162  
BOVIN PAC1 KSLDLSDMRVVSRNCTEDGWSEPFPHYFDACGFEEYESETGDQDYYYLSVKALYTVGYST 180 
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rat PAC1-sv). The conservation of alternative splicing of the PAC1 receptor gene from rats to humans 
suggest that it may represent a highly conserved an efficient mechanism for creating biological 
diversity112. The areas of alternative splicing in the N-terminal extracellular domains of the receptor do 
not include the region with the possible sulfated tyrosines. 
2.5.1 Ligands for PAC1 receptor 
PAC1 is the receptor for the peptide hormones PACAP and VIP. The biological active peptides are 
PACAP-27, PACAP-38 and VIP, the main focus here will be on the PACAP peptides since these have 
the highest affinities for the receptor. 
PACAP was first discovered in 1989 as a novel hypothalamic hormone that stimulates increases in 
cAMP in rat anterior pituitary cells118. PACAP is synthesized in the form of a precursor and is 
processed into two active α-amidated peptides of 27 or 38 amino acids respectively, differing by an 11-
amino acid extension at the carboxyl terminus118-120 (hence the names PACAP-27 and PACAP-38) (fig. 
12). PACAP share 68% sequence identity with VIP121. 
 
 
 
 
 
Figure 12: The amino acid sequences of the three peptides PACAP-27, PACAP-38 and VIP. The PACAP-38 has 
three well-defined domains: an initial partially distorted N-terminus of eight residues, followed by an extended α-helical 
region, consisting of two connected helices, and finally a C-terminal region with a short helix attached by a flexible hinge to 
the central domain. PACAP-27 and VIP corresponds strictly to the first two domains. Lysine15 and tyrosine22 in PACAP 
(bold underlined amino acids) are important for receptor binding.  
 
Structurally PACAP-27 and PACAP-38 have three well-defined domains: an initial partially distorted 
N-terminus of eight residues, presumably containing a β-bend structure, followed by an extended α-
helical region, consisting of two connected helices of which the integrity is important for high affinity 
binding, and finally for PACAP-38 a C-terminal region with a short helix attached by a flexible hinge to 
the central domain121-124 (fig. 12). The first six N-terminal residues of PACAP are important for both 
binding and signal transduction. Compared to PACAP-27, the binding affinity of PACAP-(6-27) is 
severely reduced, where the affinity of PACAP-(6-38) however remains high. Since loss of these six 
residues abolishes cAMP signaling for both PACAP-(6-27) and PACAP-(6-38), PACAP-(6-38) serves 
as an effective antagonist for the PAC1 receptor122,125. Several findings also provide evidence that 
  Distorted         Helix 1 and 2 Helix 3
 ---------------  ------------------------- -------------     ------------- 
PACAP-38: HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK-NH2 
PACAP-27: HSDGIFTDSYSRYRKQMAVKKYLAAVLG-NH2 
VIP: HSDAVFTDNYTRLRKQMAVKKYLNSILNK-NH2 
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lysine15 and tyrosine22 in PACAP is important for the high affinity binding to the receptor and these 
residues are probably located in or close to the receptor binding site124,126 (fig. 12). 
2.5.2 Distribution of PAC1 receptors  
The localization of PACAP binding sites and PAC1 receptor mRNA has been investigated thoroughly. 
The distribution of PAC1 receptor is mainly in many parts of the brain and central nervous system 
(CNS), but also in several peripheral organs and tissues such as the kidney, liver, eye, lungs, heart, testis, 
ovary, pancreas, macrophages, peripheral nervous system (PNS) and anterior pituitary104. Most recently 
the PAC1 receptor has been found in smooth muscle cells in the bladder127. An interesting aspect is the 
tissue specific expression of the different splice variants. For example, the expression of the alternative 
splice variant PAC1-very short is restricted to pituitary and adrenal glands and hypothalamus/thalamus 
(Screening various mouse tissues and human fetal brain cDNA), which suggests specific function of 
this mouse/human PAC1-very short variant101. Likewise, expression of the PAC1 receptor and the splice 
variants changes during development. At different stages of development, different splice variants are 
expressed at different levels in various tissues, a sort of time-restricted regulated expression104. 
PAC1 receptor binding sites have also been found in cancer cells, both in rat pancreatic acinar AR4-
2J128, in medullary carcinoma 6/23 cell lines129, in human neuroblastoma cell lines130-132, in human glial 
cell tumors133, and in both small cell lung cancer (SCLC)134,135 and in non-small cell lung cancer 
(NSCLC) cells134. 
2.5.3 PAC1 receptors signal transduction 
The peptide PACAP and the PAC1 receptor possess an impressive array of biological actions consistent 
with its diverse tissue distribution and suggested roles as hypophysiotropic hormone, neurotransmitter, 
neuromodulator and vasoregulator. PACAP stimulates hormone release from various cells and is the 
most potent insulin secretagogue yet described. PACAP stimulates neurite outgrowth, in 
pheochromocytoma PC12 cells, promotes mitogenesis and survival of cultured rat sympathetic 
neuroblasts, and prevents neuronal cell death induced by human immunodeficiency virus protein gp120 
in dissociated hippocampal cultures. PACAP dilates various vessels, induces hypertension, stimulates 
steroidogenesis, and stimulates hepatic glycogenolysis109. 
 
On the basal cellular level, the PAC1 receptor is coupled to adenylate cyclase (AC) or phospholipase C 
(PLC)108,112,136-138 (fig. 13).  
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Figure 13: The signaling pathways of PAC1 receptor. The adenylate cyclase pathway: Binding of the ligand to PAC1 
receptor leads to the activation of adenylate cyclase and thereby a rise in cAMP concentration. The binding of at least two 
cAMP to the regulatory subunits of the inactive protein kinase A (PKA) leads to the activation an release of the two catalytic 
subunits into the cytosol. The activated PKA subunits can then move into the nucleus where they phosphorylate gene-
regulatory proteins. The phospholipase C pathway: The activated receptor stimulates the plasma-membrane-bound 
enzymephospholipase C-β (PLC-β) via the activated α subunit of Gq136. Activated PLC-β hydrolyses phosphateidylinositol 
4,5-biphosphate [PI (4,5)P2], releasing inositol 1,4,5-triphosphate (IP3), which diffuses through the cytosol and binds to IP3-
gated Ca2+-releasing channels in the endoplasmic reticulum. Ca2+ escapes to the cytosol and together with diaglycerol and 
phosphatidylserine (not shown) recruits and activates the enzyme protein kinase C (PKC). Figure modified from Alberts 
2002139. 
 
Binding of PACAP to PAC1 receptor leads to adenylate cyclase activation through which it elevates 
cAMP and activates protein kinase A (PKA), which again can activate the mitogen-activated protein 
kinase (MAPK) pathway. PACAP binding to PAC1 can also activate mitogen-activated protein kinase 
pathway independently of adenylate cyclase activation. The activation of phospholipase C stimulates 
Ca2+ mobilization and protein kinase C (PKC) activation105. Recent studies have shown that two splice 
variants, rat PAC1-normal and rat PAC1-hop-1 also activates phospholipase D (PLD)140,141. 
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The PAC1 receptor signal transduction pathways depend not only on the specific ligand, which in itself 
can activate more than one second messenger pathway, but also on the concentration of ligand, the 
specific splice variant expressed by the cell, and the G proteins composition of the cell105. Table 2 
below describes the different responses of the different splice variants of either human or rat PAC1 
receptor to PACAP-27, PACAP-38 or VIP binding.  
 
Table 2: Pharmacological characteristics and signal transduction mechanisms associated with human and rat PAC1 receptor 
and their splice variants 101,106-108,136,138,142,143.  
 
Transduction Mechanisms 
Adenylate Cyclase Phospholipase C Calcium Receptor Binding affinity Splice Variants Stimulates cAMP 
production 
Stimulates inositol 
phosphate turnover  
null 
SV-1 
SV-2 
SV-3 
Kd 
P38 ≈ P27 >> VIP 
very short 
P38 ≈ P27 >> VIPHuman 
PAC1 
Kd 
P38 ≈ P27 ≈ VIP short P38 ≈ P27 ≈ VIP 
P38 ≈ P27 
(VIP unknown) 
Stimulates calcium 
mobilization 
short/normal 
Hop-1 
Hop-2 
Hip-Hop 
P38 > P27 >> VIP 
Hip - 
Kd 
P38 ≈ P27 >> VIP 
vs 
P38 ≈ P27 >> VIP
P38 ≈ P27 >> VIP 
Kd 
P27 > P38 3a P27 > P38 P27 > P38 
Stimulates calcium 
mobilization Rat 
PAC1 
? TM4 - - Calcium  efflux by L-type channel 
Table modified from Vaudry et al. 2000104. 
 
Differences in response seem to divide the splice variants into two groups: one containing splice 
variants in the N-terminal extracellular region, where the major effect appear to be the conformational 
changes in the receptor/ligand interaction and smaller effect on the response. For example the rat 
PAC1-3a that substantially alters PACAP-27 and PACAP-38 ligand binding affinities making PACAP-
27 the more potent agonist142. The human PAC1 receptor is the only one of the splice variants known 
to be activated by VIP, although with a slightly less efficient stimulation of cAMP production106. It is 
noteworthy that splice variants in the N-terminal extracellular domain enhances receptor coupling to 
inositol phosphate production relative to cAMP formation101. 
The other group involves the splice variants in the third intracellular loop and transmembrane domains, 
where the major effect is changes in signal response and the magnitude of signal response is no longer 
dependent on which ligand that binds to the receptor. This is not surprising since this group is able to 
interact directly with G protein subunits. Examples of highly altered responses is the rat PAC1-TM4, 
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which is coupled to Ca2+ mobilization through the activation of L-type Ca2+ channels, but without the 
activation of AC or PLC105,143, and the rat PAC1-hip splice variant which abolishes PLC stimulation and 
slightly reduces the AC stimulation108. 
 
Differences in responses also exist between species. Unlike the rat, all of the human splice variants are 
capable of stimulating both cAMP and inositol phosphate with nearly identical potencies. The efficacy 
of PACAP-stimulated activation of PLC varies for the particular human splice variant, with the human 
PAC1-SV-2 being the most efficacious. Similar to the efficacy for stimulating PLC, the human      
PAC1-SV-2 shows the strongest coupling to the expression of the immediate-early gene expression. 
The physiological significance of this differential signaling may in part be dependant on the cell-specific 
expression of human PAC1 receptor splice variants similar to that observed in the rat107.  
 
The concentration of PACAP can also influence the character of the cellular response. Observations by 
Daniel et al. 2001 suggest that, at low concentrations of PACAP (10-50% of receptor occupancy) the rat 
PAC1 receptor is coupled to exclusively to Gs and cAMP formation. At higher concentrations of 
PACAP the receptor recruits Gq, resulting in the activation of phospholipase C and the formation of 
inositol phosphates. They also suggested that the PAC1 splice variant rat PAC1-3a is predominately 
couples to Gs and the cAMP pathway at all concentrations of PACAP and only begins to recruit Gq at 
very high concentrations of PACAP, equivalent or close to 100% receptor occupancy142. This may 
indicate that the molecular interactions within the binding site, preferentially couples with a specific G 
protein i.e. G protein subtypes are critical for PACAP response in different cells137.  
 
These structural and functional differences in the PAC1 receptor splice variants may help explain the 
differences in ligand affinity and potency for stimulation of different intracellular signals observed in a 
variety of native cells, and therefore may represent a novel signaling pathway in which ligand-activation 
of a specific receptor splice variant may induce varying degrees of cellular responces107. 
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3 Experimental strategy 
As described in chapter 0, the aim of this master thesis is to investigate two problems:  
? Chemistry: Evaluating the acid hydrolysis of tyrosine sulfate in the pH 1 to 3 range, at various 
physical parameters including different temperatures, incubation times, in different acids and in 
addition the effect of primary amino acid sequence on the hydrolysis rate. 
? Biology: Search for new GPCRs that are targets for tyrosine sulfation, and determine what 
effect the sulfated tyrosines might have on ligand binding and signal transduction. 
The flow diagram below is an overview of the experiments performed within the work of this thesis:  
 
 Search for tyrosine sulfated GPCRs
I 
Acid hydrolysis – determination of the 
magnitude, reaction rates and factors 
influencing reaction rate. 
Acid incubations of a sulfated peptide at 
different: 
- Concentrations of acid.                    
- Temperatures.                    
- Incubation times.                     
- Acids. 
Peptide analysis by FPLC (ion-exchange 
column chromatography). 
II 
The effect of amino acid composition 
on hydrolysis: 
- Acid incubations of three small sulfated 
peptides. Analysis by FPLC.                       
- Hydrolysis analysis of whole cell lysates 
by [35S]-SO4 labeling of cells.  
VI 
Identification of sulfated tyrosines: 
- Expression and column purification of 
recombinant receptor.                        
- Identification of sulfated tyrosines by MS. 
IV 
Mutational analysis - effect on ligand 
binding: 
- Mutation of the tyrosines in question.          
- Saturation and competitive binding assays, 
wild type versus mutant. 
V 
Mutational analysis – effect on second 
messengers: 
- Mutation of the tyrosines in question.          
- Measure differences in cAMP levels, wild 
type versus mutant. 
Acid lability of tyrosine sulfate
STRATEGY 
III 
Selection of the PAC1 receptor: 
- Bioinformatic search though databases 
with known GPCR sequences. 
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The sulfate group has been described as very acid labile in high acid concentrations, but little is known 
about the hydrolysis at more modest acid concentrations. The experiments began with the acid 
incubations of sulfated peptides to establish the stability of tyrosine sulfate in the acids that were going 
to be used in purification of the receptor and mass spectrometry analysis. The lability of tyrosine sulfate 
was examined at different concentrations of acid, different types of acids, different incubation times 
and different temperatures. None of these parameters has previously been investigated with peptides, 
but is very relevant in laboratory praxis. Experiments were conducted with three different sulfated 
peptides and whole cell lyseates, to establish what effect differences in primary amino acid structure had 
on acid hydrolysis of the sulfated tyrosines.  
 
Within recent years a growing number of GPCRs have been found to contain tyrosine sulfate, making 
this modification more common than previously assumed. Here the available amino acid sequences of 
human GPCRs were screened to search for receptors that might be targets for tyrosine sulfation. 
Among these the PAC1 receptor was selected to be analyzed for the presence of sulfated tyrosines. The 
experiments involved mutagenesis studies of the receptor, where the tyrosines in question were 
mutated, in order to analyze changes in the binding affinity and/or second messenger coupling. 
Identification of sulfated tyrosine(s) involved expression and purification of the recombinant receptor 
before analysis for sulfated peptide fragments by mass spectrometry. 
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4 I - Acid hydrolysis of tyrosine sulfate 
To investigate the hydrolysis of tyrosine sulfate in acidic solutions the small peptide sulfated gastrin-17 
was used as a model. Sulfated gastrin-17 was incubated in various concentrations of acid, various 
temperatures and in different acids. The pH range chosen for the experiments was pH 1 to 3 since 
earlier studies79 have shown that the hydrolysis of aryl sulfates was pH-independent between pH 4 to 
12 and that the hydrolysis was greatly accelerated in strong acids pH < 1.  
4.1 Materials and methods 
Ion-exchange chromatography:  
Anion-exchange chromatography was performed on a FPLC system ÄCTA Purifier (Amersham 
Pharmacia Biotech), using a MonoQ™ HR 5/5 column (Amersham Pharmacia Biotech) and a 2 ml 
injection loop. Buffer A was 50 mM pH 8.2 with 10% acetonitrile (ACN, Rathburn Chemicals Ltd.). 
Buffer B was equivalent to A with 1 M NaCl (Sigma). The procedure was adapted from Bundgaard et al. 
1996144. Gastrin II and its decomposition products were eluted using a linear gradient (40 minutes) of 
NaCl from 0-70% buffer B at 1 ml/min. Sulfated gastrin eluted at app. 45% buffer B and nonsulfated 
gastrin eluted at app. 35% buffer B (see supplement 13.4). 
Incubation of sulfated gastrin-17 at acidic pH:  
Sulfated gastrin-17 (Gastrin II, Sigma) was dissolved in sterile water at a concentration of 1 mM. 3 µl (3 
nmoles) of sulfated gastrin-17 was incubated in 50 µl of diluted acid (for final acid concentrations se 
table 3) (TFA (Merck), Formic Acid (Merck) or HCl (Bie & Berntsen A-S)) at various temperatures and 
for increasing time points as described in results. All acid dilutions were made in water. At the end of 
incubation, the mixture was quenched/neutralized with 1.9 ml buffer A and the sample was injected 
and analyzed on the FPLC. Absorbance was measured at a wavelength of 220 nm, characteristic of the 
peptide bond. The integral of the peaks were summed as an indication of total amount of peptide 
loaded on the FPLC. The amount of sulfated gastrin remaining after acid incubation (integral of the 
sulfated gastrin peak) was calculated as the percentage of total amount of peptide. All results were 
performed at least in duplicate. 
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Statistics:  
Data are presented as mean ± SD (standard deviation). The paired t-test (GraphPad Prism software, v. 
4.0) was used to determine significant differences between different curves; P < 0.05 was considered 
statistically significant. 
4.2 Results 
4.2.1 The effect of pH on hydrolysis of tyrosine sulfate 
The first experiments were conducted to investigate the amount of hydrolysis in the pH 1 to 3 range. 
Sulfated gastrin-17 was incubated in 6.5 mM, 13.1 mM, 26.1 mM, 39.2 mM, or 65.3 mM TFA (0.05%, 
0.1%, 0.2%, 0.3% or 0.5% respectively, pH 1.3 to 2.3). The concentrations of TFA were chosen on the 
basis of percentages commonly used protein purification and analysis. In addition, the experiments 
were done at two different temperatures (24°C and 37°C) and at three different incubation times (1, 24, 
and 72 hours) to give an indication of the hydrolysis reaction rate. After incubation the samples were 
neutralized in buffer A and analyzed on the FPLC (chromatogram examples are presented in 
supplement 13.4). The results are shown in figure 14.  
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Figure 14: Hydrolysis of tyrosine sulfate in the peptide gastrin-17. Sulfated gastrin-17 incubated in various 
concentrations of TFA for either 1, 24 or 72 hours. The experiments were performed at A: 24°C and B: 37°C because of the 
small amount of hydrolysis observed at 24°C. N=1 for 1 hour incubation at both 24°C and 37°C, N=3 for 24 and 72 hour 
incubation at both 24°C and 37°C. 
 
As expected both the graphs illustrates that the amount of hydrolysis increases with the acidity of the 
solution. A rise in hydrolysis rate was observed with increasing time and higher temperatures. 
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Incubation for 1 hour had almost no effect on hydrolysis at both 24°C and little effect at 37°C. 
Increasing the incubation time to 24 or 72 hours at 24°C led to a small increase in hydrolysis, but still 
statistically significant (P < 0.005). At 37°C the hydrolysis increased more markedly, where the 
hydrolysis in all three incubation periods was statistically significant different from those observed at 
24°C (P < 0.05). It was noteworthy that leaving sulfated gastrin-17 in highest concentration of TFA 
(65.3 mM, 0.5% TFA, pH 1.3) at 37°C for 3 days only reduced the amount of sulfated peptide to 
approximately 50%.  
4.2.2 Temperature effect on the acid hydrolysis 
No exact temperature dependence has been reported for the hydrolysis of tyrosine sulfate. Experiments 
with aryl sulfates have shown that the rate of hydrolysis increased as the temperature was raised.  
In these experiments sulfated gastrin-17 was incubated in a fixed acid concentration, 13.1 mM TFA 
(0.1%, pH 2), which is the acid concentration typically used in various solutions prior to MALDI mass 
spectrometry identification. The results are shown in figure 15.  
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Figure 15: The effect of temperature on hydrolysis rate. Sulfated gastrin-17 was incubated for 3 or 24 hours in 13.1 mM 
TFA at increasing temperatures. N=2 for incubation at both 3 and 24 hours. 
 
As expected the hydrolysis rate increased with temperature. After 3 hours of incubation an increase in 
hydrolysis did not occur until the highest temperatures, 60°C and 70°C. Incubation for 24 hours 
increased hydrolysis markedly, where the increase started at around 35°C and leaving only 
approximately 10% sulfated gastrin-17 remaining at 70°C. Although hydrolysis increased at higher 
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temperatures, only marginal hydrolysis was observed at temperatures below 24°C, which means that a 
sulfated peptide might easily be handled at pH 2 at room temperature without risking hydrolysis 
4.2.3 The effect of different acids on hydrolysis rate 
Experiments with aryl sulfates have shown a difference in hydrolysis rate with different acids at 
dilutions with the same pH. The catalytic power of the three acids was in the order H2SO4 > HClO4 > 
HCl79, which indicated that not only proton concentration but also the anion of the acid influenced the 
hydrolysis reaction. To compare the effect of different acids on the hydrolysis rate of tyrosine sulfate, 
sulfated gastrin-17 was incubated in either FA or HCl and the results were compared to the results with 
TFA. The concentrations of the acids used are described in table 3:  
 
Table 3: The various concentrations of TFA, FA and HCl used in the experiments. 
 
Acid Concentration Percent pH 
6.5 mM 0.05% 2.2 
13.1 mM 0.1% 2.0 
26.1 mM 0.2% 1.7 
39.2 mM 0.3% 1.5 
TFA 
65.3 mM 0.5% 1.3 
0.027 M 0.1% 2.6 
0.053 M 0.2% 2.5 
0.106 M 0.4% 2.3 
0.212 M 0.8% 2.1 
FA 
0.398 M 1.5% 2.0 
0.003 M  2.5 
0.01 M  2.0 
0.017 M  1.75 
0.03 M  1.5 
HCl 
0.1 M  1.0 
 
The experiments were conducted at 37°C since this temperature had a greater effect on the hydrolysis 
rate and would make it easier to se a possible difference as compared to 24°C as shown in the first 
experiment. After incubation samples were neutralized in buffer A and analyzed on FPLC. The results 
are shown in figure 16. 
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Figure 16: Incubation of sulfated gastrin-17 in different acids. Sulfated gastrin-17 incubated in five concentrations of 
three different acids, hydrochloric acid (HCl), trifluoroacetic acid (TFA) and formic acid (FA), resulting in a pH range from 
pH 1 to pH 3. The samples were incubated at 37°C for 24 (A) or 72 (B) hours to evaluate difference over time. N=2 for 
HCl and FA incubations and N=3 for TFA incubations. 
 
The results showed no difference in hydrolysis rate between the three acids TFA, FA or HCl within the 
experimental setup. A difference might be seen at higher temperatures or at higher acid concentrations.  
4.2.4 Reaction rate and order for the hydrolysis of tyrosine sulfate 
Both the neutral and acid hydrolysis of nitrophenyl and dinitrophenyl sulfates (NPS) follows a first-
order reaction mechanism77-79 with the reaction rate r and reaction constant k : 
 SNPNPS +→  [ ]NPSkr =  
For a first-order reaction, the concentration of reactant, [A], decreases exponentially with time t 
[ ] [ ] tkAeAA −= 0         or 
[ ]
[ ]
tk
A
A
A−=
0
ln  
where a plot of ln ([A]/[A]0) versus t gives a straight line with the slope kA.  
 
To investigate if the hydrolysis of tyrosine sulfate was a first-order reaction, sulfated gastrin-17 (sG-17) 
was incubated in 65.3 mM TFA (0.5% TFA, pH 1.3) at 37°C for 14 to 216 hours, to do a plot of ln 
([sG-17]/[sG-17]0) versus t. The results are shown in figure 17. 
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Figure 17: Hydrolysis of tyrosine sulfate as a function of time. Sulfated gastrin-17 was incubated in 65.3 mM TFA 
(0.5% TFA, pH 1.3) at 37°C for 14 to 216 hours, N=2. A: The one phase exponential decay with t½ = 73.5 hours. B: The 
same data as A, changing the Y-axis to ln produces as a straight line, with slope ksG-17= 2.62*10-5 s-1. 
 
The graph on the left (fig. 17A) illustrates that the amount of sulfated gastrin-17 decreased 
exponentially with time. The reaction is of first-order which is illustrated with the graph in figure 17B, 
where a plot of ln[sG-17]/[sG-17]0 versus t  gives a straight line of slope ksG-17. The reaction is of first-
order with respect to [H+] and the rate law of the hydrolysis reaction is: 
r = k[sG-17]*[H+] 
The half-life, t½ , and rate constant, ksG-17, of the reaction was calculated from the curves in figure 17 
giving t½= 73.5 hours and ksG-17 = 2.62*10-5 ± 0.22 s-1, respectively (65.3 mM TFA, 37°C) (see 
supplement 13.7 for calculations).  
In the literature tyrosine sulfate is described as very acid labile, and it was therefore interesting to note 
that in this TFA concentration (65 mM) and at this temperature (37°C), the time it took to halve the 
amount of sulfated gastrin-17 was over three days. 
4.2.5 Temperature effect on the rate constant 
Rate constants depend strongly on temperature (T) typically increasing rapidly with increasing T, and 
k(T) data for many reactions fit the Arrhenius equation 
 
RTEaAek /−=  
where Ea is the Arrhenius activation energy (independent of T) end A is the Arrhenius A factor (pre-
exponential factor or frequency factor). If the Arrhenius equation is obeyed, a plot of log10k versus 1/T 
is a straight line with the slope -Ea/2.303R and the Y-intercept log10A. 
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It was tested whether the hydrolysis reaction of tyrosine sulfate obeyed the Arrhenius equation by 
repeating the time curve experiment at two other temperatures, 50°C and 70°C, and comparing the 
data with that found at 37°C (fig. 18). 
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Figure 18: Hydrolysis of tyrosine sulfate as a function of time and temperature. Sulfated gastrin-17 was incubated in 
65.3 mM TFA (0.5% TFA, pH 1.3) at 37°C, 50°C or 70°C for increasing time points. A: The graph shows the one phase 
exponential decay of the hydrolysis at the three different temperatures with the half-lives t½ = 73.5 hours at 37°C, t½ = 13.3 
hours at 50°C, and t½ = 1.8 hours at 70°C. B: The rate constants of the hydrolysis reaction at the three different 
temperatures are plotted as a function of temperature; ksG-17 = 2.62*10-5 s-1 at 37°C, ksG-17 = 1.44*10-4 s-1 at 50°C, and ksG-17 = 
1.05*10-3 s-1 at 70°C.  
 
The rate constants determined by the time curves in figure 18A (table 4) were plotted against the 
temperature (fig. 18B).  
 
Table 4: The half-lives and rate constants of the hydrolysis of tyrosine sulfate in sulfated gastrin-17. 
 
Temperature t ½ k (s-1)(*10-4) 
37°C 73.5 h 0.262 ± 0.022 
50°C 13.3 h 1.443 ± 0.853 
70°C 1.8 h 10.503 ± 0.248 
 
This produced a straight line and the hydrolysis of tyrosine sulfate therefore follows the Arrhenius 
equation. From the Y-intercept the Arrhenius A factor was calculated to be A = 1.1*1012 s-1 and from 
the slope the activation energy was calculated to be Ea = 23.6 ± 1.2 kcal mol-1 (see supplement 13.7 for 
calculations). 
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4.3 Discussion 
The small tyrosine sulfated peptide gastrin-17 has been used as a model to determine acid lability of the 
sulfate group. Incubating sulfated gastrin-17 in TFA in the pH 1.3 to 2.3 range demonstrated that the 
sulfate group was actually fairly stable when working at room temperature. At a temperature of 37°C 
and at a TFA concentration of 65.3 mM, 40% sulfated gastrin-17 still remained after three days, which 
clearly indicates that loss of the sulfate group during peptide purification can be eliminated, at least if 
the pH is kept above pH 1. Of course at lower pH (pH< 1) the hydrolysis is greatly accelerated and if 
using solutions at these pH values, it will be necessary to adjust the temperature. In earlier research 
synthetic sulfated peptides have been purified in 90% TFA, but when the sample was kept at zero 
degrees Celsius little to no hydrolysis occurred within 7 hours74.  
In this study the temperature dependency of the hydrolysis showed that, at least at pH 2, an increase in 
hydrolysis did not occur until about 40°C. This nick in the hydrolysis curve would possibly shift to a 
lower temperature as pH decreases, but this remains to be investigated. Most important is, sulfated 
peptides can easily be handled at room temperature, and for three hours it is possible work at 
temperatures up to 60-70°C only loosing 20-30% of the sulfated peptide. 
 
An interesting aspect of acid hydrolysis is the possible effect of the anion of the acid. Research by 
Fendler & Fendler 196879 demonstrated that the hydrolysis of nitrophenyl and dinitrophenyl sulfates 
were catalyzed differently by three different acids. We decided to investigate if the hydrolysis of tyrosine 
sulfate depends on more than the proton concentration, but we chose three different acids more 
commonly used when handling peptides and proteins; TFA, FA and HCl. The results showed no 
difference in the rate of hydrolysis between these three acids within the experimental setup. An 
explanation could be that the data obtained in the Fendler & Fendler 196879 study had acid 
concentrations of 1 M and higher79, which is at least 10-fold higher than the concentrations of TFA, FA 
and HCl used here. This means that there could be a difference in hydrolysis rate between TFA, FA 
and HCl but the difference is too small to be observed at the parameters investigated. Further 
experiments could include higher acid concentrations and in addition, include H2SO4 and HClO4 to 
compare the results with the data obtained from the nitrophenyl and dinitrophenyl experiments.  
 
Hydrolysis of aryl sulfates is a first-order reaction with respect to the aryl sulfate77-79. In this work the 
hydrolysis of tyrosine sulfate was also found to be of first-order with a half-life of t½ = 73.5 hours and 
the rate constant ksG-17 = 2.62*10-5 s-1 (65.3 mM TFA, pH 1.3 and 37°C). It can be argued that the 
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reaction is pseudo first- order, since some of the H+ is consumed in the reaction, owing to the higher 
pKa value of the resulting phenol. But the protons are present in great excess and the concentration will 
therefore remain virtually unchanged throughout the reaction. Secondly, the anion of the acid might 
have a catalytic influence on the hydrolysis, indicating a pseudo first-order reaction, but since the results 
at this point were unclear, this is merely speculation. 
 
At higher temperatures and lower pH an increasing amount of peptide degradation begins to occur, 
maybe resulting in side reactions that could influence the rate law, giving inaccurate t½ and k values. 
This was investigated by determining the rate constant ksG-17 at different temperatures, which were 
plotted as log10k versus 1/T. The result was a straight line indicating that the rate constant only 
depended on the temperature and was not influenced by side reactions. The data fit the Arrhenius 
equation from which Arrhenius A factor and the activation energy Ea were calculated. The Arrhenius A 
factor was calculated from the Y-intercept, A = 1.1*1012 s-1. For a unimolecular reaction A is typically145 
1012 to 1015 s-1, which together with the reaction being first-order (pseudo) could indicate that the acid 
hydrolysis of tyrosine sulfate follows a unimolecular reaction mechanism. Acid hydrolysis of aryl 
sulfates show unimolecular78,79 characteristics but at the same time seems to have water molecules 
participating in the transition state76,77,80. It can therefore not be concluded that the acid hydrolysis of 
tyrosine sulfate is a solely unimolecular reaction, since water molecules could be involved, and this 
aspect requires further investigation.  
 
From the slope of the Arrhenius plot the activation energy was calculated to Ea = 23.6 kcal mol-1. This 
value was similar to the activation energy determined for pNPS by Fendler and Fendler in 1968 where 
Ea = 22.6 kcal mol-1, Ea = 22.2 kcal mol-1, Ea = 23.1 kcal mol-1 (25°C) for hydrolysis in 1.02 M HCl, 
1.00 M HClO4 or 1 M H2SO4 respectively. The Ea value was slightly higher for tyrosine sulfate than for 
pNPS, but this was expected since tyrosine does not have an electron-withdrawing group as para-
substituent allowing resonance stabilization of the resulting phenol. The Ea value is consistent with a 
much weaker S-O bond in the ester since various S-O bond dissociation energies are normally much 
larger: the bond strength in the diatomic S-O molecule146 is 124.4 kcal mol-1, S-O bond dissociation 
energies of 84-123 kcal mol-1 for sulfoxides (R2SO) and sulfones (R2SO2) with various substitutions147, 
and the average bond dissociation enthalpy148 of S-O is ∆H° = 87 kcal mol-1. The weaker S-O bond in 
tyrosine sulfate and phenyl sulfates is most likely the reason for acid lability of the sulfate ester.
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5 II - The effect of amino acid composition on acid hydrolysis 
To evaluate the influence of the peptides amino acid composition on the acid hydrolysis, three different 
small peptides and whole cell lysates were analyzed. In the first experiments the hydrolysis of sulfated 
gastrin-17 was compared to the hydrolysis of two other small peptides, caerulein and drosulfokinin. 
The amino acid sequences of the three peptides are shown in figure 19.  
 
Figure 19: The amino acid composition of the three peptides used in the acid lability experiments. The experiments 
are conducted with the three small tyrosine sulfated peptides gastrin-17, drosulfokinin and caerulein. 
 
The three peptides used are relatively small and their structures are random coils. This limits the effect 
of structure on acid lability to the primary structure. 
To provide a more general picture of hydrolysis due to acid lability, whole cell lysates were analyzed. 
These experiments included the rat pheochromocytoma cell line PC12. The cells were incubated with 
radio labeled sulfate, to incorporate the labeled sulfate in to cellular expressed proteins. The cells were 
lyzed and proteins were separated by SDS gel electrophoresis. Acid incubations of the gels with the 
separated proteins were compared to a gel with the same samples incubated in milliQ water. This made 
it possible to compare the amount of radioactivity lost during the acid incubations, a method employed 
from Lee and Huttner 198363. To avoid contributions from the radio labeled sulfate sugar groups, two 
glycosylation inhibitors were applied, one N- and one O-glycosylation inhibitor, tunicamycin and 2-68A, 
respectively.  
5.1 Materials and methods 
Acid incubations of sulfated drosulfokinin and caerulein:  
Sulfated drosulfokinin (Cambridge Research Biochemicals) was dissolved in sterile water in a 
concentration of 1 mM. Sulfated drosulfokinin (6 µl, 6 nmoles) was incubated in 100 µl of TFA (99%, 
Merck) in the different concentrations, 6.5 mM, 13.1 mM, 26.1 mM, 39.2 mM, or 65.3 mM (0.05%, 
0.1%, 0.2%, 0.3% or 0.5% respectively, pH 1.3 to 2.3) at 37°C for 72 hours. Sulfated caerulein 
(Peninsula Laboratories Inc.) was dissolved in 0.1 M NH3/H2O to a concentration of 0.5 mg/ml    
(0.37 mM). Sulfated caerulein (16 µl, 6 nmoles) was incubated in 120 µl of TFA (Merck) of the same 
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concentrations and at the same temperature as with drosulfokinin. The shift in pH due to ammonia was 
negligible. All acid dilutions were made in milliQ water. At the end of incubation, the mixture was 
quenched/ neutralized with 1.7 ml buffer A (50 mM Trizma Base adjusted with HCl to pH 8.2, 10% 
ACN) and the sample was injected and run on the FPLC as done with gastrin-17. Drosulfokinin and its 
decomposition products were eluted using a linear gradient (60 minutes) of NaCl from 0-25% buffer B 
(50 mM Trizma Base adjusted with HCl to pH 8.2, 10% ACN, 1 M NaCl) at 1 ml/min. Sulfated 
drosulfokinin eluted at app. 10% buffer B and nonsulfated drosulfokinin eluted at app. 2% buffer B 
(see supplement 13.5). Caerulien and its decomposition products were eluted using a linear gradient (40 
minutes) of NaCl from 0-35% buffer B. Sulfated caerulein eluted in two peaks at app. 20% and 30% of 
buffer B and nonsulfated cearulein also eluted in two peaks at app. 7% and 15% buffer B (see 
supplement 13.6). The presence of two peaks was a result of oxidation of the peptide. The integral of 
the peak/peaks were summed as an indication of total amount of protein loaded on the FPLC. The 
amount of sulfated peptide remaining after acid incubation (integral of the sulfated peptide peak) was 
calculated as the percentage of total amount of peptide. All results were performed in 2 to 4 replicates. 
Confirmation of FPLC peak fractions by mass spectrometry: 
The various FPLC peak fractions of the drosulfokinin and caerulein peptides were collected and 
analyzed by mass spectrometry to determine the identity of the different peaks.  
To the collected fractions were added FA to 0.5% and they were analyzed by LC-MS on a CAP-LC / 
Q-TOF 2 system (Micromass, Waters) equipped with an analytical dC18 Atlantis column 75 µm x 150 
mm (Waters). The sample (20 µl) was injected in each run and loaded to a precolumn which was 
washed in 0.2 % FA. The sample was eluted by a gradient over the analytical column from 15-40% B 
over 25 minutes and then washed in 80 % B (A: 5% ACN, 0.2% FA and B: 95% ACN, 0,2% FA), the 
flow was app. 400 nl/min provided by flowsplitting. The mass spectra were obtained from 250 to 2000 
m/z and the most abundant ions were analyzed by MSMS for identification. 
Cell cultures:  
PC12 were grown to confluence in Dulbecco’s Modified Eagles Medium (DMEM), + 4500 mg/L 
Glucose, + GlutaMAXTMI, - Pyruvate (Gibco/Invitrogen Corporation) supplemented with 10% fetal 
bovine serum (FBS) (Gibco/Invitrogen Corporation) and 1% penicillin-streptomycin (P/S, Sigma) in 
an incubator at 10% CO2 and 37°C. In a 6 well dish, precoated with polylycin (Sigma), 106cells/well 
were plated in the same incubation medium and allowed to settle overnight. The next day the medium 
was aspirated and the cells were washed once in PBS. Fresh F12 (Ham) Nutrient mixture 
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+GlutaMAXTMI  (Gibco/Invitrogen Corporation) medium supplemented with 1% FBS was added      
(1 ml/well) and the cells were incubated for 1 hour in the incubator. Then glycosylation inhibitors were 
added; 5 µg/ml tunicamycin (Sigma) or/and 100 µM 2-68A (Kindly donated by Dr. Cheryl McVaugh, 
Howard Hughes Medical Institute, University of California) to the wells (both glycosylation inhibitors 
were dissolved in DMSO); one well with tunicamycin alone, one well with 2-68A alone, one well with 
both tunicamycin and 2-68A and one well without glycosylation inhibitors as control. No replicates 
were made. Incubation in incubator continued for another 15 minutes to allow the inhibitors to enter 
the cells. At last radio labeled 35SO42- (as sodium salt) was added in a final concentration of 0.5 Ci/ml 
and the incubation continued for two hours in the incubator. After incubation the medium was 
aspirated and the cells were again washed once in PBS. To each well 200 µl loading buffer (10 mM 
Trizma Base adjusted with HCl to pH 8, 8% SDS, 40 mM DTT, 40% glycerol and bromphenolblue) 
was added directly, a cell-scraper was used to collect the cell lysate, which was then pipetted into 
eppendorf tubes. The samples were placed directly in a heating block at 96°C for 5 minutes to denature 
the proteins. A micro-syringe was used to homogenize the samples. The samples were either loaded 
directly onto the gel or stored at -20°C. Three independent experiments were performed, for use in the 
three different acid incubations described next. 
Protein separation and acid incubations:  
Three different independent acid incubations were made from the following procedure: A 10% SDS gel 
was casted and running buffer was added to the chamber (see supplement 13.10). The PC12 cell lysate 
samples from above were loaded on the gel in duplicates (one part to use in the acid incubations and 
one part as control). The gel was run at 40V over night. The next day voltage was elevated to 80V and 
the running continued until the bromophenolblue front reached the bottom of the gel. The gel was 
then washed several times in milliQ water for half an hour and dyed in Bio SafeTM Coomassie (BioRad) 
over an hour. The gel was again washed several times in milliQ water for an hour. After wash the 
protein bands were fixated in 45% ethanol and 5% acetic acid over an hour. The part of the gel 
dedicated for acid experiments was cut out and the rest of the gel remained in milliQ water. Three 
different acid incubations were included; overnight incubation in 0.5 M HCl, overnight incubation in 
6.53 M TFA (50%) at room temperature or half an hour incubation in 1 M ice-cold HCl prior to 
incubation in 1 M HCl at 93°C as described in Huttner 19843. After the acid incubations the gel pieces 
were washed in milliQ water one hour with several water shifts, coomassie stained one hour and 
washed again in milliQ water one hour with several water shifts. The gel was then dried in a Gel Dryer 
(Model 583, BioRad) for two hours at 80°C. The dried gel was placed on a screen in a cassette for three 
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days and the amount of radiolabeling was quantified on a FUJIX BAS 2000 using the software 
programs BAS Reader 2.9 and TINA 2.0. 
Statistics:  
Data are presented as mean ± SD The paired t-test (GraphPad Prism software, v. 4.0) was used to 
determine significant differences between the different curves; P < 0.05 was considered statistically 
significant. 
5.2 Results 
5.2.1 The hydrolysis of tyrosine sulfate in three peptides 
The two peptides caerulien and drosulfokinin were incubated in the five concentrations of TFA 
described in table 3, at 37°C for 72 hours. The identities of sulfated and nonsulfated peptide peaks in 
the resulting FPLC chromatograms were determined by analyzing the collected peak fractions with LC-
MS on a CAP-LC / Q-TOF 2 system. The FPLC results were compared to those obtained with the 
acid incubations of sulfated gastrin-17 (fig. 20) (see supplement 13.5 and 13.6 for chromatograms).  
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Figure 20: Hydrolysis on the basis of different amino acid composition. Gastrin-17, caerulein or drosulfokinin were 
incubated in 65.3 mM TFA at 37°C for 72 hours. N=3 for gastrin-17, N=2 for caerulein and N=4 for drosulfokinin. 
 
The data indicated a difference in the amount of hydrolysis with different primary structure of the 
peptides. Gastrin-17 appered more prone to hydrolysis, followed by caerulein and drosulfokinin having 
the most stable sulfate group of the three peptides. The data were compared in a paired t-test and the 
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results showed statistically significant differences between the three peptides, gastrin-17 and 
drosulfokinin (P = 0.0064), gastrin-17 and caerulein (P = 0.0046), or caerulein and drosulfokinin         
(P = 0.0148). 
5.2.2 Hydrolysis of tyrosine sulfate in whole cell lysates 
PC12 cell cultures were incubated with [35S]-SO42- for two hours to allow incorporation of the radio 
labeled sulfate in to cellular expressed peptides and proteins. To minimize the amount of incorporated 
unlabeled sulfate, F12 culture media (Invitrogen) containing only 1% serum was used during the 
experiment. After incubation the cells were lyzed and proteins were separated on SDS gels. Figure 21 
below shows the radiography of three gels from three different independent experiments. In each case, 
one part of the gel was incubated in the acid and the other one in Milli-Q water, in order to compare 
the results, acid versus water, with equal loading of the samples.  
Figure 21: Radiographs of [35S]-SO42- labeled PC12 cell lysates separated by SDS gel electrophoresis. A: The 
method described by Huttner 19843, the right side of the gel has been incubated ½ hour in ice-cold 1M HCl and 5 minutes 
in 93°C 1 M HCl; B: The right side has been incubated in 0.5 M HCl over night; and C: The right side has been incubated 
in 6.53 M TFA (50%) over night. Tun – tunicamycin. 
 
The three gels each displayed a smear of radio labeled proteins with two distinct bands at approximately 
80 and 110 kDa. According to Lee & Huttner 1983 these bands contained four proteins determined by 
2-dimentional polyacrylamide gel electrophoresis (2D-PAGE) and autoradiography. These were 
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designated p113, p105, p86 and p84 on the basis of their molecular weights63 (The chromogranin 
proteins149).  
The incubation in 1 M HCl for 5 minutes at 93°C (gel A) and incubation in 6.53 M TFA (50%) over 
night at room temperature (gel C) reduced the intensities of the two bands and the intensity of the 
smear. Both the two bands and the smear were used to compare the amount of radio labeling in the 
water versus acid incubations of each experiment (table 5). 
 
Table 5: The intensity of the radioactivity from the three gels in figure 21. 
 
% Radio labeled protein remaining after acid incucbation compared to water incubation 
  
 
A: 1 M HCl B: 0.5 M HCl C: 6.53 M TFA 
[35S]-SO42- 46.1% 145.6% 42.4% 
[35S]-SO42-+ Tun 46.3% 143.0% 41.8% 
[35S]-SO42-+ 2-68A 40.4% 132.4% 44.8% 
Band ~80 kDa 
[35S]-SO42-+ Tun + 2-68A 36.5% 107.2% 41.9% 
[35S]-SO42- 58.4% 134.3% 53.1% 
[35S]-SO42-+ Tun 59.6% 111.9% - 
[35S]-SO42-+ 2-68A 51.1% 112.2% - 
Band ~120 kDa 
[35S]-SO42-+ Tun + 2-68A 53.7% 99.1% - 
[35S]-SO42- 78.9% 123.4% 55.5% 
[35S]-SO42-+ Tun 87.1% 110.6% 55.4% 
[35S]-SO42-+ 2-68A 77.8% 110.0% 56.6% 
Smear 
[35S]-SO42-+ Tun + 2-68A 75.7% 103.0% 54.5% 
A: The gel incubated in water/1M HCl, boiled; B: The gel incubated in water/0.5M HCl, overnight; and C: The gel 
incubated in water/6.53 M TFA, overnight. The intensity was measured as percent reduction in radioactivity of the gel 
incubated in acid compared to the gel incubated in water.  
 
According to the table, the largest effect seemed to be incubation over night in 6.53 M TFA (50%) 
where the band at 80 kDa was reduced to approximately 40%, and the band at 110 kDa and the smear 
reduced to approximately 50%. The table also shows that there was no effect of the glycosylation 
inhibitors, since the percentages were similar to those with [35S]-SO42- alone. Incubation over night in   
1 M HCl at room temperature increased the amount of radioactivity, indicating an experimental error, 
but of which kind was not known. 
Sulfate on sugar groups is not hydrolyzed by acid as is the sulfate bound to tyrosine residues. The 
amount of radioactivity from the bands and the smear that disappeared during the acid incubations was 
most likely from the hydrolysis of tyrosine sulfate. But this still leaves a large amount of smear most 
likely sulfate incorporated in sugar groups. Even in the lanes with samples containing glycosylation 
inhibitors showed a smear after acid incubation, indicating that the glycosylation inhibitors had little 
effect. It was not possible to increase the incubation time with the glycosylation inhibitors, in order to 
avoid this incorporation, since the O-glycosylation inhibitor 2-68A is very toxic. 
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5.3 Discussion 
Acid hydrolysis of tyrosine sulfate has been investigated on the basis primary peptide structure. The 
three peptides used, gastrin-17, caerulein and drosulfokinin are small limiting their structures to random 
coils. When incubated in aqueous TFA solution gastrin-17 was most prone to acid hydrolysis, followed 
by caerulein and drosulfokinin as the least prone to acid hydrolysis.  
 
Figure 22: The amino acid composition of the three peptides used in the acid lability experiments. The experiments 
are conducted with the three small tyrosine sulfated peptides gastrin-17, drosulfokinin and caerulein. 
 
Caerulein and drosulfokinin have almost the same number of amino acids (10 and 11, respectively), but 
the sulfate group in caerulein was slightly more acid labile than in drosulfokinin. Since the two peptides 
have almost equal length, and drosulfokinin contain more acidic amino acids than caerulein (3 vs. 2), 
the difference might be explained by drosulfokinin containing two basic amino where caerulein has 
none. Research by Yagami et al. 200074, indicated that the presence of the basic amino acid, arginine, at 
position -2 to the sulfated tyrosine in the CCK peptide stabilized the sulfate group by forming a 
conjugate acid-base pair. Drosulfokinin contains a histidine situated +2 and an arginine situated +4 
residues from the tyrosine, both basic amino acids capable of forming conjugate acid-base pairs with 
the sulfated tyrosine, which could explain the reduced hydrolysis observed.  
 
Yagami et al. 2000 found that for CCK peptides longer peptide chains protected the labile sulfated 
tyrosine residues against proton-catalyzed hydrolysis especially in the gaseous phase and to a less extend 
in acidic solutions where there is an excess of protons. In this study gastrin-17, having the longest 
peptide chain, was actually the peptide most prone to hydrolysis compared to caerulein and 
drosulfokinin. It can be argued that the presence of six acidic and no basic amino acids in gastrin-17 
probably makes the sulfate group more prone to hydrolysis, since the negative charges surrounding the 
sulfate creates electrostatic forces that repel the charged sulfate group. But at pH 1 to 3 the carboxyl 
group of both glutamate and aspartate will be almost fully protonated (pKa = 3.65 for aspartate and pKa 
= 4.25 for glutamate), neutralizing the negative charges. The reason for the higher acid lability in 
sulfated gastrin-17 is therefore difficult to evaluate. Yagami et al. 200074 also found that that the smaller 
gastrin-14 was more stable than gastrin-17 yet containing the same amount of acidic amino acids, and it 
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was even more stable than the longer gastrin-34. An argument could be that, although the peptide 
should be a random coil, the three additional N-terminal amino acids, pyroglutamic acid, glycine, and 
proline in gastrin-17 induce a conformational change in the molecule, creating electrostatic or 
electrodynamic forces that destabilize the sulfate group. This means the primary structure of the 
peptide is more important than the length of the peptide when determining the acid lability of the 
sulfate group. 
 
To evaluate the tyrosine sulfate lability in more complex protein solutions, whole cell lysates were used. 
Incorporation of radiolabeled sulfate and one-dimensional protein separation were used to visualized 
the tyrosine sulfated peptides and proteins (also sulfated sugar groups). As is seen in results, the gel-
separation resulted in a large smear, which we were unable to avoid. Although a few bands were visible, 
it is not known if other bands could be hidden within the smear of possibly sulfated proteoglycans or 
glycosaminoglycans. O-sulfation of threonine and serine could also be a factor contributing to the 
smear, but the occurrence of these modifications are generally very small compared to the amount of 
incorporated sulfate in proteoglycans or glycosaminoglycans and as tyrosine sulfate. The use of 
glycosylation inhibitors had little or no effect in reducing the smear, and elevating the concentration or 
incubation time was impossible because of the toxicity of especially the O-glycosylation inhibitor 2-68A. 
Another idea was employed to characterize the smear3, which was based on the evidence that the 
sulfated material in the high molecular regions of SDS-polyacrylamide gels (proteoglycans or 
glycosaminoglycans) does not appear to transfer very well from the gel to the nitrocellulose membranes 
used in western blots. The autoradiograms of the membranes should be “clearer” than those of the 
corresponding gels. When this method was employed to our experiments, indeed some of the smear 
remained in the gel, but much was still transferred to the nitrocellulose filter (data not shown). This 
gave no identification of the smear, and it is not plausible that the proteins transferred to the filter only 
consist of tyrosine-sulfated proteins. 
 
Another aspect is the presence of very few bands. According to Huttner 1984 only four tyrosine-
sulfated proteins have been identified in the PC12 cell line, which would give a very limited picture of 
the acid lability of proteins in general. We tried to induce cell differentiation with forskolin to enhance 
protein expression but this had little to no effect on the amounts of protein bands appearing in the gel 
(data not shown). We have also looked at other cell lines (AtT-20 and CHO), incubating the cells with 
[35S]-SO42- and separated the proteins by SDS gel electrophoresis (data not shown). All cell lines gave a 
smear, but the PC12 cells were the only ones with visible bands in the one-dimensional gel. 
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For all these reasons the experiments involving whole cell lysates were abandoned, because the results 
would be too diffuse and based on very few proteins to make any plausible and general conclusions. 
Investigations of the general acid lability of tyrosine sulfate therefore still rely on experiments on 
individual peptides.
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6 III - Screening for GPCRs with possible sulfation sites 
6.1 The choice of the PAC1 receptor 
One of the aims of this project was to identify new GPCR targets for tyrosine sulfation. Although there 
is no consensus sequence for tyrosine sulfation, some general characteristics might indicate a sulfation 
site.  
Human GPCRs with known amino acid sequences were screened manually based on the following 
three criteria’s, based on the characteristic features for tyrosine sulfation described in section 2.3.2:  
? Multiple acidic amino acids are situated close to the tyrosine, at best glutamate or aspartate at 
position –1 to the tyrosine. 
? Several tyrosines within close range or tandem repeated tyrosines. 
? The tyrosine(s) are located in the extracellular N-terminal domain and/or in the extracellular 
loop between the transmembrane segments 4 and 5 (see figure 23 below). 
 
 
Figure 23: A simplified illustration of a 7-transmembrane segment receptor (GPCR or 7TM receptors), where tyrosine 
sulfation might occur in the N-terminal extracellular domain and/or in the extracellular loop between the transmembrane 
segments 4 and 5 (2. loop). 
 
The major search was conducted on the GPCRs sequences150 where the cDNA were available for 
purchase151 (approximately 300 GPCRs). Roughly 50 of these human GPCRs posses’ candidate sites for 
tyrosine sulfation, containing the criteria listed above. These sites were screened with the Sulfinater∗ 
software tool96, but interestingly only a third of the candidate tyrosine sites mentioned above scored a 
hit in this tool, maybe questioning the predictive value of this tool (see section 2.3.2). 
                                                 
∗ http://www.expasy.org/tools/sulfinator/  
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Examples of possible tyrosine sulfated GPCRs: 
? GABA-B1 ~ Gamma-aminobutyric acid type B receptor:  PVDYEIEYVCR - Hit in Sulfinator. 
? KOR-1 ~ Kappa-type opioid receptor:   ISIDYYNMFT/FPDDDYSWWDL - Hits in Sulfinator. 
? NMU2R ~ Neuromedin U receptor type 2:  NSTEEYLAFLC - Hit in Sulfinator. 
? CALCR ~ Calcitonin receptor:   QFCPDYFPDFD - No hit in Sulfinator. 
? PTHR1 ~ Parathyroid hormon-related peptide receptor: PCPDYIYDFNH - No hit in Sulfinator. 
? SSTR2 ~ Somatostatin receptor 2:    QTEPYYDMTS - No hit in Sulfinator. 
? PAC1 ~ Pituitary a. c. activating polyp. type 1 receptor: DEYESETGDQDYYYLS - Hit in Sulfinator. 
 
The PAC1 receptor was chosen because it contains all the three criteria’s. In the N-terminal extracellular 
part of the receptor (Se sequence below), it contains four tyrosines (underlined), three of them in 
succession, surrounded by many acidic amino acids (bold) including position -1 of the candidate sites. 
 
(131) FDACGFDEYESETGDQDYYYLSVKAL (156). 
 
When the entire amino acid sequence of the receptor was analyzed using the Sulfinator program, no 
candidate sites are found, but if only the sequence above was analyzed, the first tyrosine of the triplet 
(gray shadow) was predicted to be sulfated.  
In the following sections the PAC1 receptor was experimentally analyzed, especially the role of the four 
tyrosines were evaluated. Mutational studies were undertaken to establish the involvement of the four 
tyrosines in ligand binding and signal transduction. To establish evidence for a possible tyrosine 
sulfation, the recombinant receptor was expressed in mammalian cell lines and the recombinant 
receptor attempted purified in order to accurately determine the degree of sulfation by mass 
spectrometry.
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7 IV - Mutational studies - PAC1 radioligand binding assays 
Tyrosine sulfation of GPCRs affects ligand binding in all cases studied so far7,29-34. It is generally found 
that if the tyrosines in the known tyrosine sulfated receptors are not sulfated, the binding of ligand to 
the receptor is highly reduced. 
The first step was to establish the involvement of the four tyrosines in ligand binding with the PAC1 
receptor. In this experiment, ligand binding of the wild type receptor was compared to a mutant 
receptor in which the four possible sulfated tyrosines were mutated to phenylalanines (Y139F, Y148F, 
Y149F, Y150F), the amino acid that structurally resembles tyrosine. The wild-type and mutant 
receptors were stably expressed in the CHO cell line. This cell line is naturally devoid of PACAP 
receptors136-138,143, which is why the cell line has been widely used for the pharmacological and 
functional characterization of different PAC1 receptor subtypes and in addition the CHO cells are 
known to contain TPST activity14. RT-PCR and LightCycler PCR confirmed expression of the 
recombinant receptors in the CHO cells. 
Two different experiments were conducted, a saturation binding assay and a homologous competitive 
binding assay. The saturation binding assay determines the Bmax of the receptor, that means the 
maximum number of binding sites, or in case of one binding site pr. receptor, the number of receptors 
present at the cell surface. The homologous competitive binding assay determines the affinity (Kd or 
Equilibrium dissociation constant) of the receptor and ligand, i.e. how well the receptor binds the 
ligand.  
In addition a homologous competitive binding assay was performed, in which the wild type PAC1 
expressing cells were incubated with sodium chlorate prior to the binding assay. Chlorate is a known 
inhibitor of tyrosine sulfation7,18,34,46,152,153 and if the binding affinity of the PAC1 expressing cells was 
altered it might indicate that the tyrosine(s) were sulfated. 
7.1 Materials and methods 
Site-directed mutagenesis: 
The mutations were made using the wild type hADCYAP1R1 expression vectors (pcDNA3.1/+) 
purchased from University of Missouri-Rolla (UMR) cDNA Resource Center. Site-directed 
mutagenesis was performed using PCR with Pwo polymerase (Roche) and with primers carrying the 
four desired mutations (for location of primers see supplement 13.3). The PCR products were digested 
with the restriction enzyme DpnI overnight and transformed into One Shot TOP10 Chemically 
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Competent E. Coli (Invitrogen) according to the manufactures instructions. The identity of all 
mutations was confirmed by DNA sequencing both during cloning and after propagation before cell 
culture transfection. Sequencing was performed using the BigDye® Terminator v1.1 Cycle Sequencing 
RR-100 (AB Applied Biosystems). For further experimental description see supplement 13.11. 
Cell culture and transfection: 
The CHO cells used in all experiments were cultured at 10% CO2 and 37°C in DMEM, + 4500 mg/L 
Glucose, + GlutaMAXTMI, - Pyruvate (Gibco/Invitrogen Corporation) supplemented with 10% FBS 
(Gibco/Invitrogen Corporation) and 1% P/S (Sigma). One day before transfection, the cells were 
plated on 5 ml dishes (TC Dish 60x15, NuncTM). Stable transfections were performed using FuGENE 6 
Transfection Reagent (Roche Diagnostics) method and OptiMEM 1 (Gibco/Invitrogen Corporation) 
according to the manufactures protocol. After 24 hours the culture medium with DNA/FuGENE 6 
was removed and the cells were supplemented with DMEM with 10% FBS. After another 24 hours, the 
cells were split into two 10 ml dishes (TC Dish 92x17, NuncTM) and supplemented with DMEM with 
10% FBS and 1% P/S. The cells were allowed to settle for 24 hours and selection were then added (500 
µg/ml Geneticin, Sigma). Constant selection continued for at least three weeks. For further 
experimental description see supplement 13.12. The two cell lines are denoted CHO-PAC1 for the cells 
stably transfected with the wild type receptor plasmid and CHO-mutPAC1 for the cells stably 
transfected with the mutated receptor plasmid. 
RT-PCR and LightCycler PCR: 
Stable CHO-PAC1 and CHO-mutPAC1 cells were harvested using PBS with EDTA and resuspended in 
Trizol® Reagent (Invitrogen). RNA was purified as described in supplement 13.13, resuspended in 
milliQ water and stored at -80°C until use. cDNA were made from the RNA using Reverse 
Transcriptase M-MuLV (Roche) and Random primers (Roche) according to manufactures protocol. 
LightCycler PCR was performed on the cDNA using the LC FastStart DNA Master SYBR Green I kit 
(Roche) according to protocol. For sites of PAC1 LightCycler primers see supplement 13.3. LightCycler 
primers for mouse GAPDH were also used to determine whole RNA amounts in the samples, since 
GAPDH should be unaffected by transfection with the PAC1 receptor. For further experimental 
description see supplement 13.13. 
Binding assay: 
The stably transfected cell lines CHO-PAC1, CHO-mutPAC1 and untransfected CHO cells were used 
in the two binding assays. At the day of the experiment cells were harvested using PBS with EDTA 
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(Bie & Berntsen A-S), washed once in Tris-buffer (50 mM Trizma base adjusted to pH 7.4 with HCl, 
0.5 mM MgCl2, 0.9 mM CaCl2, 1% Bovine Serum Albumin (BSA, Sigma) and resuspended in this Tris-
buffer. The cell concentration in each cell line was estimated using a Neubauer counting chamber 
(Marienfeld). For the saturation binding experiment 400 µl containing 50.000 CHO-mutPAC1 or 50.000 
CHO-PAC1 cells/tube were transferred to 1.5 ml Protein LoBind Tubes (Eppendorf). For the 
competitions binding experiment 350 µl containing 500.000 CHO-mutPAC1 or untransfected CHO 
and 50.000 CHO-PAC1 cells/tube were transferred to 1.5 ml Protein LoBind Tubes. For saturation 
binding, increasing concentrations of tracer [125I]-PACAP27-NH2 (PerkinElmer) was added                
(0-1200 pM) to a final reaction volume of 500 µl (400 µl cell solution and 100 µl tracer). For 
competition binding, 40 pM or 100 pM [125I]-PACAP27-NH2 tracer, and increasing concentrations   
(10-12 to 10-6 M) of cold peptide, PACAP27-NH2 (Phoenix Pharmaceuticals), were added to a final 
volume of 500 µl (350 µl cell solution, 100 µl tracer and 50 µl cold peptide). In all experiments, the cells 
were incubated for 120 minutes at room temperature, with frequent inverts of the tubes. The reaction 
was terminated by centrifugation (5000 rpm for 3 minutes) and aspiration of the supernatant, followed 
by a single washing step in 500 µl Tris-buffer. Finally, 500 µl 0.2 M NaOH were added and the tubes 
were incubated 15 minutes at room temperature while shaking. The cell lysate was pipetted into 
Minisorp tubes (Nunc™), and radioactivity of the cell lysate was quantitated on RIA Counter Type 
1200 (Mølsgaard Medicals) counting for five minutes. For further experimental description see 
supplement 13.14. The saturation binding assay was performed once with duplicated of each measuring 
point. The homologous competitive binding assay was repeated three independent times with all 
measuring points performed in duplicates or triplicates. The saturation binding curve was fitted using 
non-linear regression with one site binding (hyperbola) in the GraphPad Prism software and the 
homologous binding curve was fitted using the homologous competition-binding curve with global 
fitting. 
Chlorate assay: 
Chlorate inhibition experiments are performed with the CHO-PAC1 cells. The cells were grown to 70-
80% confluence in TC Flask 175 cm2 (Nunc™) in DMEM, + 4500 mg/L Glucose, + GlutaMAXTMI, - 
Pyruvate supplemented with 10% FBS (Gibco/Invitrogen Corporation, 1% P/S and 500 µg/ml 
Geneticin (Gibco/ Invitrogen Corporation). The day before the experiment the incubation medium 
was aspirated from the cell culture flask and the cells were washed once in PBS. Fresh F12 (Ham) 
Nutrient mixture + GlutaMAXTMI  (Gibco/Invitrogen Corporation) medium supplemented with 0%, 
1% or 10% FBS and containing 10 mM, 20 mM or 50 mM sodium chlorate (NaClO3, Sigma) was 
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added and the cells were incubated for 16 hours in the incubator. After the incubation, a homologue 
competitive binding assay was performed as above. 
7.2 Results 
For the CHO cell lines stably expressing either the wild-type or the mutant receptor, Bmax and Kd were 
estimated from a saturation binding assay and a homologous competitive binding assay, respectively.  
The saturation binding experiment illustrates the amount of radiolabeled tracer bound to the receptors 
binding site with increasing concentrations of the tracer in the incubation media. When the 
concentration of tracer is high, all the receptors are saturated and the curve flattens at the designated 
value, Bmax . Kd can be read from the curve at half Bmax. 
The homologous competitive binding assay uses a fixed concentration of tracer in every sample and an 
increasing concentration of the same non-radiolabeled ligand to compete for binding to the receptor. 
The GraphPad Prism software was used to calculate the Kd from the IC50 of the curve (inhibitory 
concentration - the concentration of competitor that competes for half the specific tracer binding). The 
results of the binding assays are shown in figure 24 (see supplement 13.8 for calculations).  
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Figure 24: Saturation binding curve and homologous one site competition binding curve for the stably 
transcfected CHO-PAC1 and CHO-mutPAC1 cell lines. A: In the saturation binding experiment either cell line was 
incubated with increasing concentrations of [125I]-PACAP27-NH2. The two binding curves were the result of the increase in 
tracer binding including the deduction of the nonspecific binding (NS). Each sample was performed in duplicate and the 
average plotted. B: In the homologous competitive binding experiment either cell line was incubated in a constant 
concentration (40 pM) of the tracer, [125I]-PACAP27-NH2, and with increasing concentrations of unlabeled PACAP27-NH2 
(10-12 to 10-6 M). Results are given in percent of total binding (i.e. without inhibitor and NS) and are presented as mean ± 
SD.  
 
From the saturation binding curve and the homologous competitive binding curve Bmax and Kd  were 
calculated. The data are presented in table 6. 
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Table 6: The Bmax and Kd  values for the CHO-PAC1 and CHO-mutPAC1 cell lines. 
 
 Cell line Bmax Kd 95% Conf. int. on Kd 
CHO-PAC1  37.33 fmol 1.10 nM 0 - 2.28 nM Saturation binding  
(50.000cells) CHO-mutPAC1 4.51 fmol 0.46 nM 0 - 1.72 nM 
CHO-PAC1 - 1.56 nM 1.26 - 1.91 nM 
CHO-mutPAC1 - 0.43 nM 0.25 - 0.74 nM 
Homologous  
competitive binding 
CHO-PAC1 (chlorate incub.) - 1.32 nM 1.05 – 1.64 nM 
The Bmax and Kd were calculated from the two experiments; saturation binding and homologous competitive binding shown 
in figure 24 (see supplement 13.8). In the saturation binding experiment the Bmax and Kd values were estimated from a single 
experiment, with duplicates of measuring point (N=2). In the homologous competitive assay, the measured Kd was the 
estimate from two different experiments with two different tracer concentrations (40 pM and 100 pM). The 40 pM results 
were based on at three independent experiments containing double or triple determinations of each measuring point (N=8) 
and the 100 pM results were from a single experiment with triplicates of each measuring point (N=3). 
 
From the saturation binding experiment, it was clear that Bmax of the mutant receptor was lower than 
for the wild-type receptor. The untransfected CHO cell line showed no binding (not shown). Bmax of 
the CHO-PAC1 cells was 37.33 fmol (fig. 24A and table 6) of tracer bound/50.000 cells, and Bmax of the 
CHO-mutPAC1 cells was only 4.51 fmol/50.000 cells, corresponding to approximately 8-fold lower 
ligand binding in the CHO-mutPAC1 cells. Since an equal number of cells was used from both cell lines 
in the experiment, the lower Bmax of the mutant receptor cells could be a result of two incidents; either 
the mutant receptor displayed defective ligand binding properties, or the number of binding sites 
present on the surface of each cell in the CHO-mutPAC1 was lower than in the CHO-PAC1 cell line.  
Since differences in receptor numbers on the cell surface might be caused by differences in receptor 
RNA levels, extracted RNA from the two cell lines was investigated through RT-PCR and LightCycler 
PCR to determine the PAC1 receptor RNA levels. The results are presented in figure 25, where PAC1 
RNA levels in the CHO-mutPAC1 and the untransfected CHO cells were estimated in relation to the 
PAC1 RNA level in the CHO-PAC1 cells (see supplement 13.9 for calculations).   
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Figure 25: PAC1 and mutPAC1 RNA amounts in the in the stable CHO cell lines. RNA extracted from the CHO-
PAC1 and CHO-mutPAC1 cell lines was subjected to RT-PCR and lightCycler PCR. The results were normalized to total 
RNA amount in the cells determined by GAPDH measurements and plotted as compared to the amount of PAC1 RNA. 
 
The level of PAC1 RNA was approximately 5-fold higher than mutPAC1 RNA in the same amount of 
total RNA, indicating different receptor expression levels between the two cell lines. The difference 
could be a result of both cell lines being polyclones, i.e. single colonies of high receptor expression 
were not selected in the beginning of cell selection. 
The binding affinity, Kd was determined from the saturation binding curve. CHO-PAC1 had a Kd of  
1.10 nM and CHO-mutPAC1 a Kd of 0.46 nM (table 6) indicating that there was a difference in ligand 
binding of the two receptors towards the same ligand. However this difference was not statistically 
significant. 
In the homologous competitive binding assay Kd was measured at two different tracer concentrations 
(40 pM and 100 pM) to determine a more accurate Kd. The receptor Kd should be the same at any 
concentration of tracer, but errors such as ligand depletion during the experiment might influence the 
IC50 and therefore the Kd. The two Kd’s measured with different tracer concentrations were almost 
identical, and the Kd’s for CHO-PAC1 and CHO-mutPAC1 presented in table 6 are joint values 
calculated using global fitting in GraphPad Prism program (see supplement 13.8). The CHO-PAC1 had 
an apparent Kd of 1.56 nM and CHO-mutPAC1 a Kd of 0.43 nM (fig. 24B and table 6) in the 
competitive binding assay, almost the same as in the saturation binding assay. However, in the 
homologous competitive assay the difference between the binding affinities of the two receptors was 
statistically significant. The lower Kd of the mutant receptor indicated that the mutant receptor had a 
higher affinity for the ligand than the wild-type receptor. Determination of the affinity of the two 
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receptors is not influenced by the differences in cell surface binding sites determined in the saturation 
binding experiment. 
An experiment was conducted in which the CHO-PAC1 cells was treated with 10 mM, 20 mM or       
50 mM chlorate, an inhibitor of tyrosine sulfation, prior to the binding assay. The homologous 
competitive binding assay was performed as before and the results are shown in figure 26:  
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Figure 26: Homologous competition binding curve for the stably transcfected CHO-PAC1 incubated with chlorate 
prior to the assay. Before the homologous competitive binding experiment, the PAC1 cell line was incubated with sodium 
chlorate in concentrations of 10 mM, 20 mM, or 50 mM. Results are given in percent of total binding (i.e. without inhibitor 
and NS) and are presented as mean ± SD. 
 
The experiment was performed with three concentrations of chlorate, where 10 mM is the 
concentration most often used in the literature7,18,34. Increasing the amount of chlorate did not have an 
effect since the order of the efficiency was 20 mM > 10 mM > 50 mM. So the value of Kd = 1.32 nM 
(table 6) was calculated using global curve fitting of the data from all three experiments. This value was 
significant different from the Kd of mutCHO-PAC1 but not from the Kd of CHO-PAC1 not incubated 
with chlorate. 
7.3 Discussion 
In these binding experiments the total amount of binding sites (Bmax) and the affinity (Kd) has been 
established for CHO cells stably expressing the wild-type PAC1 receptor and the mutated PAC1 
receptor. The saturation binding experiment with the radiolabeled ligand [125I]-PACAP27-NH2 showed 
an approximately 8-fold difference in Bmax of the two cell lines. It could be assumed that mutation of 
the four tyrosines to phenylalanines resulted in a reduced binding capability of the receptor, meaning 
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the mutations created a distorted binding site, reducing the total binding. This conclusion was not the 
only possible explanation since receptor RNA levels determined by RT-PCR and LightCycler PCR, 
showed an approximately 5-fold lower CHO-mutPAC1 RNA level compared to CHO-PAC1 RNA. 
This means that the observed difference in Bmax in the saturation binding assay is most likely due to 
differences in cell surface binding sites i.e. receptor number between the CHO-PAC1 and the CHO-
mutPAC1 cell lines, as a result of different RNA levels. 
 
The homologues competitive binding assay (unaffected by Bmax) indicated differences in binding affinity 
of the PAC1 receptor and the mutPAC1 receptor, with the mutant having an approximately 3-fold 
higher affinity for the ligand PACAP-27. The observation that the mutant receptor had a higher affinity 
for the ligand than the wild-type receptor was somewhat surprising. If the tyrosines were sulfated and if 
this sulfation was involved in ligand binding, mutating them to phenylalanine was expected to reduce 
the affinity for the ligand, which has been observed for example in binding assays with the chemokine 
receptor CXCR431. Since the various splice variants of the PAC1 receptor has different affinities for its 
ligands, other possible experiments could involve binding assays with the ligands PACAP-38 and VIP, 
to determine if the observed difference in receptor affinity between the CHO-PAC1 and the CHO-
mutPAC1 cells is a general feature or only valid for PACAP-27. 
 
Chlorate is an inhibitor of tyrosine sulfation and it was investigated if incubating the CHO-PAC1 cells 
with chlorate, would affect the receptors binding affinity. The Kd for ligand binding with the chlorate 
treated CHO-PAC1 cells was close to the Kd of the untreated CHO-PAC1, indicating chlorate had little 
to no effect on ligand-binding of the wild-type PAC1 receptor. The chlorate concentration and 
experimental conditions in this experiment were done according to earlier research7,18,34,152,153 and 
included two higher concentrations of chlorate to ensure complete chlorate effect, but since no positive 
control was included, it can be argued that the lack of effect was because chlorate did not work.  
Another argument could be that the tyrosines are sulfated, but sulfation has no effect on the receptor-
ligand interaction, and incubation with chlorate would have no effect on receptor affinity. This would 
although be highly unlikely since tyrosine sulfation affects receptor-ligand interaction in all cases of 
known sulfated GPCRs7,29-35. So the most likely explanation is that the tyrosines are probably not 
sulfated.
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8 V - The effect on second messengers - cAMP measurements 
The PAC1 receptor activates several signal transduction pathways, and since mutation of four tyrosines 
in the N terminal extracellular region of the PAC1 receptor increased the affinity for the ligand  
PACAP-27, it was interesting to investigate if it also influences signal transduction. This was done by 
measuring the rise in cAMP levels when the cells (CHO-PAC1, CHO-mutPAC1 and untransfected 
CHO cells) were incubated with the ligand, PACAP-27. cAMP measurements have been chosen based 
on the fact that all splice variants of PAC1 receptor except the TM4 variant stimulates cAMP 
production104. As in the binding assay the tyrosine sulfation inhibitor chlorate was used in this cAMP 
assay, in order to determine the effect of a possible sulfation.  
8.1 Materials and methods 
cAMP assay: 
The stable cell lines CHO-PAC1, the CHO-mutPAC1 and the nontransfected CHO cell line were plated 
in 5 ml dishes (TC Dish 60x15, NuncTM, 500.000 cell/dish) in incubation medium DMEM,                  
+4500 mg/L Glucose, + GlutaMAXTMI, - Pyruvate (Gibco/Invitrogen Corporation) supplemented 
with 10% FBS (Gibco/Invitrogen Corporation) and 1% P/S (Sigma). The cells were allowed to settle 
for 24 hours in an incubator (10% CO2 and 37°C). On the day of the experiment, the medium was 
removed and fresh incubation medium was added now containing PACAP27-NH2 (Phoenix 
Pharmaceuticals, Inc.) in a final concentration of 1 nM. The cells were incubated for 15 minutes in the 
incubator. The medium was aspirated and the cells were washed once in PBS. Cells were lyzed in 1 ml 
0.1 M HCl for 20 minutes at room temperature. The crude extract was transferred to 1.5 ml eppendorf 
tubes, and centrifuged for 2 minutes at 600 rpm, the supernatant was collected in clean 1.5 ml 
Eppendorf tube. cAMP content in each sample was measured using a complete kit, Cyclic AMP (low 
pH) immunoassay (R&D systems). The procedure was performed according to manufactures protocol. 
The measured cAMP levels were normalized to total protein content in each sample. Total protein 
content in the samples was measured with the BCATM Protein Assay Kit (Pierce), according to 
manufactures protocol. 
Chlorate assay: 
Chlorate inhibition experiments were performed with the CHO-PAC1 cells. 500.000 cells/dish were 
plated in 5 ml dishes in incubation medium DMEM, + 4500 mg/L Glucose, + GlutaMAXTMI, -
 
  Summer 2006 
V - The effect on second messengers - cAMP measurements  Roskilde University Center 
 61
Pyruvate, supplemented with 10% FBS and 1% P/S the day before the experiment and allowed to 
settle. The next day the medium was aspirated and the cells were washed once in PBS. Fresh F12 
(Ham) Nutrient mixture + GlutaMAXTMI  (Gibco/Invitrogen Corporation) medium supplemented 
with 1% FBS and containing 10 mM NaClO3 (Sigma) was added and the cells were incubated for       
16 hours in the incubator. PACAP27-NH2 was added to a final concentration of 1 nM and the 
incubation continued for another 15 minutes in the incubator. The final steps of the experiment were 
performed as described above.  
Statistics:  
Data are presented in a bar diagram as mean ± SD. The unpaired t-test (GraphPad Prism software, v. 
4.0) was used to determine differences between bars; P < 0.05 was considered statistically significant. 
8.2 Results 
The cAMP levels were measured in CHO-PAC1, CHO-mutPAC1, chlorate treated CHO-PAC1 and 
untransfected CHO cells with or without incubation with the natural ligand PACAP-27 (1 nM). The 
results are presented in the bar diagram (fig. 27). 
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Figure 27: cAMP measurements in the three cell lines: The untransfected CHO, CHO-PAC1, CHO-mutPAC1 and 
chlorate treated cells with or without the presence of the natural ligand PACAP-27 ( - : without ligand; + : with ligand). The 
diagram is a result of three independent experiments performed in duplicate or triplicates (N=8), except for the chlorate 
assay which was a single experiment with three replicates (N=3). 
 
There was no difference in cAMP levels of untransfected CHO cells stimulated with PACAP-27, 
compared to the same unstimulated cells. There was a basal cAMP level of the three unstimulated cell 
lines of 4.5 to 5.5 pmol/mg protein (table 7). However, both the CHO-PAC1 and the CHO-mutPAC1 
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cell lines showed increased cAMP levels when stimulated with PACAP-27, compared to the 
unstimulated control. The induced cAMP level in the stimulated CHO-mutPAC1 cells was half of that 
of the CHO-PAC1 cells; 8.8 pmol/mg protein compared to 14.4 pmol/mg protein, respectively. To 
evaluate if these results were significant, the data was compared in an unpaired t-test. The results are 
shown in the table 7: 
 
Table 7: Statistical analysis of the cAMP measurements. 
 
Cell line Mean* (pmol/mg protein) ± SD N P value when compared to**: 
CHO- 5.54 ± 1.16 8 CHO+:                     P > 0.05 
CHO+ 5.98 ± 1.35 8 CHO-PAC1+:           P < 0.0001 
CHO-PAC1- 4.66 ± 0.87 8 CHO-PAC1+:           P < 0.0001 
CHO-PAC1+ 14.44 ± 3.11 8 CHO-mutPAC1+: P < 0.001 
CHO-mutPAC1- 5.59 ± 2.04 8 CHO-mutPAC1+:     P < 0.01 
CHO-mutPAC1+ 8.80 ± 1.92 8 CHO+:                     P < 0.01 
CHO-PAC1 chl - 5.18 ± 0.41 3 CHO-PAC1 chl +:    P < 0.0001 
CHO-PAC1 chl + 13.36 ± 0.86 3 
CHO-PAC1 +: 
CHO-mutPAC1+:          
P > 0.05 
P < 0.01 
* cAMP concentrations were normalized to total protein in the cell extract.  
** All cAMP measurements from each cell line were compared in an unpaired t-test.  
 
The statistical calculations corresponded to the observed data in the bar diagram (fig. 27). There was no 
statistical significant difference between the untransfected CHO cells with and without stimulation 
(CHO+ and CHO-). When stimulated with ligand, both the cells expressing the wild-type receptor and 
the mutant receptor showed significant increases in cAMP levels compared to the same unstimulated 
cells. The most interesting difference was between CHO-PAC1+ and CHO-mutPAC1+ (P < 0.001) 
indicating a statistically significant lower increase in cAMP levels of cells expressing the mutant 
receptor. This might be because of lower receptor numbers on the CHO-mutPAC1 cell surface 
determined in the saturation binding experiment (see section 7.2).  
Increases in cAMP levels were measured in the stimulated CHO-PAC1 cells pretreated with the tyrosine 
sulfation inhibitor chlorate. CHO-PAC1 cells treated with 10 mM sodium chlorate prior to PACAP27-
NH2 stimulation resulted in a cAMP level of 13.3 pmol/mg protein. This result was statistically 
significant different from the cAMP levels observed for the stimulated mutant receptor cells. But not 
significantly different from the wild-type receptor results even though the cAMP level in the chlorate 
treated cells was slightly lower. 
The unpaired t-test assumes that the two populations have the same variance. In this cAMP assay the 
CHO-PAC1+ samples showed significantly different variances when compared with the CHO-PAC1- 
or the CHO+ samples. In these cases, the P value was calculated using the unpaired t-test with Welch's 
correction since this test does not assume equal variances.  
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8.3 Discussion 
This experiment has shown that, when stimulating cells expressing the wild type PAC1 receptor or the 
mutated PAC1 receptor with the ligand PACAP-27, there were different cAMP level responces. As 
discussed in the binding experiments, this difference could be a question of differences in the amount 
of receptors expressed at the surface of the cells. In the binding assays it was necessary to have 5 to 8 
times as many CHO-mutPAC1 cells to achieve roughly the same number of binding sites as the CHO-
PAC1. In this cAMP assay the amount of cells analyzed were the same for CHO-PAC1 and CHO-
mutPAC1. This indicated that if both cell lines produced equal amounts of cAMP, the levels in the 
CHO-mutPAC1 cell line would be 5 to 8 times lower than the levels in CHO-PAC1. The difference in 
cAMP levels of the CHO-mutPAC1 cells and the CHO-PAC1 cells were only approximately 2-fold. 
This could indicate that the increased ligand affinity observed in the CHO-mutPAC1 cells also resulted 
in an increased cAMP production. If the measured CHO-mutPAC1 cAMP result is multiplied by 5 to 
normalize the result equalizing the receptor number between the two cell lines, the CHO-mutPAC1 
cAMP increase is approximately 3-fold higher than the CHO-PAC1 cAMP level, which corresponds 
almost exactly to the 3-fold increase in the CHO-mutPAC1 affinity determined in the binding assays. 
There is thus a good correlation between the binding affinities and the cAMP response from the two 
cell lines CHO-PAC1 and CHO-mutPAC1.  
 
It has previously been shown that CHO cells transfected with PAC1 receptor and stimulated with 
PACAP-27 have an EC50 value of 0.010 ± 0.002 nM137. Since this value is 100-fold lower than the 
concentration of PACAP-27 used in this experiment, the cAMP increases in this experiment were 
presumably the maximal or close to the maximal cAMP increase, which means that all cell surface 
receptors were saturated with ligand. This is however not known, but could be investigated by 
performing an experiment measuring the increase in cAMP levels when stimulating the cells with 
increasing concentrations of PACAP-27. These data would show both the maximal increase in cAMP 
and the EC50 values for the two cell lines. 
 
cAMP measurements of CHO-PAC1 cells, treated with chlorate prior to PACAP-27 stimulation 
resulted in a cAMP response close to the untreated CHO-PAC1 cells, indicating no effect of chlorate.  
This was consistent with the binding assay results, and together these data suggests that the PAC1 
receptor is not tyrosine sulfated.
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9 VI - Purification of the recombinant PAC1 receptor 
The binding assay and cAMP measurements have determined that the tyrosines in the N-terminal 
extracellular part of the PAC1 receptor have an important function, but it is necessary to accurately 
prove whether they are sulfated or not. The PAC1 expression plasmid used in the binding assay and 
cAMP measurements does not have a tag containing an epitope and there are no antibodies publicly 
available for the receptor it self, which makes it difficult to purify the receptor for further analysis.  
New plasmids were designed to express tagged versions of the receptor. The purchased plasmid from 
UMR resource Center was used to PCR amplify both the full length PAC1 cDNA and the part of the 
PAC1 cDNA corresponding to the N-terminal extracellular region of the receptor. These were then 
cloned into different constructs. One construct contained a preprogastrin signal peptide attached to the 
C-terminal of the short version of the receptor and an N-terminally Hpc4 tag (Protein C epitope) 
cloned into the pcDNA3.1/V5-His TOPO vector (Invitrogen) (fig. 28). The preprogastrin signal 
peptide should lead the expressed protein through the secretory pathway and secreted by the cell into 
the medium, and the Hpc4 tag should allow for detection and purification of the expressed protein.  
 
 
 
Figure 28: Cloning strategy for the short-PAC1-Hpc4 plasmid. The N-terminal extracellular part of the PAC1 receptor 
(short-PAC1) was PCR amplified and cloned into pcDNA3.1/V5-His-TOPO vector system. An oligo containing the 
preprogastrin signal sequence and the Hpc4 sequence was PCR amplified and cloned into pcDNA3.1/V5-His-TOPO 
vector. Both the newly cloned short-PAC1 and the signal-Hpc4 vectors were digested with the restriction enzyme XhoI and 
the short-PAC1 fragment was ligated into the signal-Hpc4 vector. XhoI, NheI, HindIII, BamHI and XbaI are restriction 
enzyme cleavage sites. 
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The other constructs contained either the short or the full-length version of the receptor cDNA with 
the receptors own signal peptide, cloned into the pcDNA3.2/GW/D-TOPO vector (Invitrogen) that 
attaches a V5 tag to the C-terminal of the cloned product (fig. 29). As with the Hpc4 epitope the V5 
epitope allows for detection and purification. 
 
 
 
 
Figure 29: Cloning strategy for the short-PAC1-V5 and full-PAC1-V5 plasmids. The N-terminal extracellular part of 
the PAC1 receptor and the full length DNA were PCR amplified of and cloned into the pcDNA3.2/GW/D-TOPO vector 
system.  
 
The different constructs were then expressed in different cell lines (CHO, Hit, and PC12), which have 
the ability to sulfate tyrosines. The molecular weight of the unmodified receptor is 53 kDa whereas the 
weight of the different unmodified constructs is:  
? short-PAC1-Hpc4 approximately 22 kDa.              
? short-PAC1-V5 approximately 21 kDa. 
?  full-PAC1-V5 approximately 57 kDa.  
Which might all be slightly higher depending on the amount of post-translational modifications. 
9.1 Materials and methods 
Construction of short-PAC1 Hpc4-tagged expression plasmid: 
First an oligo template was designed containing an N-terminal signal peptide, preprogastrin, a C-
terminal Hpc4 tag and NheI, HindIII, BamHI, XhoI and XbaI cloning sites (se fig. 28 and supplement 
13.15). The construct was PCR amplified and the product was cloned into pcDNA3.1/V5-His TOPO 
TA Expression vector (Invitrogen). The cloned plasmid was transformed into One ShotTop10 
Chemically Competent Cells (Invitrogen) according to protocol. 
The N-terminal PAC1 fragment was PCR amplified from the wild type hADCYAP1R1 expression 
vector (pcDNA3.1/+) purchased from UMR cDNA Resource Center151, using the Elongase 
polymerase (Invitrogen) and primers carrying a XhoI site. The PCR product was first cloned into 
pcDNA3.1/V5-His TOPO TA Expression vector and transformed into One ShotTop10 Chemically 
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Competent Cells (Invitrogen) according to protocol. The clones containing the correct insert were 
digested with XhoI (Roche) restriction enzyme in order to release the insert and be able to clone it into 
the preprogastrin-Hpc4 plasmid construct also digested with XhoI. The digested PAC1 fragment and 
Hpc4 plasmid were ligated with T4 DNA Ligase (Roche Diagnostics) and transformed into One 
ShotTop10 Chemically Competent Cells according to protocol. The plasmid was named short-PAC1-
Hpc4. For further experimental description see supplement 13.15. The identity of all the cloned 
plasmids was confirmed by DNA sequencing both during cloning and after propagation before cell 
culture transfection. Sequencing was performed using the BigDye® Terminator v1.1 Cycle Sequencing 
RR-100 (AB Applied Biosystems). 
Construction of PAC1 V5 tagged expression plasmids: 
The short and full-length versions of the PAC1 receptor were made using the wild type hADCYAP1R1 
expression vector (pcDNA3.1/+) purchased from UMR cDNA Resource Center151. DNA fragments 
were amplified in a PCR with Pwo polymerase (Roche) and with primers carrying the sequences 
required to facilitate directional cloning (for sites of primers see supplement 13.3). The short and full-
length PAC1 PCR fragments were cloned into the pcDNA3.2/GW/D-TOPO vector using the 
pcDNA3.2/GW/D-TOPO Expression Kit (Invitrogen). The identity of both short and full-length 
PAC1 carrying plasmids was confirmed by DNA sequencing both during cloning and after propagation 
before cell culture transfection. Sequencing was performed using the BigDye® Terminator v1.1 Cycle 
Sequencing RR-100 (AB Applied Biosystems). The two plasmids were named short-PAC1-V5 and full-
PAC1-V5. For further experimental description see supplement 13.16.  
Expression by transient transfection: 
CHO cells were cultured at 10% CO2 and 37°C in DMEM, + 4500 mg/L Glucose, + GlutaMAXTMI, - 
Pyruvate (Gibco/Invitrogen Corporation) supplemented with 10% FBS (Gibco/Invitrogen 
Corporation) and 1% P/S (Sigma). The Hamster islet derived cell line (Hit) was cultured at 10% CO2 
and 37°C in Dulbecco’s Modified Eagles Medium (DMEM), + 1000 mg/L Glucose, + GlutaMAXTMI, 
- Pyruvate supplemented with 10% (FBS) and 1% P/S. One day before transfection 800.000 cells 
(corresponding to 60-80% confluence) were plated on either 5 ml dishes (TC Dish 60x15, NuncTM) 
(samples for western blot and column purification) or 2 ml glass bottom dishes (WillCo-dish®, Willco 
Wells BV) (samples for immunostaining). Both the CHO and the Hit cell lines were used to do parallel 
transfections of both the short-PAC1-V5 and full-length-PAC1-V5 plasmids, whereas only the CHO cell 
line was used to express the short-PAC1-Hpc4 plasmid. Transient transfections were performed using 
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FuGENE 6 Transfection Reagent (Roche Diagnostics) method and OptiMEM 1 (Gibco/Invitrogen 
Corporation) according to the manufactures protocol. After 24 hours the culture medium with 
FuGENE 6/DNA /OptiMEM was removed and the cells were supplemented with DMEM with 1% 
or 10% FBS and 1% P/S. The cells were allowed to incubate for another 24 or 48 hours before to 
further analysis, i.e. immunostaining, western blot, and column purification. The different transfection 
series were named short-PAC1-V5-CHO, full-PAC1-V5-CHO, short-PAC1-V5-Hit, full-PAC1-V5-Hit, and 
short-PAC1-Hpc4-CHO. For further experimental description see supplement 13.17.  
Western blot: 
General description: The samples were loaded on prefabricated 4-20% SDS-PAGE gels (either 4-
20% NOVEX-Tris-Glycine Gel 1.0 x 10 well (Invitrogen), or PAGEr® Duramide® Precast Gels 4-
20% 10 wells (Cambrex)), which were submerged in Novex Tris-Gly SDS Running Buffer (Invitrogen). 
A biotinylated Protein ladder and a Precision Plus Protein™ Dual Color Standard (BioRad) were also 
loaded on the gel. The gel was run at 130V for approx. 90 minutes until the blue dye reached the 
bottom of the gel. The gel was then blotted onto a hydrophobic polyvinylidene difluoride (PVDF) 
Hybond™-P membrane (Amersham Biosciences) at 175 mA for 2 hours using the Novex Tris-Gly 
SDS Running Buffer (x10) stock solution diluted 100 times and containing 20% Ethanol. After 
antibody binding and detection the blots were scanned with Fujifilm LAS-1000, Fujifilm Intelligent 
Dark Box II and the programs Fujifilm Image Reader LAS-1000 Pro V2.5 and Image Gauge V4.0. For 
further experimental description see supplement 13.18. 
Hpc4 detection: The short-PAC1-Hpc4-CHO cell samples were harvested 24 or 48 hours after 
transfection. Both the medium and cell lysates were collected. The cells were washed once in PBS and 
then lysed in sample buffer (10 mM Trizma pH 8, 8% SDS, 40% Glycerol, 40 mM DTT and 
bromephenol blue). A sample of the medium was also mixed with sample buffer in 3:1 ratio. Samples in 
buffer were heated at 96oC for 5 minutes and the cell lysates homogenized using a 1 ml Syringe with 
needle (BD Plastipak). After gel-separation and blotting, the membrane was then incubated in blocking 
buffer (10 mM Trizma Base adjusted with HCl to pH 7.5, 150 mM NaCl, 1 mM CaCl2 and 5% skim 
milk powder) for a minimum of 1 hour. The antibody Hpc4 tag is calcium dependant and it is therefore 
necessary for all buffers to contain calcium. The Anti-[Protein C]-peroxidase conjugate and HRP-
conjugated Anti-Biotin Antibody (Cell Signalling Technologies) were diluted in half blocking buffer half 
TBS-Ca solution (10 mM Trizma Base adjusted with HCl to pH 7.5, 150 mM NaCl, 1 mM CaCl2) and 
the membrane were incubated in the mixture for 1 hour. The membrane was then washed four times in 
the TBS-Ca solution supplemented with 0.05% Tween 20, and detection was performed using the 
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SuperSignal® West Pico Chemiluminescent Substrate solutions (Pierce). All washing and incubation 
steps were performed at room temperature with gentle shaking. 
V5 detection: The short-PAC1-V5-CHO, full-PAC1-V5-CHO, short-PAC1-V5-CHO, and full-PAC1-V5-
CHO samples and the control protein CAT (Expression control pcDNA™3.2/V5/GW/CAT, 
Invitrogen) were harvested 24 hours after transfection. Both the medium and cell lysates were collected. 
The cells were washed once in PBS and then lysed in sample buffer (10 mM Trizma pH~8, 8% SDS, 
40% Glycerol, 40 mM DTT and bromephenol blue) or lysis buffer (50 mM Trizma Base adjusted with 
HCl to pH 7.5, 150 mM NaCl, 1 mM CaCl2, 0.5% Cymal 5 (Anatrace), 0.05% Deoxycholate, and 
Complete® Tablets (Roche)). Protease inhibitors (Complete® tablets) were also added to the aspirated 
medium samples to avoid proteolysis). Fractions of the medium samples were also mixed with sample 
buffer in 3:1 ratio. All samples in buffer were heated at 96oC for 5 minutes and the cell lysates 
homogenized using a 1 ml Syringe with needle. A control protein (Positope™, Invitrogen) containing 
the V5 epitope was loaded on the SDS-gel along with the cell and medium samples. After gel-
separation and blotting, the membrane was then incubated in blocking buffer (Wash buffer from Bie & 
Berndtsen A-S supplemented with 5% Skim milk powder) over night. The Anti-V5-HRP Antibody, the 
HRP-conjugated Anti-Biotin Antibody and Mouse Monoclonal [mAbcam 9484] to GAPDH-loading 
control (HRP) (Abcam) were diluted in the blocking buffer and the membrane was incubated in the 
antibody mixture for 1 hour. The membrane was washed 3 times in washing buffer and detection was 
performed using the SuperSignal® West Pico Chemiluminescent Substrate solutions. All washing and 
incubation steps were performed at room temperature with gentle shaking. 
Column purification: 
Hpc4: For protein purification the Anti-Protein C Affinity Matrix (Roche) was used and column 
preparation was performed according to protocol. The culture medium aspirated from the short-PAC1-
Hpc4-CHO transfected cells and CaCl2 was added to a final concentration of 1 mM. The protein 
extract was loaded with the column matrix and incubated overnight at 4°C on an end-over-end rocker. 
After incubation the column matrix was allowed to settle for 10 minuttes and then the lysate flow-
through was eluted. The column was washed with 10x1 ml of wash buffer (20 mM Trizma Base 
adjusted with HCl to pH 7.5, 1.0 M NaCl, 1 mM CaCl2) and reequilibrated with 10 ml of equilibration 
buffer (20 mM Trizma Base adjusted with HCl to pH 7.5, 0.1 M NaCl, 1 mM CaCl2). The first elution 
step was performed overnight in 1 bed-volume elution buffer (20 mM Trizma Base adjusted with HCl 
to pH 7.5, 0.1 M NaCl, 5 mM EDTA). The other 9 elution steps were performed with reducing 
incubation times, from 2 hours to 10 minutes. Fractions from all steps were collected and the OD280 
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was measured to estimate protein levels. Samples were kept at 4°C until analysis. The fractions were 
also used for western blotting. 
V5: Lyzed and centrifuged full-PAC1-V5-Hit cells were incubated 2 hours at room temperature with 
Anti-V5 Agarose Affinity Gel (Sigma), which was prepared as described in the protocol. The resin was 
washed with 10x resin volume PBS and 2x in milliQ. Two elution methods were used; one was using 
10x½ resin volume of acetic acid pH 2.3 to elute protein and the other was the method described in the 
Anti-V5 Agarose Affinity Gel protocol where 50 µl sample buffer was added to the resin matrix and 
the tube was incubated for 5 minutes at 100°C. The acetic acid elution fractions were evaporated to 
app. 10 µl, dissolved in 100 µl milliQ and the OD280 was measured to estimate protein levels. All 
fractions from both elution procedures were used for western blotting. 
Immunostaining - Visualization of expression: 
The transiently transfected full-PAC1-V5-CHO and full-PAC1-V5-Hit cells in the glass bottom dishes 
were used for immunostaining with a FITC-conjugated antibody. First the cells were fixated with 
methanol (99.8%, Merck), washed in PBS and then permeabilized with 0.1% Triton-X 100 /PBS 
solution containing 10% FBS. The cells were incubated in blocking buffer (PBS with 10% FBS) for 20 
minutes The Anti-V5-FITC-conjugated antibody (Invitrogen) was diluted 1:500 in blocking buffer and 
added to the cells, incubation continued for 1 hour. The cells were observed using a confocal 
microscope (Axiovert 200M, Zeiss, equipped with a Lasos, Laser Fertigung GmbH) equipped with a 
FITC filter. For further experimental description see supplement 13.19. 
9.2 Results 
9.2.1 Western blots and column purifications of PAC1 receptor 
The short-PAC1-Hpc4 construct contains the N-terminal extracellular part of the receptor and a signal 
peptide that ensures direction to the secretory pathway and out of the cell into the culture medium. The 
first short-PAC1-Hpc4 construct transfection series and western blots were done on CHO, HeLa and 
PC12 cells. Three cell lines were chosen to find the cell line with optimal expression and to make sure 
that a lack of expression was not cell line specific. Culture medium and cell lysates were collected at 
different times after transfection: samples from HeLa and CHO cell culture medium and cell lysates 
were taken after 18, 26, 42, 46, 54, and 66 hours, and from PC12 cells after 50 and 66 hours, to examine 
the point in time of maximum expression. Unfortunately, no protein-construct was detected in the 
western blots using the Hpc4 antibody neither in the medium samples nor in the cell lysates. Whether 
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this was due to lack of expression or if the expression was too low to be detected by western blot is 
unknown.  
Several experiments were done solely on the CHO cell line with 24- and 48-hour incubation in either 
Hams F12 culture medium or with rabbit serum (Invitrogen) to check whether low or lack of 
expression was a culture medium or serum related problem. These experiments were also unsuccessful, 
showing no protein bands on a western blot.  
To test if it was a matter of very limited expression 2x20 ml bottles of CHO cells were transfected and 
the media was used for column purification. The collected media was incubated with the Anti-Protein 
C Affinity Matrix (Roche) that binds the Hpc4 epitope of the short-PAC1-Hpc4 construct. All fractions 
from the various steps of the column purification were collected and subjected to western blot and 
OD280 measurement. No receptor protein was found in any of the fractions, indicating a lack of 
expression and not just low expression. 
At this time a new plasmid was designed containing a different tag, the V5 epitope, and the PAC1 
receptors own signal peptide. Both the N-terminal extracellular part of the receptor and the full-length 
receptor were cloned into the pcDNA3.2/GW/D-TOPO Expression vector. Lack of protein bands in 
the western blots was unfortunately also the case with the V5 tagged plasmid constructs: short-PAC1-
V5-CHO, the full-PAC1-V5-CHO, the short-PAC1-V5-Hit, and the full-PAC1-V5-Hit. Two controls were 
included in the V5 tag experiments: the expression control protein CAT (Expression control 
pcDNA™3.2/V5/GW/CAT) and the Positope™ control protein containing the V5 tag. In the 
western blot only the Positope™ band and the expression control protein CAT were visible, 
confirming that the expression and western blot procedure worked. The problem with the V5 tagged 
proteins must be located in procedures prior to western blotting. 
9.2.2 Visualization of the expressed recombinant PAC1 receptor 
To determine if the receptor was actually expressed and present on the cell surface, CHO and Hit cells 
were transiently transfected with the full-length PAC1-V5 plasmid (full-PAC1-V5-CHO and full-PAC1-
V5-Hit) in glass bottom dishes. If the receptor was expressed correctly the V5 epitope should be 
located on the C-terminal end of the receptor, which means it would be present on the cytosolic side of 
the cells. 24 hours after transfection the cells were fixed and permeabilized to allow cell entry of the 
antibody. The Anti-V5-FITC-conjugated antibody (Invitrogen) was used to bind to the V5 epitope of 
the receptor. A confocal microscope was used to visualize the immunostaining. The results are shown 
in figure 30: 
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Figure 30: Confocal microscope pictures of the untransfected CHO and Hit cells and the transient transfected 
full-PAC1-V5-CHO and full-PAC1-V5-Hit cells. The images are cross-sections of the cells visualized with the Anti-V5-
FITC-conjugated antibody and taken 24 hours after transfection. A: The fluorescent image; B: The microscope image; and 
C:  The overlay of A and B.  
 
In the untransfected CHO cell line there was a rather large cytosol background staining, making it 
difficult to observe a membrane staining, but there seemed to be a difference between the 
untransfected CHO and the full-PAC1-V5-CHO images. From the green staining of the membranes in 
the transfected full-PAC1-Hit cells, the receptor appeared to be expressed since no staining was 
observed in the untransfected cells, but the Hit cells contain a large nucleus limiting the space between 
the nucleus and the cell membrane, and the possibility of cytosol staining can not be excluded. 
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9.3 Discussion 
The purification and analysis of the PAC1 receptor was unsuccessful, making it difficult to determine if 
the receptor is tyrosine sulfated. Many different assay procedures have been used to locate the problem. 
Two different plasmid constructions were tried, one expressing only the short N-terminal part of the 
PAC1 receptor fused with a signal peptide and a Hpc4 epitope, and another expressing both the short 
and the full length receptor with the receptors own signal peptide and fused with the V5 epitope.  
The short-PAC1-Hpc4 construct yielded no bands in western blots and no protein in column 
purification, although different cell lines, culture media, sera and expression periods were applied. Since 
the signal peptide in the short-PAC1-Hpc4 construct would secrete the recombinant protein to the 
culture medium, it was difficult to determine if the unsuccessful western blots and purification 
procedures were a result of lack of expression, if it was not expressed correctly, or if it was rapidly 
degraded by proteases either in the cell or once it reached the culture medium. 
 
The same was true for the short-PAC1-V5 construct, which gave no bands in the western blot in the 
expected region. Unlike the short-PAC1-Hpc4, the short-PAC1-V5 construct contained the PAC1 
receptors own signal peptide, which might pose a problem, since the signal peptide will send the 
construct to the cell membrane, and it does not contain any transmembrane segments. It might be 
possible that the construct is not secreted but remains in the cytosol. This was tested by including cell 
lysates from the short-PAC1-V5 transfection in the western blot, and no bands were observed in the 
expected region, making it difficult to determine the reason for the lack positive western blots. 
 
With the full-PAC1-V5 in western blots and protein purification, it should be taken into consideration 
that a 7-transmembrane receptor contains both large hydrophilic areas and large very hydrophopic 
areas which can make it difficult to keep the receptor solubilized. Three alternative lysis solutions were 
tried on the cells carrying the full-PAC1-V5 protein. One was direct lysis in the western blot sample 
buffer, the second was the lysis buffer suggested by Invitrogen containg the detergent NP-40, and the 
third lysis solution contained Cymal-5, a nonionic detergent used in the solubilization of another 
GPCR, the CCR5154. But none of these procedures resulted in successful western blots or column 
purified protein.  
 
To determine if the unsuccessful western blots were because lack of expression, the full-PAC1-V5 
construct, which should be situated at the cell membrane, was subjected to immunostaining. The results 
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showed a large background staining in the cytosol, which made it difficult to conclude if the full-length 
receptor was expressed.  
 
Further experiments will include repeating the immunostaining experiment with dilutions of the 
antibody, trying to avoid much of the background, and making the expression, western blot and 
column purification work with the control expression vector from Invitrogen and then try with the full-
PAC1-V5 and the short-PAC1-V5 constructs again. Another possibility is to do a northern blot on 
purified RNA from the full-PAC1-V5 and the short-PAC1-V5 transfected cells, which would indicate if 
the constructs were expressed.
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10 Discussion and Perspectives 
10.1 Acid lability of tyrosine sulfate 
Tyrosine sulfation of peptides and proteins is a post-translational modification, which is not very well 
described. Only approximately 70 tyrosine sulfated peptides and proteins have been identified so far, 
but it is estimated that the modification is more common. In many cases the biological function of 
tyrosine sulfation is unknown, but in those described the sulfated tyrosine is involved in protein-protein 
interactions. It has not been determined whether sulfation affects the inter- or intramolecular structure, 
and if it is the negative charge of the sulfate that is involved in ionic bonds or hydrogen bonds within 
the protein or between proteins13. In fact very little is known about the chemical properties of the 
sulfate group.  
Hydrolysis experiments have been performed using aryl sulfates, not as models for tyrosine sulfate, but 
as simpler experiments to obtain data about the hydrolysis of phenyl sulfates. Some of these data have 
been found also to be valid for the hydrolysis of tyrosine sulfate. Tyrosine sulfate is described as very 
acid labile but alkali stable3. Tyrosine sulfate is often not identified during sequencing of a protein 
because the strong acids used in amino acid sequencing, hydrolyses the sulfate group leaving the 
unsulfated tyrosine. Contrary, tyrosine sulfate can withstand alkaline hydrolysis, making this chemical 
process the preferred analyses to detect tyrosine sulfate. 
 
Experiments involving purification and identification of peptides and proteins often involve milder 
acidic solutions and it is not known how these affect the sulfated tyrosine. In the present study the acid 
hydrolysis of tyrosine sulfate was investigated at acid concentrations with a pH range of pH 1 to 3. 
Using the sulfated gastrin-17 as model of tyrosine sulfate it was found that in the pH 1.3 to 2.3 range 
the sulfate group was rather stable. Only longer periods of incubation (> 72 hours) and elevated 
temperatures (>37°C) increased hydrolysis of tyrosine sulfate markedly. The half-life of the hydrolysis 
reaction at pH 1.3 and 37°C was 73.5 hours. This indicated that it is possible to handle tyrosine-sulfated 
peptides in mildly acidic solution at room temperature without the risk of hydrolysis.  
The observed half-life t½ = 73.5 hours for the acid hydrolysis at 37°C is relatively long and might be 
due to the fact that only a small portion of the sulfated tyrosine will be in the neutral form. During the 
acid hydrolysis the reactive species is the neutral form, but the pKa of sulfate group is too low to obtain 
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a large proportion of the neutral species, even in 1 M HCl, less than 1% of the compound will be in the 
neutral form76,77 and it is only in very strong acids that the hydrolysis rate is highly accelerated. 
 
The acid hydrolysis of tyrosine sulfate in the gastrin-17 peptide, was found to be a first-order reaction, 
just like the hydrolysis of various aryl sulfates77-79. Though the reaction is more likely a pseudo first-
order since protons participate owing to the higher pKa value of the resulting phenol. The rate 
constants found for hydrolysis of sulfated gastrin-17 at 37°C, 50°C and 70°C (pH 1.3) showed a linear 
relationship between temperature and the rate constants, thus fitting the Arrhenius equation. The 
equation allows estimation of the rate constant at any given temperature (65.3 mM TFA, pH 1.3), but 
the rate constants will of course be different in hydrolysis experiments at other pH values.  
From the Arrhenius equation the activation energy of the hydrolysis reaction was estimated to   
Ea=23.6 kcal mol-1, which is slightly higher than those observed for the hydrolysis of pNPS79. This is 
not surprising since para-substituents such as NO2 (in pNPS) stabilize the phenol by resonance 
interactions, which are not likely to be observed in the starting sulfate O2N-Ar-O-SO3-. This causes the 
Ea for the hydrolysis to be somewhat less than it would for the unsubstituted aryl sulfate78. Sulfated 
tyrosine has a CH2 group as para-substituent but this is not an electron-withdrawing group, so the 
phenol in tyrosine will not have the same resonance stabilizing effect observed with NO2 as para-
substituent. The Ea tyrosine sulfate hydrolysis should therefore be somewhat larger than for pNPS, 
which is also observed. 
 
The acid hydrolysis reaction mechanism of aryl sulfates have been proposed to be unimolecular78,79 
characterized by S-O bond fission between the phenolic oxygen and the sulfur trioxide. The bond to 
the phenol group is largely broken in the transition state, and the sulfuryl group resembles sulfur 
trioxide77. Experiments have shown some involvement of water in the transition state, facilitating the 
transfer of the proton from the sulfate group to phenolic oxygen76,77,80. In the present study the low Ea 
value found for the hydrolysis of sulfated gastrin-17 is consistent with a much weaker S-O bond in the 
ester since various S-O bond dissociation energies are normally much larger. Together with displaying 
first-order (pseudo) reaction kinetics, the hydrolysis of sulfated gastrin-17 had an Arrhenius A factor 
within the range of a typical unimolecular reaction. The hydrolysis mechanism for tyrosine sulfate 
therefore shows great resemblance to the hydrolysis of aryl sulfates. But further experiments will 
elucidate the exact reaction mechanism for the hydrolysis of tyrosine sulfate. 
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Contrary to aryl sulfates, tyrosine sulfate is part of a much larger molecule and the hydrolysis can be 
affected by other factors than the proton concentration. Peptides have the ability to form numerous 
amounts of intramolecular interactions such as hydrogen bonds and conjugate acid-base pairs. The 
latter has been proven important in the hydrolysis of tyrosine sulfate. Yagami et al. 2000 discovered that 
long peptide chains and the presence of basic amino acids, especially arginine, increased the stability of 
the sulfate group in both acidic aqueous solutions and during mass spectrometry analysis.  
In this study the hydrolysis of three sulfated peptides, gastrin-17, drosulfokinin, and caerulein were 
compared and the results showed that the amino acid composition is much more important than the 
length of the peptide chain. Sulfated gastrin-17 being the longest peptide of the three was hydrolyzed to 
a greater extent than both drosulfokinin and caerulein. Drosulfokinin and caerulein are of almost the 
same length, but caerulein was the most labile probably due to the absence of the basic amino acid 
arginine, which drosulfokinin contains. The stabilization provided by basic amino acids and longer 
peptide chains might be because a higher energy barrier would have to be overcome in order to form 
the intermediate ions during the course of the hydrolysis reaction. Thus the Ea of the hydrolysis might 
depend on the amino acid composition of the protein/peptide. The Ea values of drosulfokinin or 
caerulein will probably not be the same as the Ea of sulfated gastrin-17, since the hydrolysis rate 
differed. The Ea will most likely be larger for drosulfokinin and caerulein because they were less labile 
compared to gastrin-17. 
 
A question arises if an acidic amino acid is located between the sulfated tyrosine and the basic amino 
acid, the question is whether the basic amino acid will acid-base pair with the glutamate or aspartate, or 
with the sulfated tyrosine. In some cases sulfated peptides and proteins contain more than one sulfated 
tyrosine, and it remains to be investigated what influence additional sulfated tyrosines will have on the 
acid lability of the sulfate groups. Synthetic peptides or mutational studies might be used in further 
experiments to establish positions of highest importance. Secondary and tertiary structures in larger 
peptides and proteins will also contribute to the overall acid lability of the sulfate group, since basic 
amino acids situated far from the sulfated tyrosine, can be brought closer due to protein folding. 
 
When handling solubilized sulfated peptides and proteins it is necessary not only to be aware of the 
proton concentration, but also to the solvent. Solvent effects have been found for the hydrolysis of aryl 
sulfates, where the reaction was accelerated when reducing the concentration of water in DMSO, DMF 
or dioxane77-79,81. Contrary, the hydrolysis rate decreased when changing the medium to aqueous 
acetonitril79,80 or tert-amyl alcohol77. Different acids also display different catalytic effects as Fendler & 
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Fendler 1968 demonstrated, where the hydrolysis of nitrophenyl and dinitrophenyl sulfates were 
catalyzed by three different acids in the order H2SO4 > HClO4 > HCl79. No difference in hydrolysis 
rate of tyrosine sulfate was observed between TFA, FA or HCl within the experimental setup 
investigated in this study. The data obtained with H2SO4, HClO4 and HCl had acid concentrations of 1 
M and higher79, which is at least 10-fold higher than the concentrations of TFA, FA and HCl used in 
this study. This means that there could be a difference in hydrolysis rate between TFA, FA and HCl but 
that the difference is too small to be observed at the parameters investigated. A difference would mean 
that it is necessary to consider which acid is used at certain temperatures and incubation times, since the 
hydrolysis rate will vary from acid to acid at otherwise identical experimental setups. But as this work 
demonstrates one will have to use high concentrations of acid (pH < 1), at higher temperatures          
(T > 24°C) or for longer periods of time (> 24 hours) to increase hydrolysis markedly. A noticeable 
point is that within the pH 1 to 3 range investigated, all three acids display limited effects on hydrolysis 
in the first 24 hours (37°C). This indicates that a sulfated protein or peptide might easily be analyzed in 
these acid concentrations at room temperature as long as the samples are not left for days. 
10.2 Tyrosine sulfation of the PAC1 receptor 
The PAC1 receptor contains four tyrosines in the N-terminal extracellular part, which display the 
characteristics for tyrosine sulfation. When the amino acids stretch containing the four tyrosines were 
analyzed by the software tool, the Sulfinator, one tyrosine was predicted to be sulfated. Mutational 
studies were performed where all four tyrosines were mutated to phenylalanines, to avoid problems if 
more than the one predicted tyrosine was sulfated.  The observation that the mutant receptor had an 
approximately 3-fold higher affinity for the ligand than the wild-type receptor, suggests that these 
mutations alter the binding site of the receptor. The finding of 3-fold increased binding affinity for the 
mutant receptor was somewhat unexpected; if the tyrosines were sulfated and if this sulfation is 
involved in ligand binding, mutating the tyrosines to phenylalanine was expected to reduce the affinity 
for the ligand. Mutating four tyrosines to phenylalanines eliminates eight possible intra-/intermolecular 
hydrogen-binding sites. It could therefore be argued that the tyrosines could be mutated to amino acids 
with the possibility to form hydrogen bonds, such as aspartic/glutamic acid, in order to maintain 
roughly the same hydrogen bonds. On the other hand both aspartic/glutamic acid are smaller than 
tyrosine, posing a sterical problem. The closest resemblance in size to tyrosine is phenylalanine since 
this contains the same phenyl group. Research supporting the use of acidic amino acids substitutions to 
study tyrosine sulfation was done by Farzan et al. 19997 who mutated tyrosines to either phenylalanine 
or aspartic acid This showed that mutation of tyrosine (Y) to phenylalanine (F) almost abolished 
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sulfation unless the first tyrosine was not mutated (FFFF no sulfation, YFFF sulfation, 
FYFF/FFYF/FFFY marginal sulfation) whereas mutation of Y to aspartic acid (D) resulted in 
complete sulfation (DDDD no sulfation, YDDD/DYDD/ DDYD/DDDY sulfation). Further 
research with the PAC1 receptor could implement mutating the tyrosines in the PAC1 receptor to 
aspartic/glutamic acid in order to determine if this reduces/increases the affinity of the receptor, and 
whether the tyrosines might be involved in ligand binding.  
 
As with the binding experiments if the tyrosines were sulfated and if the sulfation was involved in 
ligand binding, mutating the tyrosines to phenylalanine was expected to reduce or abolish the signal 
transduction in response to ligand stimulation i.e. reduced cAMP levels. But since the mutant PAC1 
receptor had an increased binding affinity, it was expected to show increased cAMP levels in response 
to PACAP-27 stimulation. Indeed, when the cAMP levels were normalized in relation to Bmax and 
receptor RNA levels between the two cell lines, the result was an approximately 3-fold increase in 
cAMP response in the mutant. Thus this corresponded to the 3-fold increase in receptor affinity of the 
mutant observed in the binding assays. 
Research by Ciccarelli et al. 1995 showed that pretreament of CHO cells transfected with the rat PAC1 
or rat PAC1-hop receptors with increasing concentrations of PACAP-27 for 24 hours reduced the total 
number of receptors, increased the EC50 values and reduced the amplitude of the response138. It might 
be possible that mutating the four tyrosines in the human PAC1 have different effects on receptor 
numbers at the cell surface, EC50 values and response, but this requires further experiments with 
prolonged exposure to the ligand. 
 
Research by McCulloch et al. 2001 showed an internalization of the rat PAC1 and rat PAC1-hop 
receptors when bound to the ligand 125I-PACAP-27141. However there was no difference in amounts of 
internalized ligand between the two receptor subtypes. In this study there might be different 
internalization patterns between the human wild-type PAC1 receptor and the mutant PAC1 receptor, 
which could influence the ligand binding results and cAMP response, but this requires further 
experiments. 
 
Inhibition of tyrosine sulfation with sodium chlorate had no significant effect on PAC1 receptor 
binding affinity and the cAMP response. Research with the tyrosine sulfated TSH receptor34 showed a 
10-fold increase in EC50 of the cAMP response when treated with chlorate, so if the PAC1 receptor was 
sulfated a similar result was expected. The present study thus suggests that the tyrosines are not sulfated 
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since no effect is observed when treating the PAC1 receptor with chlorate. It is however not direct 
evidence and the possibility of the tyrosines being sulfated cannot be excluded. It shows that if the 
tyrosines are sulfated, they are not involved in ligand binding and signal transduction. 
 
To achieve direct evidence for tyrosine sulfation it was necessary to purify the receptor protein and 
analyze it by mass spectrometry. To purify the PAC1 receptor protein Hpc4- and V5 tagged versions of 
the PAC1 receptor, including the short N-terminal extracellular part of the receptor and the full-length 
receptor were cloned. Using both western blot and column affinity purification, it was not possible to 
detect any protein, either the short or the full-length receptor. It was difficult to determine if it was a 
lack of expression, since immunostaining of the full-PAC1-V5 receptor in the CHO and Hit cell 
membranes seemed to show membrane staining, but the background was too large make conclusions. 
The problem was not the western blot since both the expression control and the positive control 
protein for the antibody showed visible bands. Further experiments would of course involve locating 
and eliminating these problems but if the problem lies with the receptor construct, it will be necessary 
to create a new plasmid. Maybe like the one made by Shintani et al. 2000114 who placed a HA epitope in 
the N-terminal extracellular part of the receptor, successfully enabling detection of the whole receptor 
in both northern and western blots. 
 
If the PAC1 receptor was sulfated, it would have been interesting to investigate the PAC1 receptor in 
cell membranes from the TPST-1 and TPST-2 knockout mice, because of a possible connection 
between the PAC1 receptor, which has been shown to be involved in fertility155, and the decreased 
female fertility and male sterility, that are some of the unexplained phenotypes of the TPST knockout 
mice57,89. 
 
Sulfated tyrosines are also of clinical relevance: Several tyrosine-sulfated proteins involved in cellular 
trafficking are up regulated in autoimmune disease models156. Inhibitors of tyrosine sulfation might 
reduce inflammation by decreasing the affinity of cell adhesion between mononuclear cells and 
inflamed endothelium156. This information suggests that inhibitors of tyrosine sulfation might also serve 
as anti-HIV therapeutics, since sulfation of the CCR5 chemokine receptor allows HIV-1 entry157. 
Because tyrosine sulfation sites are found in other peptides and proteins, and not only in chemokine 
receptors it will be a challenge to develop methods that target the specificity for inhibition of sulfation 
to the desired area. Alternatively, a tyrosine sulfated therapeutic agent based on the N-terminus of 
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CCR5 would interact with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and 
inhibit HIV-1 entry by blocking viral adhesion157. 
This could also have been exploited if the PAC1 receptor was sulfated, and if sulfation affected ligand 
binding. The PAC1 receptor and its ligands are involved in a variety of deceases including cancer. 
Overexpression of PACAP has been reported in several tumors, and because some cells are 
programmed to proliferate in response to cAMP, it is conceivable that PACAP contributes to 
tumorgenesis104. Creating tyrosine-sulfated peptides based on the N-terminus of the PAC1 receptor, cell 
proliferation might be blocked by the reduction in PACAP bound to the PAC1 receptor, but it will not 
to remove the tumor. The distribution and functions of PACAP and the PAC1 receptors are vast, and 
thus limiting the effect to a specific area could be difficult.
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11 Conclusion 
The present work has shown that tyrosine sulfate was fairly stable in the pH 1 to 3 range. Incubation 
for several days has little to no effect on hydrolysis of sulfated gastrin-17 when keeping the temperature 
at 24°C or lower. With respect to the solvent no difference in hydrolysis rate was observed between 
TFA, FA and HCl at the parameters tested indicating an equal effect of the three acids i.e. the proton 
concentration.  
As determined for aryl sulfates the hydrolysis reaction of tyrosine sulfate in a peptide was of pseud 
first-order and followed the Arrhenius equation. At pH 1.3 the half-life of the hydrolysis reaction lasted 
for over three days, displaying a rather slow hydrolysis rate. The activation energy was found to be close 
to those observed for aryl sulfates, indicating a weakened S-O bond between the phenolic oxygen and 
the sulfuryl group. The hydrolysis rate depended on the amino acid structure of the peptide to a higher 
extent than the length of the peptide. Especially the lack of basic amino acids in the peptide chain 
increased the hydrolysis rate. 
The PAC1 receptor contains sites in the N terminal extracellular part of the receptor that have the 
features of a tyrosine sulfation site. Mutational studies revealed a connection between the four tyrosines 
in question and ligand binding, increasing the affinity of the receptor when mutating four tyrosines to 
phenylalanine. Mutation of the tyrosines also had an effect on signal transduction, showing an increase 
in cAMP levels in response to ligand, of the same magnitude as the increase in receptor affinity. 
Inhibition of sulfation had no effect on both receptor affinity and signal transduction indicating no 
involvement of sulfated tyrosine(s) in ligand binding, if the tyrosine(s) are sulfated. Purification of the 
receptor was unsuccessful so the final evidence for tyrosine sulfation could not be established.
 
  Summer 2006 
Reference list  Roskilde University Center 
 82
12 Reference list 
 
 1.  Bettelheim,F.R. Tyrosine-O-Sulfate in A Peptide from Fibrinogen. Journal of the American 
Chemical Society 76, 2838-2839 (1954). 
 2.  Huttner,W.B. Sulphation of tyrosine residues-a widespread modification of proteins. Nature 
299, 273-276 (1982). 
 3.  Huttner,W.B. Determination and occurrence of tyrosine O-sulfate in proteins. Methods Enzymol. 
107, 200-223 (1984). 
 4.  Danielsen,E.M. Tyrosine sulfation, a post-translational modification of microvillar enzymes in 
the small intestinal enterocyte. EMBO J. 6, 2891-2896 (1987). 
 5.  Tait,A.S., Dong,J.F., Lopez,J.A., Dawes,I.W. & Chong,B.H. Site-directed mutagenesis of 
platelet glycoprotein Ib alpha demonstrating residues involved in the sulfation of tyrosines 276, 
278, and 279. Blood 99, 4422-4427 (2002). 
 6.  Wilkins,P.P., Moore,K.L., McEver,R.P. & Cummings,R.D. Tyrosine sulfation of P-selectin 
glycoprotein ligand-1 is required for high affinity binding to P-selectin. J. Biol. Chem. 270, 22677-
22680 (1995). 
 7.  Farzan,M. et al. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 
96, 667-676 (1999). 
 8.  Choe,H. et al. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 
binding region of HIV-1 gp120. Cell 114, 161-170 (2003). 
 9.  Huang,C.C. et al. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that 
recognize the HIV type 1 coreceptor-binding site on gp120. Proc. Natl. Acad. Sci. U. S. A 101, 
2706-2711 (2004). 
 10.  Niehrs,C., Beisswanger,R. & Huttner,W.B. Protein tyrosine sulfation, 1993--an update. Chem. 
Biol. Interact. 92, 257-271 (1994). 
 11.  Huttner,W.B. Protein Tyrosine Sulfation. Trends in Biochemical Sciences 12, 361-363 (1987). 
 12.  Baeuerle,P.A. & Huttner,W.B. Tyrosine sulfation of yolk proteins 1, 2, and 3 in Drosophila 
melanogaster. J. Biol. Chem. 260, 6434-6439 (1985). 
 13.  Dong,J. et al. Tyrosine sulfation of glycoprotein I(b)alpha. Role of electrostatic interactions in 
von Willebrand factor binding. J. Biol. Chem. 276, 16690-16694 (2001). 
 14.  Dong,J.F., Li,C.Q. & Lopez,J.A. Tyrosine sulfation of the glycoprotein Ib-IX complex: 
identification of sulfated residues and effect on ligand binding. Biochemistry 33, 13946-13953 
(1994). 
 
  Summer 2006 
Reference list  Roskilde University Center 
 83
 15.  Marchese,P. et al. Identification of 3 Tyrosine Residues of Glycoprotein Ib-Alpha with Distinct 
Roles in Von-Willebrand-Factor and Alpha-Thrombin Binding. Journal of Biological Chemistry 270, 
9571-9578 (1995). 
 16.  Kanamori,A. et al. Distinct sulfation requirements of selectins disclosed using cells that support 
rolling mediated by all three selectins under shear flow. L-selectin prefers carbohydrate 6-
sulfation totyrosine sulfation, whereas p-selectin does not. J. Biol. Chem. 277, 32578-32586 
(2002). 
 17.  Sako,D. et al. A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-
selectin binding. Cell 83, 323-331 (1995). 
 18.  Pouyani,T. & Seed,B. PSGL-1 recognition of P-selectin is controlled by a tyrosine sulfation 
consensus at the PSGL-1 amino terminus. Cell 83, 333-343 (1995). 
 19.  Hortin,G.L. Sulfation of Tyrosine Residues in Coagulation Factor-V. Blood 76, 946-952 (1990). 
 20.  Pittman,D.D., Wang,J.H. & Kaufman,R.J. Identification and functional importance of tyrosine 
sulfate residues within recombinant factor VIII. Biochemistry 31, 3315-3325 (1992). 
 21.  Leyte,A. et al. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the 
interaction of factor VIII with von Willebrand factor. J. Biol. Chem. 266, 740-746 (1991). 
 22.  Liu,M.C., Yu,S., Sy,J., Redman,C.M. & Lipmann,F. Tyrosine sulfation of proteins from the 
human hepatoma cell line HepG2. Proc. Natl. Acad. Sci. U. S. A 82, 7160-7164 (1985). 
 23.  Suiko,M. & Liu,M.C. Change in binding affinities of 3Y1 secreted fibronectin upon desulfation 
of tyrosine-O-sulfate. Biochem. Biophys. Res. Commun. 154, 1094-1098 (1988). 
 24.  Jukkola,A., Risteli,J., Niemela,O. & Risteli,L. Incorporation of sulphate into type III 
procollagen by cultured human fibroblasts. Identification of tyrosine O-sulphate. Eur. J. Biochem. 
154, 219-224 (1986). 
 25.  Jenne,D., Hille,A., Stanley,K.K. & Huttner,W.B. Sulfation of two tyrosine-residues in human 
complement S-protein (vitronectin). Eur. J. Biochem. 185, 391-395 (1989). 
 26.  Hortin,G., Fok,K.F., Toren,P.C. & Strauss,A.W. Sulfation of a tyrosine residue in the plasmin-
binding domain of alpha 2-antiplasmin. J. Biol. Chem. 262, 3082-3085 (1987). 
 27.  Hortin,G., Tollefsen,D.M. & Strauss,A.W. Identification of two sites of sulfation of human 
heparin cofactor II. J. Biol. Chem. 261, 15827-15830 (1986). 
 28.  Bohme,C. et al. Tyrosine sulfation and N-glycosylation of human heparin cofactor II from 
plasma and recombinant Chinese hamster ovary cells and their effects on heparin binding. Eur. 
J. Biochem. 269, 977-988 (2002). 
 29.  Gutierrez,J. et al. Analysis of post-translational CCR8 modifications and their influence on 
receptor activity. J. Biol. Chem. 279, 14726-14733 (2004). 
 
  Summer 2006 
Reference list  Roskilde University Center 
 84
 30.  Preobrazhensky,A.A. et al. Monocyte chemotactic protein-1 receptor CCR2B is a glycoprotein 
that has tyrosine sulfation in a conserved extracellular N-terminal region. J. Immunol. 165, 5295-
5303 (2000). 
 31.  Farzan,M. et al. The role of post-translational modifications of the CXCR4 amino terminus in 
stromal-derived factor 1 alpha association and HIV-1 entry. J. Biol. Chem. 277, 29484-29489 
(2002). 
 32.  Fong,A.M., Alam,S.M., Imai,T., Haribabu,B. & Patel,D.D. CX3CR1 tyrosine sulfation enhances 
fractalkine-induced cell adhesion. J. Biol. Chem. 277, 19418-19423 (2002). 
 33.  Farzan,M. et al. Sulfated tyrosines contribute to the formation of the C5a docking site of the 
human C5a anaphylatoxin receptor. J. Exp. Med. 193, 1059-1066 (2001). 
 34.  Costagliola,S. et al. Tyrosine sulfation is required for agonist recognition by glycoprotein 
hormone receptors. EMBO J. 21, 504-513 (2002). 
 35.  Fieger,C.B., Huang,M.C., Van Brocklyn,J.R. & Goetzl,E.J. Type 1 sphingosine 1-phosphate G 
protein-coupled receptor signaling of lymphocyte functions requires sulfation of its extracellular 
amino-terminal tyrosines. FASEB J. (2005). 
 36.  Bundgaard,J.R., Vuust,J. & Rehfeld,J.F. Tyrosine O-sulfation promotes proteolytic processing 
of progastrin. EMBO J. 14, 3073-3079 (1995). 
 37.  Mutt,V. & Jorpes,J.E. Structure of porcine cholecystokinin-pancreozymin. 1. Cleavage with 
thrombin and with trypsin. Eur. J. Biochem. 6, 156-162 (1968). 
 38.  Jensen,R.T., Lemp,G.F. & Gardner,J.D. Interactions of COOH-terminal fragments of 
cholecystokinin with receptors on dispersed acini from guinea pig pancreas. J. Biol. Chem. 257, 
5554-5559 (1982). 
 39.  Anastasi,A., Erspamer,V. & Endean,R. Isolation and amino acid sequence of caerulein, the 
active decapeptide of the skin of hyla caerulea. Arch. Biochem. Biophys. 125, 57-68 (1968). 
 40.  Johnson,L.R., Stening,G.F. & Grossman,M.I. Effect of sulfation on the gastrointestinal actions 
of caerulein. Gastroenterology 58, 208-216 (1970). 
 41.  Johnsen,A.H. & Rehfeld,J.F. Cionin: a disulfotyrosyl hybrid of cholecystokinin and gastrin from 
the neural ganglion of the protochordate Ciona intestinalis. J. Biol. Chem. 265, 3054-3058 (1990). 
 42.  Kubiak,T.M. et al. Cloning and functional expression of the first Drosophila melanogaster 
sulfakinin receptor DSK-R1. Biochem. Biophys. Res. Commun. 291, 313-320 (2002). 
 43.  Nachman,R.J., Holman,G.M., Cook,B.J., Haddon,W.F. & Ling,N. Leucosulfakinin-II, a blocked 
sulfated insect neuropeptide with homology to cholecystokinin and gastrin. Biochem. Biophys. Res. 
Commun. 140, 357-364 (1986). 
 44.  Nichols,R., Schneuwly,S.A. & Dixon,J.E. Identification and characterization of a Drosophila 
homologue to the vertebrate neuropeptide cholecystokinin. J. Biol. Chem. 263, 12167-12170 
(1988). 
 
  Summer 2006 
Reference list  Roskilde University Center 
 85
 45.  Yun,H.Y., Keutmann,H.T. & Eipper,B.A. Alternative splicing governs sulfation of tyrosine or 
oligosaccharide on peptidylglycine alpha-amidating monooxygenase. J. Biol. Chem. 269, 10946-
10955 (1994). 
 46.  Hortin,G.L., Farries,T.C., Graham,J.P. & Atkinson,J.P. Sulfation of tyrosine residues increases 
activity of the fourth component of complement. Proc. Natl. Acad. Sci. U. S. A 86, 1338-1342 
(1989). 
 47.  Hortin,G., Sims,H. & Strauss,A.W. Identification of the site of sulfation of the fourth 
component of human complement. J. Biol. Chem. 261, 1786-1793 (1986). 
 48.  Bagdy,D., Barabas,E., Graf,L., Petersen,T.E. & Magnusson,S. Hirudin. Methods Enzymol. 45, 
669-678 (1976). 
 49.  Stone,S.R. & Hofsteenge,J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry 25, 
4622-4628 (1986). 
 50.  Muramatsu,R. et al. Structure-activity studies on C-terminal hirudin peptides containing sulfated 
tyrosine residues. Int. J. Pept. Protein Res. 48, 167-173 (1996). 
 51.  Baeuerle,P.A., Lottspeich,F. & Huttner,W.B. Purification of yolk protein 2 of Drosophila 
melanogaster and identification of its site of tyrosine sulfation. J. Biol. Chem. 263, 14925-14929 
(1988). 
 52.  Baeuerle,P.A. & Huttner,W.B. Tyrosine sulfation is a trans-Golgi-specific protein modification. 
J. Cell Biol. 105, 2655-2664 (1987). 
 53.  Ouyang,Y., Lane,W.S. & Moore,K.L. Tyrosylprotein sulfotransferase: purification and 
molecular cloning of an enzyme that catalyzes tyrosine O-sulfation, a common posttranslational 
modification of eukaryotic proteins. Proc. Natl. Acad. Sci. U. S. A 95, 2896-2901 (1998). 
 54.  Niehrs,C. & Huttner,W.B. Purification and characterization of tyrosylprotein sulfotransferase. 
EMBO J. 9, 35-42 (1990). 
 55.  Ouyang,Y.B. & Moore,K.L. Molecular cloning and expression of human and mouse 
tyrosylprotein sulfotransferase-2 and a tyrosylprotein sulfotransferase homologue in 
Caenorhabditis elegans. J. Biol. Chem. 273, 24770-24774 (1998). 
 56.  Beisswanger,R. et al. Existence of distinct tyrosylprotein sulfotransferase genes: molecular 
characterization of tyrosylprotein sulfotransferase-2. Proc. Natl. Acad. Sci. U. S. A 95, 11134-
11139 (1998). 
 57.  Moore,K.L. The biology and enzymology of protein tyrosine O-sulfation. J. Biol. Chem. 278, 
24243-24246 (2003). 
 58.  Hanai,H. et al. Existence of a plant tyrosylprotein sulfotransferase: novel plant enzyme 
catalyzing tyrosine O-sulfation of preprophytosulfokine variants in vitro. FEBS Lett. 470, 97-
101 (2000). 
 59.  Suiko,M. et al. Post-translational modification of protein by tyrosine sulfation: active sulfate 
PAPS is the essential substrate for this modification. Nucleic Acids Symp. Ser. 183-184 (1992). 
 
  Summer 2006 
Reference list  Roskilde University Center 
 86
 60.  Kamiyama,S. et al. Molecular cloning and identification of 3'-phosphoadenosine 5'-
phosphosulfate transporter. J. Biol. Chem. 278, 25958-25963 (2003). 
 61.  Kamiyama,S. et al. Molecular Cloning and Characterization of a Novel 3'-Phosphoadenosine 5'-
Phosphosulfate Transporter, PAPST2. J. Biol. Chem. 281, 10945-10953 (2006). 
 62.  Lee,R.W. & Huttner,W.B. (Glu62, Ala30, Tyr8)n serves as high-affinity substrate for 
tyrosylprotein sulfotransferase: a Golgi enzyme. Proc. Natl. Acad. Sci. U. S. A 82, 6143-6147 
(1985). 
 63.  Lee,R.W. & Huttner,W.B. Tyrosine-O-sulfated proteins of PC12 pheochromocytoma cells and 
their sulfation by a tyrosylprotein sulfotransferase. J. Biol. Chem. 258, 11326-11334 (1983). 
 64.  William,S., Ramaprasad,P. & Kasinathan,C. Purification of tyrosylprotein sulfotransferase from 
rat submandibular salivary glands. Arch. Biochem. Biophys. 338, 90-96 (1997). 
 65.  Niehrs,C., Huttner,W.B., Carvallo,D. & Degryse,E. Conversion of recombinant hirudin to the 
natural form by in vitro tyrosine sulfation. Differential substrate specificities of leech and 
bovine tyrosylprotein sulfotransferases. J. Biol. Chem. 265, 9314-9318 (1990). 
 66.  Goettsch,S., Goettsch,W., Morawietz,H. & Bayer,P. Shear stress mediates tyrosylprotein 
sulfotransferase isoform shift in human endothelial cells. Biochemical and Biophysical Research 
Communications 294, 541-546 (2002). 
 67.  Dodgson,K.S., Rose,F.A. & TUDBALL,N. Studies on sulphatases. 23. The enzymic 
desulphation of tyrosine O-sulphate. Biochem. J. 71, 10-15 (1959). 
 68.  Suiko,M. et al. Desulfation of tyrosine-O-sulfated peptides by some eukaryotic sulfatases. Biosci. 
Biotechnol. Biochem. 60, 137-138 (1996). 
 69.  Ranasinghe,J.G.S. et al. Structural identification of sulfated tyrosine in human urine. Bioscience 
Biotechnology and Biochemistry 63, 229-231 (1999). 
 70.  TALLAN,H.H., BELLA,S.T., STEIN,W.H. & MOORE,S. Tyrosine-O-sulfate as a constituent 
of normal human urine. J. Biol. Chem. 217, 703-708 (1955). 
 71.  Liu,M.C., Suiko,M. & Lipmann,F. Rapid Catabolism of Tyrosine-O-Sulfated Proteins and the 
Formation of Free Tyrosine O-Sulfate As An End-Product in Rat Embryo Fibroblasts. 
Biochemical Journal 243, 555-559 (1987). 
 72.  Seibert,C., Cadene,M., Sanfiz,A., Chait,B.T. & Sakmar,T.P. Tyrosine sulfation of CCR5 N-
terminal peptide by tyrosylprotein sulfotransferases 1 and 2 follows a discrete pattern and 
temporal sequence. Proc. Natl. Acad. Sci. U. S. A 99, 11031-11036 (2002). 
 73.  Guthrie,J.P. Free-Energy of Formation of Sulfur-Trioxide in Aqueous-Solution - Methods for 
Determining the Energy-Level of An Unobservable Intermediate. Journal of the American Chemical 
Society 102, 5177-5180 (1980). 
 74.  Yagami,T., Kitagawa,K., Aida,C., Fujiwara,H. & Futaki,S. Stabilization of a tyrosine O-sulfate 
residue by a cationic functional group: formation of a conjugate acid-base pair. J. Pept. Res. 56, 
239-249 (2000). 
 
  Summer 2006 
Reference list  Roskilde University Center 
 87
 75.  Gorman,G.S., Speir,J.P., Turner,C.A. & Amster,I.J. Proton Affinities of the 20 Common 
Alpha-Amino-Acids. Journal of the American Chemical Society 114, 3986-3988 (1992). 
 76.  Hengge,A.C. Isotope effects in the study of phosphoryl and sulfuryl transfer reactions. Accounts 
of Chemical Research 35, 105-112 (2002). 
 77.  Hoff,R.H., Larsen,P. & Hengge,A.C. Isotope effects and medium effects on sulfuryl transfer 
reactions. J. Am. Chem. Soc. 123, 9338-9344 (2001). 
 78.  Kice,J.L. & Anderson,J.M. Mechanism of Acid Hydrolysis of Sodium Aryl Sulfates. Journal of the 
American Chemical Society 88, 5242-& (1966). 
 79.  Fendler,E.J. & Fendler,J.H. Hydrolysis of Nitrophenyl and Dinitrophenyl Sulfate Esters. Journal 
of Organic Chemistry 33, 3852-& (1968). 
 80.  Benkovic,S.J. & Benkovic,P.A. Studies on Sulfate Esters .I. Nucleophilic Reactions of Amines 
with P-Nitrophenyl Sulfate. Journal of the American Chemical Society 88, 5504-& (1966). 
 81.  Davis,J.M., Cameron,D.R., Kubanek,J.M., Mizuyabu,L. & Thatcher,G.R.J. Acceleration of 
Sulfate Ester Hydrolysis in Hydrophobic Environments. Tetrahedron Letters 32, 2205-2206 
(1991). 
 82.  Friederich,E., Fritz,H.J. & Huttner,W.B. Inhibition of tyrosine sulfation in the trans-Golgi 
retards the transport of a constitutively secreted protein to the cell surface. J. Cell Biol. 107, 
1655-1667 (1988). 
 83.  Baeuerle,P.A. & Huttner,W.B. Inhibition of N-glycosylation induces tyrosine sulphation of 
hybridoma immunoglobulin G. EMBO J. 3, 2209-2215 (1984). 
 84.  Hille,A., Rosa,P. & Huttner,W.B. Tyrosine sulfation: a post-translational modification of 
proteins destined for secretion? FEBS Lett. 177, 129-134 (1984). 
 85.  Edson,C.M. Tyrosine sulfation of varicella-zoster virus envelope glycoprotein gpl. Virology 197, 
159-165 (1993). 
 86.  Ludlow,J.W. & Consigli,R.A. Polyomavirus major capsid protein VP1 is modified by tyrosine 
sulfuration. J. Virol. 61, 1708-1711 (1987). 
 87.  Lin,H.C. et al. Prediction of tyrosine sulfation sites in animal viruses. Biochem. Biophys. Res. 
Commun. 312, 1154-1158 (2003). 
 88.  Ouyang,Y.B., Crawley,J.T., Aston,C.E. & Moore,K.L. Reduced body weight and increased 
postimplantation fetal death in tyrosylprotein sulfotransferase-1-deficient mice. J. Biol. Chem. 
277, 23781-23787 (2002). 
 89.  Borghei,A. et al. Targeted Disruption of Tyrosylprotein Sulfotransferase-2, an Enzyme That 
Catalyzes Post-translational Protein Tyrosine O-Sulfation, Causes Male Infertility. J. Biol. Chem. 
281, 9423-9431 (2006). 
 90.  Niehrs,C., Kraft,M., Lee,R.W. & Huttner,W.B. Analysis of the substrate specificity of 
tyrosylprotein sulfotransferase using synthetic peptides. J. Biol. Chem. 265, 8525-8532 (1990). 
 
  Summer 2006 
Reference list  Roskilde University Center 
 88
 91.  Hortin,G., Folz,R., Gordon,J.I. & Strauss,A.W. Characterization of sites of tyrosine sulfation in 
proteins and criteria for predicting their occurrence. Biochem. Biophys. Res. Commun. 141, 326-333 
(1986). 
 92.  Bundgaard,J.R., Vuust,J. & Rehfeld,J.F. New consensus features for tyrosine O-sulfation 
determined by mutational analysis. J. Biol. Chem. 272, 21700-21705 (1997). 
 93.  Andersen,B.N. Species variation in the tyrosine sulfation of mammalian gastrins. Gen. Comp 
Endocrinol. 58, 44-50 (1985). 
 94.  Johnsen,A.H. et al. Unique progastrin processing in equine G-cells suggests marginal tyrosyl 
sulfotransferase activity. Eur. J. Biochem. 255, 432-438 (1998). 
 95.  Jonson,L., Bundgaard,J.R., Johnsen,A.H. & Rourke,I.J. Identification and expression of gastrin 
and cholecystokinin mRNAs from the turtle, Pseudemys scripta: evidence of tissue-specific 
tyrosyl sulfation(1). Biochim. Biophys. Acta 1435, 84-93 (1999). 
 96.  Monigatti,F., Gasteiger,E., Bairoch,A. & Jung,E. The Sulfinator: predicting tyrosine sulfation 
sites in protein sequences. Bioinformatics. 18, 769-770 (2002). 
 97.  Gether,U. Uncovering molecular mechanisms involved in activation of G protein-coupled 
receptors. Endocr. Rev. 21, 90-113 (2000). 
 98.  Harmar,A.J. et al. International Union of Pharmacology. XVIII. Nomenclature of receptors for 
vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol. 
Rev. 50, 265-270 (1998). 
 99.  Ohtaki,T. et al. Molecular identification of receptor for pituitary adenylate cyclase activating 
polypeptide. Biochem. Biophys. Res. Commun. 171, 838-844 (1990). 
 100.  Ogi,K. et al. Molecular cloning and functional expression of a cDNA encoding a human 
pituitary adenylate cyclase activating polypeptide receptor. Biochem. Biophys. Res. Commun. 196, 
1511-1521 (1993). 
 101.  Pantaloni,C. et al. Alternative splicing in the N-terminal extracellular domain of the pituitary 
adenylate cyclase-activating polypeptide (PACAP) receptor modulates receptor selectivity and 
relative potencies of PACAP-27 and PACAP-38 in phospholipase C activation. J. Biol. Chem. 
271, 22146-22151 (1996). 
 102.  Vertongen,P., Velkeniers,B., Hooghe-Peters,E. & Robberecht,P. Differential alternative splicing 
of PACAP receptor in pituitary cell subpopulations. Mol. Cell Endocrinol. 113, 131-135 (1995). 
 103.  Robberecht,P. et al. The two forms of the pituitary adenylate cyclase activating polypeptide 
(PACAP (1-27) and PACAP (1-38)) interact with distinct receptors on rat pancreatic AR 4-2J 
cell membranes. FEBS Lett. 286, 133-136 (1991). 
 104.  Vaudry,D. et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: from 
structure to functions. Pharmacol. Rev. 52, 269-324 (2000). 
 105.  Somogyvari-Vigh,A. & Reglodi,D. Pituitary adenylate cyclase activating polypeptide: a potential 
neuroprotective peptide. Curr. Pharm. Des 10, 2861-2889 (2004). 
 
  Summer 2006 
Reference list  Roskilde University Center 
 89
 106.  Dautzenberg,F.M., Mevenkamp,G., Wille,S. & Hauger,R.L. N-terminal splice variants of the 
type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants. 
J. Neuroendocrinol. 11, 941-949 (1999). 
 107.  Pisegna,J.R., Moody,T.W. & Wank,S.A. Differential signaling and immediate-early gene 
activation by four splice variants of the human pituitary adenylate cyclase-activating polypeptide 
receptor (hPACAP-R). Ann. N. Y. Acad. Sci. 805, 54-64 (1996). 
 108.  Spengler,D. et al. Differential signal transduction by five splice variants of the PACAP receptor. 
Nature 365, 170-175 (1993). 
 109.  Chatterjee,T.K., Liu,X., Davisson,R.L. & Fisher,R.A. Genomic organization of the rat pituitary 
adenylate cyclase-activating polypeptide receptor gene. Alternative splicing within the 5'-
untranslated region. J. Biol. Chem. 272, 12122-12131 (1997). 
 110.  Cao,Y.J., Gimpl,G. & Fahrenholz,F. The amino-terminal fragment of the adenylate cyclase 
activating polypeptide (PACAP) receptor functions as a high affinity PACAP binding domain. 
Biochem. Biophys. Res. Commun. 212, 673-680 (1995). 
 111.  Lutz,E.M. et al. Domains determining agonist selectivity in chimaeric VIP2 (VPAC2)/PACAP 
(PAC1) receptors. Br. J. Pharmacol. 128, 934-940 (1999). 
 112.  Pisegna,J.R. & Wank,S.A. Cloning and characterization of the signal transduction of four splice 
variants of the human pituitary adenylate cyclase activating polypeptide receptor. Evidence for 
dual coupling to adenylate cyclase and phospholipase C. J. Biol. Chem. 271, 17267-17274 (1996). 
 113.  Knudsen,S.M., Tams,J.W., Wulff,B.S. & Fahrenkrug,J. Importance of conserved cysteines in the 
extracellular loops of human PACAP/VIP1 receptor for ligand binding and stimulation of 
cAMP production. Ann. N. Y. Acad. Sci. 865, 259-265 (1998). 
 114.  Shintani,N. et al. Desensitization, surface expression, and glycosylation of a functional, epitope-
tagged type I PACAP (PAC(1)) receptor. Biochim. Biophys. Acta 1509, 195-202 (2000). 
 115.  Lutz,E.M. et al. The VIP2 receptor: molecular characterisation of a cDNA encoding a novel 
receptor for vasoactive intestinal peptide. FEBS Lett. 334, 3-8 (1993). 
 116.  Ishihara,T. et al. Molecular cloning and expression of a cDNA encoding the secretin receptor. 
EMBO J. 10, 1635-1641 (1991). 
 117.  Thorens,B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin 
hormone glucagon-like peptide 1. Proc. Natl. Acad. Sci. U. S. A 89, 8641-8645 (1992). 
 118.  Miyata,A. et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates 
adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun. 164, 567-574 (1989). 
 119.  Miyata,A. et al. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the 
pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem. Biophys. 
Res. Commun. 170, 643-648 (1990). 
 
  Summer 2006 
Reference list  Roskilde University Center 
 90
 120.  Kimura,C. et al. A novel peptide which stimulates adenylate cyclase: molecular cloning and 
characterization of the ovine and human cDNAs. Biochem. Biophys. Res. Commun. 166, 81-89 
(1990). 
 121.  Wray,V., Kakoschke,C., Nokihara,K. & Naruse,S. Solution structure of pituitary adenylate 
cyclase activating polypeptide by nuclear magnetic resonance spectroscopy. Biochemistry 32, 
5832-5841 (1993). 
 122.  Robberecht,P. et al. Structural requirements for the occupancy of pituitary adenylate-cyclase-
activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma 
NB-OK-1 cell membranes. Discovery of PACAP(6-38) as a potent antagonist. Eur. J. Biochem. 
207, 239-246 (1992). 
 123.  Inooka,H., Endo,S., Kitada,C., Mizuta,E. & Fujino,M. Pituitary adenylate cyclase activating 
polypeptide (PACAP) with 27 residues. Conformation determined by 1H NMR and CD 
spectroscopies and distance geometry in 25% methanol solution. Int. J. Pept. Protein Res. 40, 456-
464 (1992). 
 124.  Cao,Y.J. et al. Identification of binding domains of pituitary adenylate cyclase activating 
polypeptide (PACAP) for its type 1 receptor by photoaffinity labeling. Ann. N. Y. Acad. Sci. 
865, 82-91 (1998). 
 125.  Robberecht,P. et al. Receptor occupancy and adenylate cyclase activation in AR 4-2J rat 
pancreatic acinar cell membranes by analogs of pituitary adenylate cyclase-activating peptides 
amino-terminally shortened or modified at position 1, 2, 3, 20, or 21. Mol. Pharmacol. 42, 347-
355 (1992). 
 126.  Cao,Y.J. et al. Photoaffinity labeling analysis of the interaction of pituitary adenylate-cyclase-
activating polypeptide (PACAP) with the PACAP type I receptor. Eur. J. Biochem. 244, 400-406 
(1997). 
 127.  Braas,K.M. et al. Role for Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) in 
Cystitis-induced Plasticity of Micturition Reflexes. Am. J. Physiol Regul. Integr. Comp Physiol (2005). 
 128.  Buscail,L. et al. Presence of highly selective receptors for PACAP (pituitary adenylate cyclase 
activating peptide) in membranes from the rat pancreatic acinar cell line AR 4-2J. FEBS Lett. 
262, 77-81 (1990). 
 129.  Vertongen,P. et al. Pituitary adenylate cyclase-activating polypeptide receptors of types I and II 
and glucagon-like peptide-I receptors are expressed in the rat medullary carcinoma of the 
thyroid cell line 6/23. Endocrinology 135, 1537-1542 (1994). 
 130.  Vertongen,P. et al. Comparison between vasoactive intestinal polypeptide and pituitary 
adenylate cyclase activating polypeptide levels in neuroblastoma tumour tissues. Neuropeptides 31, 
409-413 (1997). 
 131.  Cauvin,A. et al. The novel VIP-like hypothalamic polypeptide PACAP interacts with high 
affinity receptors in the human neuroblastoma cell line NB-OK. Peptides 11, 773-777 (1990). 
 132.  Lutz,E.M. et al. Characterization of novel splice variants of the PAC(1) receptor in human 
neuroblastoma cells: Consequences for signaling by VIP and PACAP. Mol. Cell Neurosci. (2005). 
 
  Summer 2006 
Reference list  Roskilde University Center 
 91
 133.  Robberecht,P. et al. Expression of pituitary adenylate cyclase activating polypeptide (PACAP) 
receptors in human glial cell tumors. Peptides 15, 661-665 (1994). 
 134.  Zia,F. et al. Pituitary adenylate cyclase activating peptide receptors regulate the growth of non-
small cell lung cancer cells. Cancer Res. 55, 4886-4891 (1995). 
 135.  Moody,T.W., Zia,F. & Makheja,A. Pituitary adenylate cyclase activating polypeptide receptors 
are present on small cell lung cancer cells. Peptides 14, 241-246 (1993). 
 136.  Van Rampelbergh,J. et al. The pituitary adenylate cyclase activating polypeptide (PACAP I) and 
VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO 
cells through interaction with different G proteins. Biochim. Biophys. Acta 1357, 249-255 (1997). 
 137.  Delporte,C. et al. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive 
intestinal peptide stimulate two signaling pathways in CHO cells stably transfected with the 
selective type I PACAP receptor. Mol. Cell Endocrinol. 107, 71-76 (1995). 
 138.  Ciccarelli,E. et al. Pharmacological properties of two recombinant splice variants of the PACAP 
type I receptor, transfected and stably expressed in CHO cells. Eur. J. Pharmacol. 288, 259-267 
(1995). 
 139.  Alberts,B. et al. Molecular Biology of the Cell. GS Garland Science, Taylor and Francis Group 
USA, (2002). 
 140.  McCulloch,D.A., Lutz,E.M., Johnson,M.S., MacKenzie,C.J. & Mitchell,R. Differential activation 
of phospholipase D by VPAC and PAC1 receptors. Ann. N. Y. Acad. Sci. 921, 175-185 (2000). 
 141.  McCulloch,D.A. et al. ADP-ribosylation factor-dependent phospholipase D activation by VPAC 
receptors and a PAC(1) receptor splice variant. Mol. Pharmacol. 59, 1523-1532 (2001). 
 142.  Daniel,P.B., Kieffer,T.J., Leech,C.A. & Habener,J.F. Novel alternatively spliced exon in the 
extracellular ligand-binding domain of the pituitary adenylate cyclase-activating polypeptide 
(PACAP) type 1 receptor (PAC1R) selectively increases ligand affinity and alters signal 
transduction coupling during spermatogenesis. J. Biol. Chem. 276, 12938-12944 (2001). 
 143.  Chatterjee,T.K., Sharma,R.V. & Fisher,R.A. Molecular cloning of a novel variant of the pituitary 
adenylate cyclase-activating polypeptide (PACAP) receptor that stimulates calcium influx by 
activation of L-type calcium channels. J. Biol. Chem. 271, 32226-32232 (1996). 
 144.  Bundgaard,J.R., Cowland,J.B., Vuust,J. & Rehfeld,J.F. An efficient cellular system for 
mutational analysis of prohormone processing. DNA Cell Biol. 15, 147-157 (1996). 
 145.  Ira N.Levine. Physical Chemistry. McGraw-Hill Companies, Inc. New York, (2002). 
 146.  Lide,D.R. CRC Handbook of Chemistry and Physics 1999-2000. (1999). 
 147.  Chesnut,D.B. & Quin,L.D. Nature of bonding in the sulfuryl group. J. Comput. Chem. 25, 734-
738 (2004). 
 148.  Michigan State University,D.o.C. http://www.chemistry.msu.edu/.  2006.  
 
  Summer 2006 
Reference list  Roskilde University Center 
 92
 149.  Taupenot,L., Harper,K.L. & O'Connor,D.T. The chromogranin-secretogranin family. N. Engl. 
J. Med. 348, 1134-1149 (2003). 
 150.  The ExPASy (Expert Protein Analysis System) proteomics server of the Swiss Institute of 
Bioinformatics (SIB). www.expasy.org.  2006.  
 
 151.  UMR cDNA Resource Center. www.cdna.org.  2006.  
 
 152.  Mintz,K.P., Fisher,L.W., Grzesik,W.J., Hascall,V.C. & Midura,R.J. Chlorate-induced inhibition 
of tyrosine sulfation on bone sialoprotein synthesized by a rat osteoblast-like cell line (UMR 
106-01 BSP). J. Biol. Chem. 269, 4845-4852 (1994). 
 153.  Baeuerle,P.A. & Huttner,W.B. Chlorate - A Potent Inhibitor of Protein Sulfation in Intact-Cells. 
Biochemical and Biophysical Research Communications 141, 870-877 (1986). 
 154.  Mirzabekov,T. et al. Enhanced expression, native purification, and characterization of CCR5, a 
principal HIV-1 coreceptor. J. Biol. Chem. 274, 28745-28750 (1999). 
 155.  Jamen,F. et al. PAC1 null females display decreased fertility. Ann. N. Y. Acad. Sci. 921, 400-404 
(2000). 
 156.  Hsu,W., Rosenquist,G.L., Ansari,A.A. & Gershwin,M.E. Autoimmunity and tyrosine sulfation. 
Autoimmun. Rev. 4, 429-435 (2005). 
 157.  Farzan,M. et al. A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a 
CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry. J. 
Biol. Chem. 275, 33516-33521 (2000). 
 
 
  Summer 2006 
Supplements  Roskilde University Center 
 93
13 Supplements 
13.1 Alignment data of the PAC1 receptor family: 
Alignment length : 520 
Identity (*) : 90 is 17.31 % 
Strongly similar (:) : 65 is 12.50 % 
Weakly similar (.) : 23 is 4.42 % 
Different : 342 is 65.77 % 
Sequence 0001 : PACR_HUMAN ( 468 residues); PAC1 receptor. 
Sequence 0002 : VIPR2_HUMAN ( 438 residues); VPAC1 receptor. 
Sequence 0003 : VIPR1_HUMAN ( 457 residues); VPAC2 receptor. 
Sequence 0004 : SCTR_HUMAN ( 440 residues); Secretin receptor. 
Sequence 0005 : GLR_HUMAN ( 477 residues); Glucagon receptor. 
Sequence 0006 : GLP1R_HUMAN ( 463 residues); Glucagon-Like Peptide 1 receptor. 
Sequence 0007 : CALCR_HUMAN ( 490 residues); Calcitonin receptor.  
 
Color codes: Yellow:  Cysteine residues, possible of disulfide bridge. 
Green: Possible N-linked glycosylation site. 
Red: Possible sulfated tyrosines. 
CLUSTAL W (1.8) multiple sequence alignment 
PACR_HUMAN       MAGVVHVSLAALLLLP---------------MAPAMHSDCIFKKEQAMCLEKIQRANELM 
VIPR2_HUMAN      MRTLLPPALLTCWLLA---------------PVNSIHPECRFHLEIQE--EETKCAELLR 
VIPR1_HUMAN      MRPPSPLPARWLCVLAGALAWALGPAG---GQAARLQEECDYVQMIEV--QHKQCLEEAQ 
SCTR_HUMAN       MRPHLSPPLQQLLLPVLLACAAH--------STGALPRLCDVLQVLWE--EQDQCLQELS 
GLR_HUMAN        MPPCQ-PQRPLLLLLLLLACQP---------QVPSAQVMDF--LFEKWKLYGDQCHHNLS 
GLP1R_HUMAN      MAGAPGPLRLALLLLGMVGRAG---------PRPQGATVSLWETVQKWREYRRQCQRSLT 
CALCR_HUMAN      MRFTFTSRCLALFLLLNHPTPILPAFSNQTYPTIEPKPFLYVVGRKKMMDAQYKCYDRMQ 
                 *            :                                       :       
 
PACR_HUMAN       GFNDSS-------PGCPGMWDNITCWKPAHVGEMVLVSCPELFRIFNPDQVWETETIGES 
VIPR2_HUMAN      SQTEKH-------KACSGVWDNITCWRPANVGETVTVPCPKVFSNFY------------- 
VIPR1_HUMAN      LENET--------IGCSKMWDNLTCWPATPRGQVVVLACPLIFKLFSS------------ 
SCTR_HUMAN       REQTGDLGTEQPVPGCEGMWDNISCWPSSVPGRMVEVECPRFLRMLT------------- 
GLR_HUMAN        LLPPP------TELVCNRTFDKYSCWPDTPANTTANISCPWYLPWHHK------------ 
GLP1R_HUMAN      EDPPPA-----TDLFCNRTFDEYACWPDGEPGSFVNVSCPWYLPWASS------------ 
CALCR_HUMAN      QLPAYQ---G-EGPYCNRTWDGWLCWDDTPAGVLSYQFCPDYFPDFD------------- 
                                *   :*   **     .      **  :                  
 
PACR_HUMAN       DFGDSNSLDLSDMGVVSRNCTEDGWSEPFP-HYFDACGFDEYESET--------GD-QDY 
VIPR2_HUMAN      ----------SKAGNISKNCTSDGWSETFP-DFVDACGYSDPEDES-----------KIT 
VIPR1_HUMAN      ----------IQGRNVSRSCTDEGWTHLEPGPYPIACGLDDKAASL--------DEQQTM 
SCTR_HUMAN       ----------SRNGSLFRNCTQDGWSETFP-RPNLACGVNVNDSSN--------EK-RHS 
GLR_HUMAN        ----------VQHRFVFKRCGPDGQWVR-GPRGQPWRDASQCQMD--GEEIEVQ-KEVAK 
GLP1R_HUMAN      ----------VPQGHVYRFCTAEGLWLQKDNSSLPWRDLSECEESKRGERSSPE-EQLLF 
CALCR_HUMAN      -----------PSEKVTKYCDEKGVWFKHPENNRTWSNYTMCNAFT---------PEKLK 
                                : : *  .*             .                       
 
PACR_HUMAN       YYLSVKALYTVGYSTSLVTLTTAMVILCRFRKLH----------------CTRNFIHMNL 
VIPR2_HUMAN      FYILVKAIYTLGYSVSLMSLATGSIILCLFRKLH----------------CTRNYIHLNL 
VIPR1_HUMAN      FYGSVKTGYTIGYGLSLATLLVATAILSLFRKLH----------------CTRNYIHMHL 
SCTR_HUMAN       YLLKLKVMYTVGYSSSLVMLLVALGILCAFRRLH----------------CTRNYIHMHL 
GLR_HUMAN        MYSSFQVMYTVGYSLSLGALLLALAILGGLSKLH----------------CTRNAIHANL 
GLP1R_HUMAN      LY----IIYTVGYALSFSALVIASAILLGFRHLH----------------CTRNYIHLNL 
CALCR_HUMAN      NAYVLYYLAIVGHSLSIFTLVISLGIFVFFRKLTTIFPLNWKYRKALSLGCQRVTLHKNM 
                           :*:. *:  *  .  *:  : :*                 * *  :* :: 
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PACR_HUMAN       FVSFMLRAISVFIKDWILYAEQD-------SNHC---FISTVECKAVMVFFHYCVVSNYF 
VIPR2_HUMAN      FLSFILRAISVLVKDDVLYSSSG-------TLHCPDQPSSWVGCKLSLVFLQYCIMANFF 
VIPR1_HUMAN      FISFILRAAAVFIKDLALFDSGE-------SDQCS---EGSVGCKAAMVFFQYCVMANFF 
SCTR_HUMAN       FVSFILRALSNFIKDAVLFSSDD-------VTYCD---AHRAGCKLVMVLFQYCIMANYS 
GLR_HUMAN        FASFVLKASSVLVIDGLLRTRYSQKIGDDLSVSTWLSDGAVAGCRVAAVFMQYGIVANYC 
GLP1R_HUMAN      FASFILRALSVFIKDAALKWMYS-TAAQQHQWDGLLSYQDSLSCRLVFLLMQYCVAANYY 
CALCR_HUMAN      FLTYILNSMIIIIHLVEVVPNGE-------LVRR-----DPVSCKILHFFHQYMMACNYF 
                 * :::*.:   ::    :                         *:   .: :* : .*:  
 
PACR_HUMAN       WLFIEGLYLFTLLVETFFPERRYFYWYTIIGWGTPTVCVTVWATLRLYFDDTGCWDMNDS 
VIPR2_HUMAN      WLLVEGLYLHTLLVAMLPP-RRCFLAYLLIGWGLPTVCIGAWTAARLYLEDTGCWDTNDH 
VIPR1_HUMAN      WLLVEGLYLYTLLAVSFFSERKYFWGYILIGWGVPSTFTMVWTIARIHFEDYGCWDTIN- 
SCTR_HUMAN       WLLVEGLYLHTLLAISFFSERKYLQGFVAFGWGSPAIFVALWAIARHFLEDVGCWDINAN 
GLR_HUMAN        WLLVEGLYLHNLLGLATLPERSFFSLYLGIGWGAPMLFVVPWAVVKCLFENVQCWTSNDN 
GLP1R_HUMAN      WLLVEGVYLYTLLAFSVFSEQWIFRLYVSIGWGVPLLFVVPWGIVKYLYEDEGCWTRNSN 
CALCR_HUMAN      WMLCEGIYLHTLIVVAVFTEKQRLRWYYLLGWGFPLVPTTIHAITRAVYFNDNCWLSVE- 
                 *:: **:**..*:     . :  :  :  :*** *          :    :  **      
 
PACR_HUMAN       TALWWVIKGPVVGSIMVNFVLFIGIIVILVQKLQSPDMGGNESSIYLRLARSTLLLIPLF 
VIPR2_HUMAN      SVPWWVIRIPILISIIVNFVLFISIIRILLQKLTSPDVGGNDQSQYKRLAKSTLLLIPLF 
VIPR1_HUMAN      SSLWWIIKGPILTSILVNFILFICIIRILLQKLRPPDIRKSDSSPYSRLARSTLLLIPLF 
SCTR_HUMAN       ASIWWIIRGPVILSILINFILFINILRILMRKLRTQETRGNEVSHYKRLARSTLLLIPLF 
GLR_HUMAN        MGFWWILRFPVFLAILINFFIFVRIVQLLVAKLRARQMHHTDYK--FRLAKSTLTLIPLL 
GLP1R_HUMAN      MNYWLIIRLPILFAIGVNFLIFVRVICIVVSKLKANLMCKTDIK--CRLAKSTLTLIPLL 
CALCR_HUMAN      THLLYIIHGPVMAALVVNFFFLLNIVRVLVTKMR--ETHEAESHMYLKAVKATMILVPLL 
                      ::: *:. :: :**.::: :: ::: *:        :     : .::*: *:**: 
 
PACR_HUMAN       GIHYTVFAFSPENV----SKRERLVFELGLGSFQGFVVAVLYCFLNGEVQAEIKRKWRSW 
VIPR2_HUMAN      GVHYMVFAVFPISI----SSKYQILFELCLGSFQGLVVAVLYCFLNSEVQCELKRKWRSR 
VIPR1_HUMAN      GVHYIMFAFFPDNF----KPEVKMVFELVVGSFQGFVVAILYCFLNGEVQAELRRKWRRW 
SCTR_HUMAN       GIHYIVFAFSPED-----AMEIQLFFELALGSFQGLVVAVLYCFLNGEVQLEVQKKWQQW 
GLR_HUMAN        GVHEVVFAFVTDEHAQGTLRSAKLFFDLFLSSFQGLLVAVLYCFLNKEVQSELRRRWHRW 
GLP1R_HUMAN      GTHEVIFAFVMDEHARGTLRFIKLFTELSFTSFQGLMVAILYCFVNNEVQLEFRKSWERW 
CALCR_HUMAN      GIQFVVFPWRPSNK---MLGKIYDYVMHSLIHFQGFFVATIYCFCNNEVQTTVKRQWAQF 
                 * :  :*.    .                .  ***:.** :*** * ***  .:: *    
 
PACR_HUMAN       KVNRYFAV--DFKHRHPSLASSGVNGGTQLSILSKSSSQIRMSGLPADNLAT-------- 
VIPR2_HUMAN      CPTPSASR--DYRVCGSSFSRNGSEGALQFHRGSRAQSFLQTETSVI------------- 
VIPR1_HUMAN      HLQGVLGW--NPKYRHPSGGSNGATCSTQVSMLTRVSPGARRSSSFQAEVSLV------- 
SCTR_HUMAN       HLR-------EFPLHPVASFSN----STKASHLEQSQGTCRTSII--------------- 
GLR_HUMAN        RLGKVLWEERNTSNHRASSSPGHGPPSKELQFGRGGGSQDSSAETPLAGGLPRLAESPF- 
GLP1R_HUMAN      RLEHLHIQ-------RDSSMKPLKCPTSSLSSGATAGSSMYTATCQASCS---------- 
CALCR_HUMAN      KIQWNQRWGRRPSNRSARAAAAAAEAGDIPIYICHQEPRNEPANNQGEESAEIIPLNIIE 
                                                                              
 
PACR_HUMAN       ----- 
VIPR2_HUMAN      ----- 
VIPR1_HUMAN      ----- 
SCTR_HUMAN       ----- 
GLR_HUMAN        ----- 
GLP1R_HUMAN      ----- 
CALCR_HUMAN      QESSA 
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13.2  Alignment data of the PAC1 receptor in different species: 
Alignment length : 541   Sequence 0001 : PACR_MOUSE ( 496 residues). 
Identity (*) : 423 is 78.19 %   Sequence 0002 : PACR_RAT ( 523 residues). 
Strongly similar (:) : 26 is 4.81 %   Sequence 0003 : PACR_HUMAN ( 468 residues). 
Weakly similar (.) : 9 is 1.66 %   Sequence 0004 : PACR_BOVIN ( 513 residues). 
Different : 83 is 15.34 % 
Color codes: Yellow:  Cysteine residues, possible of disulfide bridge. 
Green: Possible N-linked glycosylation site. 
Red: Possible sulfated tyrosines. 
 
CLUSTAL W (1.8) multiple sequence alignment 
 
PACR_MOUSE      -----------------MARTLQLSLTALLLLPMAIAMHSDCIFKKEQAMCLERIQRAND 
PACR_RAT        -----------------MARVLQLSLTA-LLLPVAIAMHSDCIFKKEQAMCLERIQRAND 
PACR_HUMAN      -----------------MAGVVHVSLAALLLLPMAPAMHSDCIFKKEQAMCLEKIQRANE 
PACR_BOVIN      MRGGRHWPEPPCRLRSVMASIAQVSLAALLLLPMATAMHSDCIFKKEQAMCLEKIQRVND 
                                 **   ::**:* ****:* *****************:***.*: 
 
PACR_MOUSE      LMGLNESSPGCPGMWDNITCWKPAQIGEMVLVSCPEVFRIFNPDQVWMTETIGDSGFADS 
PACR_RAT        LMGLNESSPGCPGMWDNITCWKPAQVGEMVLVSCPEVFRIFNPDQVWMTETIGDSGFADS 
PACR_HUMAN      LMGFNDSSPGCPGMWDNITCWKPAHVGEMVLVSCPELFRIFNPDQVWETETIGESDFGDS 
PACR_BOVIN      LMGLNDSSPGCPGMWDNITCWKPAHVGEMVLVSCPELFRIFNPDQVWETETIGEFGFADS 
                ***:*:******************::**********:********** *****: .*.** 
 
PACR_MOUSE      NSLEITDMGVVGRNCTEDGWSEPFPHYFDACGFDDYEPESGDQDYYYLSVKALYTVGYST 
PACR_RAT        NSLEITDMGVVGRNCTEDGWSEPFPHYFDACGFDDYEPESGDQDYYYLSVKALYTVGYST 
PACR_HUMAN      NSLDLSDMGVVSRNCTEDGWSEPFPHYFDACGFDEYESETGDQDYYYLSVKALYTVGYST 
PACR_BOVIN      KSLDLSDMRVVSRNCTEDGWSEPFPHYFDACGFEEYESETGDQDYYYLSVKALYTVGYST 
                :**:::** **.*********************::**.*:******************** 
 
PACR_MOUSE      SLVTLTTAMVILCRFRKLHCTRNFIHMNLFVSFMLRAISVFIKDWILYAEQDSSHCFVST 
PACR_RAT        SLATLTTAMVILCRFRKLHCTRNFIHMNLFVSFMLRAISVFIKDWILYAEQDSSHCFVST 
PACR_HUMAN      SLVTLTTAMVILCRFRKLHCTRNFIHMNLFVSFMLRAISVFIKDWILYAEQDSNHCFIST 
PACR_BOVIN      SLVTLTTAMVILCRFRKLHCTRNFIHMNLFVSFMLRAISVFIKDWILYAEQDSNHCFVST 
                **.**************************************************.***:** 
 
PACR_MOUSE      VECKAVMVFFHYCVVSNYFWLFIEGLYLFTLLVETFFPERRYFYWYTIIGWGTPTVCVTV 
PACR_RAT        VECKAVMVFFHYCVVSNYFWLFIEGLYLFTLLVETFFPERRYFYWYTIIGWGTPTVCVTV 
PACR_HUMAN      VECKAVMVFFHYCVVSNYFWLFIEGLYLFTLLVETFFPERRYFYWYTIIGWGTPTVCVTV 
PACR_BOVIN      VECKAVMVFFHYCVVSNYFWLFIEGLYLFTLLVETFFPERRYFYWYIIIGWGTPTVCVSV 
                ********************************************** ***********:* 
 
PACR_MOUSE      WAVLRLYFDDAGCWDMNDSTALWWVIKGPVVGSIMVNFVLFIGIIIILVQKLQSPDMGGN 
PACR_RAT        WAVLRLYFDDAGCWDMNDSTALWWVIKGPVVGSIMVNFVLFIGIIIILVQKLQSPDMGGN 
PACR_HUMAN      WATLRLYFDDTGCWDMNDSTALWWVIKGPVVGSIMVNFVLFIGIIVILVQKLQSPDMGGN 
PACR_BOVIN      WAMLRLYFDDTGCWDMNDNTALWWVIKGPVVGSIMVNFVLFIGIIVILVQKLQSPDMGGN 
                ** *******:*******.**************************:************** 
 
PACR_MOUSE      ESSIYFS----------------------------CVQKCYCKPQRAQQHSCKMSELSTI 
PACR_RAT        ESSIYLTNLRLRVPKKTREDPLPVPSDQHSPPFLSCVQKCYCKPQRAQQHSCKMSELSTI 
PACR_HUMAN      ESSIY------------------------------------------------------- 
PACR_BOVIN      ESSIYFS----------------------------CVQKCYCKPQRAQQHSCKMSELSTI 
                *****                                                        
 
PACR_MOUSE      TLRLARSTLLLIPLFGIHYTVFAFSPENVSKRERLVFELGLGSFQGFVVAVLYCFLNGEV 
PACR_RAT        TLRLARSTLLLIPLFGIHYTVFAFSPENVSKRERLVFELGLGSFQGFVVAVLYCFLNGEV 
PACR_HUMAN      -LRLARSTLLLIPLFGIHYTVFAFSPENVSKRERLVFELGLGSFQGFVVAVLYCFLNGEV 
PACR_BOVIN      TLRLARSTLLLIPLFGIHYTVFAFSPENVSKRERLVFELGLGSFQGFVVAVLYCFLNGEV 
                 *********************************************************** 
 
PACR_MOUSE      QAEIKRKWRSWKVNRYFTMDFKHRHPSLASSGVNGGTQLSILSKSSSQLRMSSLPADNLAT 
PACR_RAT        QAEIKRKWRSWKVNRYFTMDFKHRHPSLASSGVNGGTQLSILSKSSSQLRMSSLPADNLAT 
PACR_HUMAN      QAEIKRKWRSWKVNRYFAVDFKHRHPSLASSGVNGGTQLSILSKSSSQIRMSGLPADNLAT 
PACR_BOVIN      QAEIKRKWRSWKVNRYFTMDFKHRHPSLASSGVNGGTQLSILSKSSSQIRMSGLPADNLAT 
                *****************::*****************************:***.******** 
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13.3 The cDNA sequence of PAC1 receptor: 
Human pituitary adenyl cyclase activating polypeptide 1 receptor type 1 (ADCYAP1R1) in 
pcDNA3.1(+) purchased from UMR resource center. 
 
      >KpnI 
                          | 
           >AflII >Asp7181| 
             |        |   | 
>NheI >PmeI  |>HindIII|   |    >BamHI 
|        |   |  |     |   |       | 
|       10   |  | 20  |   | 30    |   40        50 
GCTAGCGTTTAAACTTAAGCTTGGTACCGAGCTCGGATCCACTAGTCCAG 
CGATCGCAAATTTGAATTCGAACCATGGCTCGAGCCTAGGTGATCAGGTC 
    >EcoRI 
       | 
>BstXI | 
   |   | 
   |   |60        70        80        90       100 
TGTGGTGGAATTCACCATGGCTGGTGTCGTGCACGTTTCCCTGGCTGCTC Yellow: PAC1-V5-forward primer 
ACACCACCTTAAGTGGTACCGACCACAGCACGTGCAAAGGGACCGACGAG  
                 M  A  G  V  V  H  V  S  L  A  A 
 
       110       120       130       140       150 
TCCTCCTGCTGCCTATGGCCCCTGCCATGCATTCTGACTGCATCTTCAAG Purple: PAC1-F-XhoI primer 
AGGAGGACGACGGATACCGGGGACGGTACGTAAGACTGACGTAGAAGTTC 
L  L  L  L  P  M  A  P  A  M  H  S  D  C  I  F  K 
 
       160       170       180       190       200 
AAGGAGCAAGCCATGTGCCTGGAGAAGATCCAGAGGGCCAATGAGCTGAT 
TTCCTCGTTCGGTACACGGACCTCTTCTAGGTCTCCCGGTTACTCGACTA 
 K  E  Q  A  M  C  L  E  K  I  Q  R  A  N  E  L  M 
  
       210       220       230       240       250 
GGGCTTCAATGATTCCTCTCCAGGCTGTCCTGGGATGTGGGACAACATCA 
CCCGAAGTTACTAAGGAGAGGTCCGACAGGACCCTACACCCTGTTGTAGT 
  G  F  N  D  S  S  P  G  C  P  G  M  W  D  N  I 
 
       260       270       280       290       300 
CGTGTTGGAAGCCCGCCCATGTGGGTGAGATGGTCCTGGTCAGCTGCCCT 
GCACAACCTTCGGGCGGGTACACCCACTCTACCAGGACCAGTCGACGGGA 
T  C  W  K  P  A  H  V  G  E  M  V  L  V  S  C  P 
 
       310       320       330       340       350 
GAGCTCTTCCGAATCTTCAACCCAGACCAAGTCTGGGAGACCGAAACCAT 
CTCGAGAAGGCTTAGAAGTTGGGTCTGGTTCAGACCCTCTGGCTTTGGTA 
 E  L  F  R  I  F  N  P  D  Q  V  W  E  T  E  T  I 
   
       360       370       380       390       400 
TGGAGAGTCTGATTTTGGTGACAGTAACTCCTTAGATCTCTCAGACATGG 
ACCTCTCAGACTAAAACCACTGTCATTGAGGAATCTAGAGAGTCTGTACC 
  G  E  S  D  F  G  D  S  N  S  L  D  L  S  D  M 
 
       410       420       430       440       450 
GAGTGGTGAGCCGGAACTGCACGGAGGATGGCTGGTCGGAACCCTTCCCT Blue: PAC1-RT3-For 
CTCACCACTCGGCCTTGACGTGCCTCCTACCGACCAGCCTTGGGAAGGGA 
G  V  V  S  R  N  C  T  E  D  G  W  S  E  P  F  P 
 
       460       470       480       490       500 
CATTACTTTGATGCCTGTGGGTTTGATGAATATGAATCTGAGACTGGGGA Gray: mADCYAP1R1-forward and 
GTAATGAAACTACGGACACCCAAACTACTTATACTTAGACTCTGACCCCT mADCYAP1R1-reverse primers 
 H  Y  F  D  A  C  G  F  D  E  Y  E  S  E  T  G  D 
 
       510       520       530       540       550 
CCAGGATTATTACTACCTGTCAGTGAAGGCCCTCTACACGGTTGGCTACA Yellow: PAC1-R-XhoI primer and 
GGTCCTAATAATGATGGACAGTCACTTCCGGGAGATGTGCCAACCGATGT  PAC1-V5-half-reverse primer 
  Q  D  Y  Y  Y  L  S  V  K  A  L  Y  T  V  G  Y 
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       560       570       580       590       600 
GCACATCCCTCGTCACCCTCACCACTGCCATGGTCATCCTTTGTCGCTTC 
CGTGTAGGGAGCAGTGGGAGTGGTGACGGTACCAGTAGGAAACAGCGAAG 
S  T  S  L  V  T  L  T  T  A  M  V  I  L  C  R  F 
 
       610       620       630       640       650 
CGGAAGCTGCACTGCACACGCAACTTCATCCACATGAACCTGTTTGTGTC 
GCCTTCGACGTGACGTGTGCGTTGAAGTAGGTGTACTTGGACAAACACAG Blue: PAC1-RT3-Rev 
 R  K  L  H  C  T  R  N  F  I  H  M  N  L  F  V  S 
 
       660       670       680       690       700 
GTTCATGCTGAGGGCGATCTCCGTCTTCATCAAAGACTGGATTCTGTATG 
CAAGTACGACTCCCGCTAGAGGCAGAAGTAGTTTCTGACCTAAGACATAC 
  F  M  L  R  A  I  S  V  F  I  K  D  W  I  L  Y 
  
       710       720       730       740       750 
CGGAGCAGGACAGCAACCACTGCTTCATCTCCACTGTGGAATGTAAGGCC 
GCCTCGTCCTGTCGTTGGTGACGAAGTAGAGGTGACACCTTACATTCCGG 
A  E  Q  D  S  N  H  C  F  I  S  T  V  E  C  K  A 
 
       760       770       780       790       800 
GTCATGGTTTTCTTCCACTACTGTGTTGTGTCCAACTACTTCTGGCTGTT 
CAGTACCAAAAGAAGGTGATGACACAACACAGGTTGATGAAGACCGACAA 
 V  M  V  F  F  H  Y  C  V  V  S  N  Y  F  W  L  F 
 
       810       820       830       840       850 
CATCGAGGGCCTGTACCTCTTCACTCTGCTGGTGGAGACCTTCTTCCCTG 
GTAGCTCCCGGACATGGAGAAGTGAGACGACCACCTCTGGAAGAAGGGAC 
  I  E  G  L  Y  L  F  T  L  L  V  E  T  F  F  P 
 
       860       870       880       890       900 
AAAGGAGATACTTCTACTGGTACACCATCATTGGCTGGGGGACCCCAACT 
TTTCCTCTATGAAGATGACCATGTGGTAGTAACCGACCCCCTGGGGTTGA 
E  R  R  Y  F  Y  W  Y  T  I  I  G  W  G  T  P  T 
 
       910       920       930       940       950 
GTGTGTGTGACAGTGTGGGCTACGCTGAGACTCTACTTTGATGACACAGG 
CACACACACTGTCACACCCGATGCGACTCTGAGATGAAACTACTGTGTCC 
 V  C  V  T  V  W  A  T  L  R  L  Y  F  D  D  T  G 
 
       960       970       980       990      1000 
CTGCTGGGATATGAATGACAGCACAGCTCTGTGGTGGGTGATCAAAGGCC 
GACGACCCTATACTTACTGTCGTGTCGAGACACCACCCACTAGTTTCCGG 
  C  W  D  M  N  D  S  T  A  L  W  W  V  I  K  G 
 
      1010      1020      1030      1040      1050 
CTGTGGTTGGCTCTATCATGGTTAACTTTGTGCTTTTTATTGGCATTATC 
GACACCAACCGAGATAGTACCAATTGAAACACGAAAAATAACCGTAATAG 
P  V  V  G  S  I  M  V  N  F  V  L  F  I  G  I  I 
 
      1060      1070      1080      1090      1100 
GTCATCCTTGTGCAGAAACTTCAGTCTCCAGACATGGGAGGCAATGAGTC 
CAGTAGGAACACGTCTTTGAAGTCAGAGGTCTGTACCCTCCGTTACTCAG 
 V  I  L  V  Q  K  L  Q  S  P  D  M  G  G  N  E  S 
 
      1110      1120      1130      1140      1150 
CAGCATCTACTTGCGACTGGCCCGGTCCACCCTGCTGCTCATCCCACTAT 
GTCGTAGATGAACGCTGACCGGGCCAGGTGGGACGACGAGTAGGGTGATA 
  S  I  Y  L  R  L  A  R  S  T  L  L  L  I  P  L 
 
      1160      1170      1180      1190      1200 
TCGGAATCCACTACACAGTATTTGCCTTCTCCCCAGAGAATGTCAGCAAA 
AGCCTTAGGTGATGTGTCATAAACGGAAGAGGGGTCTCTTACAGTCGTTT 
F  G  I  H  Y  T  V  F  A  F  S  P  E  N  V  S  K 
 
      1210      1220      1230      1240      1250 
AGGGAAAGACTCGTGTTTGAGCTGGGGCTGGGCTCCTTCCAGGGCTTTGT 
TCCCTTTCTGAGCACAAACTCGACCCCGACCCGAGGAAGGTCCCGAAACA 
 R  E  R  L  V  F  E  L  G  L  G  S  F  Q  G  F  V 
  
      1260      1270      1280      1290      1300 
GGTGGCTGTTCTCTACTGTTTTCTGAATGGTGAGGTACAAGCGGAGATCA 
CCACCGACAAGAGATGACAAAAGACTTACCACTCCATGTTCGCCTCTAGT 
  V  A  V  L  Y  C  F  L  N  G  E  V  Q  A  E  I 
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      1310      1320      1330      1340      1350 
AGCGAAAATGGCGAAGCTGGAAGGTGAACCGTTACTTCGCTGTGGACTTC 
TCGCTTTTACCGCTTCGACCTTCCACTTGGCAATGAAGCGACACCTGAAG 
K  R  K  W  R  S  W  K  V  N  R  Y  F  A  V  D  F 
 
      1360      1370      1380      1390      1400 
AAGCACCGACACCCGTCTCTGGCCAGCAGTGGGGTGAATGGGGGCACCCA 
TTCGTGGCTGTGGGCAGAGACCGGTCGTCACCCCACTTACCCCCGTGGGT 
 K  H  R  H  P  S  L  A  S  S  G  V  N  G  G  T  Q 
 
      1410      1420      1430      1440      1450 
GCTCTCCATCCTGAGCAAGAGCAGCTCCCAAATCCGCATGTCTGGCCTCC 
CGAGAGGTAGGACTCGTTCTCGTCGAGGGTTTAGGCGTACAGACCGGAGG 
  L  S  I  L  S  K  S  S  S  Q  I  R  M  S  G  L 
 
                                          >PmeI 
                                            | 
                     >XhoI >XbaI     >ApaI  | 
                       |     |         |    | 
      1460      1470   |  1480      1490    | 
CTGCTGACAATCTGGCCACCTGACTCGAGTCTAGAGGGCCCGTTTAAAC 
GACGACTGTTAGACCGGTGGACTGAGCTCAGATCTCCCGGGCAAATTTG Yellow: PAC1-V5-full-reverse primer 
P  A  D  N  L  A  T  * 
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13.4 Examples of FPLC chromatograms of gastrin-17: 
Sulfated gastrin-17 incubated in 6.5 mM TFA for 1 hour at 37ºC (top) and in 65.3 mM TFA for 24 
hours at 37ºC (bottom). 
 
 
 
s 
ns TFA 
s 
ns 
TFA
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13.5 Examples of FPLC chromatograms of drosulfokinin: 
Sulfated drosulfokinin incubated in H2O for 72 hours at 37ºC (top) and in 65.3 mM TFA for 72 hours 
at 37ºC (bottom). 
 
 
 
s 
s 
ns 
TFA
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13.6 Examples of FPLC chromatograms of caerulein: 
Sulfated caerulein incubated in H2O for 72 hours at 37ºC (top) and in 65.3 mM TFA for 24 hours at 
37ºC (bottom). 
 
   
s 
s 
s 
ns 
TFA
ns 
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13.7 Calculations for the time curve and the Arrhenius plot  
Nonlinear regression curve fit of the incubation at increasing time points are shown in the table below: 
 
One phase exponential decay 37oC 50oC 70oC 
Best-fit values    
     SPAN 100.2 102.5 103.7 
     K 0.009426 0.05196 0.3781 
     PLATEAU -2.006 -1.886 -0.7410 
     HalfLife 73.54 13.34 1.833 
Std. Error  
     SPAN 3.856 2.435 0.9836 
     K 0.0007868 0.003070 0.008943 
     PLATEAU 4.196 1.970 0.5360 
95% Confidence Intervals  
     SPAN 92.12 to 108.3 97.21 to 107.8 101.6 to 105.8 
     K 0.007773 to 0.01108 0.04527 to 0.05864 0.3591 to 0.3970 
     PLATEAU -10.82 to 6.809 -6.177 to 2.406 -1.877 to 0.3954 
     HalfLife 62.56 to 89.18 11.82 to 15.31 1.746 to 1.930 
Goodness of Fit  
     Degrees of Freedom 18 12 16 
     R² 0.9906 0.9933 0.9987 
     Absolute Sum of Squares 125.8 85.56 29.61 
     Sy.x 2.644 2.670 1.360 
Constraints  
     K K > 0.0 K > 0.0 K > 0.0 
Data  
     Number of X values 21 16 12 
     Number of Y replicates 2 2 2 
     Total number of values 21 15 19 
     Number of missing values 21 17 5 
 
Calculations of log k and 1/T: 
37°C: k = 0.009426 h-1 = 2.62*10-5 ± 0.22 s-1   T = 37°C = 310.15 K 
logk = -4.5817  1/T = 0.003224 
 
50°C: k = 0.05196 h-1 = 1.44*10-4 ± 0.85 s-1   T = 50°C = 323.15 K 
logk = -3.8406  1/T = 0.003095 
    
70°C: k = 0.3781 h-1 = 1.05*10-3 ± 0.02 s-1   T = 70°C = 343.15 K 
logk = -2.9787  1/T = 0.002914 
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Arrhenius plot: 
The logk and 1/T values are plotted: 
Arrhenius Plot
2.8×10-3 3.0×10-3 3.3×10-3 3.5×10-3
-5
-4
-3
-2
1/T (K)
lo
g 
(k
/s
-1
)
 
Data sheet: 
Linear regression of the Arrhenius plot are shown in the table below: 
Linear reg. of Arrhenius plot  
Best-fit values  
     Slope -5146 ± 260.8
     Y-intercept 12.04 ± 0.8034
     X-intercept 0.002339
     1/slope -0.0001943
95% Confidence Intervals 
     Slope -8460 to -1832
     Y-intercept when X=0.0 1.830 to 22.25
     X-intercept when Y=0.0 0.0009964 to 0.002635
Goodness of Fit 
     r² 0.9974
     Sy.x 0.05744
Is slope significantly non-zero? 
     F 389.3
     DFn, DFd 1.000, 1.000
     P value 0.0322
     Deviation from zero? Significant
Data 
     Number of X values 3
     Maximum number of Y replicates 1
     Total number of values 3
     Number of missing values 0
 
Calculation of A from the Y intercept: YInt. = logA = 12.04   =>   A = 1012.04 s-1 = 1.1*1012 s-1   
Calculation of Ea from the slope: slope = -Ea/2.303R = -5146 K      R =1.987 cal mol-1 K-1   
Ea = 23548 cal mol-1 = 23.5 ± 1.2 kcal mol-1 
The ±1.2 std. error is calculated by + or - 260.8 from -5146 and repeating the slope equation. 
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13.8 Calculations for the binding assay data 
CHO-PAC1 ligand binding measured in counts per minute (cpm): 
CHO-PAC1
-13 -12 -11 -10 -9 -8 -7 -6 -5
0
5000
10000
15000
20000
25000
30000
35000
0.04 nM
0.1 nM
Log conc. PACAP27-NH2
cp
m
 
Data sheet:  
homologue competitive binding curve analysis for PAC1 binding data (GraphPad Prism): 
Homologous competitive 
binding curve. One class of 
binding sites. 
0.04 nM 0.1 nM Global (shared) 
Best-fit values  
     LOGKD -8.700 -9.042 -8.808 
     BMAX 1.2908e+006 240869  
     HOTNM 0.0400 0.1000  
     NS 2378 3532  
Std. Error  
     LOGKD 0.05107 0.05885 0.04449 
     BMAX 151813 29014  
     NS 416.6 391.8  
95% Confidence Intervals  
     LOGKD -8.804 to -8.596 -9.168 to -8.917 -8.898 to -8.718 
     BMAX 980794 to 1.6008e+006 179039 to 302699  
     NS 1527 to 3229 2697 to 4366  
Goodness of Fit  
     Degrees of Freedom 30 15 46 
     R² 0.9862 0.9906 0.9835 
     Absolute Sum of Squares 5.4595e+007 1.6655e+007 9.5194e+007 
     Sy.x 1349 1054 1439 
Constraints  
     HOTNM HOTNM = column title HOTNM = column title  
Data  
     Number of X values 7 6  
     Number of Y replicates 5 5  
     Total number of values 33 18  
     Number of missing values 2 12  
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Calculation of the CHO-PAC1 dissociation constant Kd: 
The Kd value is calculated from the globally shared logKd value between 0.04 nM and 0.1 nM data sets: 
nMMKLogK dd 56.110808.8
808.8 ≈=⇒−= −  
The 95% confidence intervals are calculated in the same manner from the globally shared data: 
nMMKLogK dd 26.110898.8
898.8 ≈=⇒−= −  
nMMKLogK dd 91.110718.8
718.8 ≈=⇒−= −  
 
The same calculations are used for the binding data with the CHO-mutPAC1 cell line, and the binding 
data from the chlorate incubation experiment. The data for these experiments are shown on the next 
pages. 
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CHO-mutPAC1 ligand binding measured in counts per minute (cpm): 
 
CHO-mutPAC1
-12 -11 -10 -9 -8 -7 -6 -5
0
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15000
20000
25000
0.04 nM
0.1 nM
Log conc. PACAP27-NH2
cp
m
 
Data sheet:  
Homologue competitive binding curve analysis for mutPAC1 binding data (GraphPad Prism): 
Homologous competitive 
binding curve. One class of 
binding sites. 
0.04 nM 0.1 nM Global (shared) 
Best-fit values  
     LOGKD -9.319 -9.499 -9.363 
     BMAX 205708 60744  
     HOTNM 0.0400 0.1000  
     NS 2342 2879  
Std. Error  
     LOGKD 0.1672 0.08128 0.1162 
     BMAX 70993 8268  
     NS 695,0 235,7  
95% Confidence Intervals  
     LOGKD -9.662 to -8.975 -9.672 to -9.326 -9.598 to -9.129 
     BMAX 59746 to 351671 43124 to 78363  
     NS 913.2 to 3771 2377 to 3382  
Goodness of Fit  
     Degrees of Freedom 26 15 42 
     R² 0.8847 0.9888 0.9166 
     Absolute Sum of Squares 1.5319e+008 6.7724e+006 1.6146e+008 
     Sy.x 2427 671,9 1961 
Constraints  
     HOTNM HOTNM = column title HOTNM = column title  
Data  
     Number of X values 6 6  
     Number of Y replicates 5 5  
     Total number of values 29 18  
     Number of missing values 1 12  
 
 
  Summer 2006 
Supplements  Roskilde University Center 
 107
Chlorate treated CHO-PAC1 assay; ligand binding measured in counts per minute (cpm): 
Chlorate incubation
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Data sheet:  
Homologue competitive binding curve analysis for PAC1 binding data with chlorate incubation 
(GraphPad Prism): 
 
Homologous competitive 
binding curve. One class of 
binding sites. 
10 mM 20 mM 50 mM Global (shared)
Best-fit values  
     LOGKD -8.909 -8.929 -8.816 -8.881
     BMAX 553616 579804 755724 
     HOTNM 0.0400 0.0400 0.0400 
     NS 241.8 1129 343.9 
Std. Error  
     LOGKD 0.1043 0.09182 0.05006 0.04760
     BMAX 127763 117452 84553 
     NS 551.3 529.8 296.4 
95% Confidence Intervals  
     LOGKD -9.145 to -8.673 -9.137 to -8.722 -8.929 to -8.702 -8.979 to -8.784
     BMAX 264617 to 842614 314127 to 845481 564465 to 946982 
     NS -1005 to 1489 -69.62 to 2327 -326.5 to 1014 
Goodness of Fit  
     Degrees of Freedom 9 9 9 29
     R² 0.9802 0.9846 0.9955 0.9868
     Absolute Sum of Squares 1.2679e+007 1.1809e+007 3.5129e+006 2.9017e+007
     Sy.x 1187 1145 624.8 1000
Constraints  
     HOTNM HOTNM = 0.0400 HOTNM = 0.0400 HOTNM = 0.0400 
Data  
     Number of X values 6 6 6  
     Number of Y replicates 2 2 2  
     Total number of values 12 12 12  
     Number of missing values 0 0 0  
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13.9 Calculations of LightCycler data  
Using the second derivative maximum analysis in the LightCycler software v. 3.5, the amounts of 
receptor cDNA and control GAPDH cDNA were estimated and presented in the table below.   
 
Sample Standard Calculated conc. GAPDH 
Calculated conc. 
PAC1 Proportion
1:10 0.1  96.23
1:100 0.01 10.0 11.23
1:1000 0.001 1.0 0.8893
1:10000 0.0001 0.1259 0.104
CHO untransf. 93.61 9.698 0.0067
CHO-PAC1 223.2 3352 1
CHO-mutPAC1 105.7 318.3 0.2
 
The 1:10, 1:100, 1:1000, and 1:10000 dilutions are made from the CHO-PAC1 cDNA, from which the 
untransfected CHO cell cDNA and the CHO-mutPAC1 cell cDNA are normalized. 
Calculations: 
CHO untransf.: 9.698/93.61 = 0.1036 compared to PAC1: 0.06/7.62*100 = 0.0067 
PAC1:  3352/223.2 = 15.0179 compared to PAC1: 1 
mutPAC1:  318.3/105.7 = 3.0114 compared to PAC1: 7.32/7.62*100 = 0.2005 
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13.10 Experimental procedures for acid lability analysis of whole cell 
lysates: 
SDS-gel casting and electrophoresis 
10% SDS Gel: 
13.3 ml 30% Proto acrylamide (National Diagnostics) 
21.1 ml H2O 
5.0 ml Buffer II-A (3.0 M Tris-HCl pH 8.9, Sigma) 
200 µl 20% SDS (Sodium dodecyl sulfate, Bie & Berndtsen A-S) 
400 µl 10% v/w APS (Ammoniumpersulfate dissolved in H2O, Bio-Rad) 
30 µl TEMED (N,N,N’,N’-tetramethylethylenediamine, Sigma) 
 
The components were mixed in the order above and the mixture was subsequently added to the glass 
container. An overlay of 1-2 ml of 0.1% SDS was added and the gel rested for ca. 30 minutes. After 
resting, the stacking gel was mixed. 
 
Stacking gel: 
3 ml 30% Proto acrylamide 
12.2 ml H2O 
2.5 ml Buffer II-B (Stacking buffer pH 6.8, Bie & Berndtsen A-S) 
100 µl 20% SDS 
200 µl 10% v/w APS 
20 µl TEMED  
 
The components were mixed in the order above and the mixture was added to the gel after the 0.1% 
SDS overlay was removed. The comb was inserted and the gel rested for another 30 minutes, while 
making sure the glass container did not leak. The gel was now ready for use. 
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Sample buffer for SDS electrophoresis: 
10 mM Tris-HCl pH 8 (Sigma) 
8% SDS 
40 mM DTT (DL-Dithiotheitol, Sigma) 
40% Glycerol (Merck) 
Bromephenolblue 
 
The sample was mixed with the sample buffer in 3:1 ratio, and boiled on a heating block at 96°C for 5 
minutes. If the sample was a whole cell lysate, it was necessary to homogenize the sample with a syringe 
needle after heating.  
 
Running buffer: 
100 ml 10x Running buffer (192 mM glycin; 25 mM Tris-HCl pH 8.3, Bie & Berndtsen A-S) 
5 ml 20% SDS 
900 ml H2O 
The gel was placed in a Vertical Gel Electrophoresis Apparatus model 15·17 (Life Technologies) and 
running buffer was added. The comb was removed and the slots were rinsed with running buffer. The 
samples were loaded and the gel was run over night at 40-50 volt (BioRad PowerPac 200). 
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13.11 Experimental procedures for site-directed mutagenesis of PAC1: 
Site directed mutagenesis PCR: 
PCR mix: 
2 µl DNA template (final conc. 200 ng) 
1 µl Forward primer (stock conc. 20 µM) 
1 µl Reverse primer (stock conc. 20 µM) 
2 µl Pwo PCR buffer (10x , Roche) 
1.6 µl MgSO4 (stock conc. 25 mM, Roche) 
1 µl Pwo polymerase (Roche) 
1 µl dNTP’s (stock conc. 10 mM, Invitrogen) 
10.4 µl H2O 
 
Primers:    
mADCYAP1R1 forward: 5’-GGGTTTGATGAATTTGAATCTGAGACTGGGG 
ACCAGGATTTTTTCTTCCTGTCAGTGAAGG-3’ and  
mADCYAP1R1 reverse: 5’-CCTTCACTGACAGGAAGAAAAAATCCTGGT 
CCCCAGTCTCAGATTCAAATTCATCAAACCC-3’  
(Oligos were purchased from MWG-Biotech) For sites of primers see supplement 13.3. 
 
PCR program: 
1. 95°C 30 sec 
2. 95°C 30 sec 
3. 55°C   1 min 
4. 68°C 12 min (2 min/kb plasmid) Step 2-4 was rep. through 16 cycles.   
Hold 4°C 
 
When the PCR was finished 1 µl DpnI (restriction enzyme, Roche) was added to each tube and the 
samples were incubated at 37°C overnight. After this, the samples could be frozen at -20°C or 
transformed into competent cells as described below. 
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Transformation: 
One Shot® TOP10 Chemically Competent  E. coli (Invitrogen) 
1. One 50 µl vial of One Shot® cell for each transformation was placed on ice. 
2. 5 µl of the cloning mixture was added directly into the vial of competent cells and was mixed by 
gently tapping the vial. The vial(s) were incubated on the ice for 15-30 minutes. 
3. The vials were then incubated for exactly 30 seconds in a 42°C water bath without shaking. 
4. The vials were again placed on ice for a few minutes. 
5. 150 µl pre-warmed S.O.C. medium (supplied with the competent cells) was added to each vial. 
The vials were placed in a heating block at 37°C for 1 hour while shaking. 
6. The mixture was spread on LB agar plates (prefabricated using LB agar tablets, Sigma) 
supplemented with ampicillin (100mg/L LB agar solution). The plates were inverted and 
incubated at 37°C overnight. 
Plasmid preparation – alkaline lysis miniprep: 
Colonies from transformation were picked and transferred to 13 ml tubes (Sarstedt) containing ~5 ml 
LB medium supplemented with 100 mg/L ampicillin. Grow to saturation at 37°C (overnight). 
 
1. 1.5 ml of the overnight culture was centrifuged 20 sec. in a microcentrifuge at maximum speed 
to pellet. The supernatant was removed by decanting or with a Pasteur pipette. 
The spins in step 2 and 6 could be performed at room temperature or at 4°C. Longer spins would make it difficult to 
resuspend cells. 
2. The pellet was resuspended in 100 µl GTE solution and left for 5 minutes at room temperature. 
(GTE solution: 50 mM Glucose; 25 mM Trizma Base adjusted with HCl to pH 8.0; 10 mM 
EDTA; 10 mg/ml RNase). 
3. 200 µl NaOH/SDS solution was added, the tubes were inverted gently a few times and 
incubated for 5 minutes (NaOH/SDS solution: 0.2 M NaOH; 1% SDS). 
4. 150 µl acetate solution were added and the vials vortexed at maximum speed for 2 sec. to mix. 
Assuring mixing was complete and the vials were placed on ice for 5 minutes (acetate solution: 
3 M Potassium or sodium acetate adjusted to pH 4.8 with acidic acid glacial). 
5. The vials were centrifuged 3 minutes to pellet cell debris and chromosomal DNA. 
6. 450 µl supernatant were transferred to a fresh tube, and mixed with 0.8 ml 96% ethanol. The 
mixture incubated at least 5 minutes in the freezer. 
7. The vials were centrifuged 5 minutes at maximum speed and 4°C to pellet plasmid DNA. 
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8. The supernatant was decantated and, the pellet was washed with 1 ml 70% ethanol, and dried in 
a speed vacuum (max. 5 minutes). 
9. The pellet was resuspended in 50 µl H2O. The DNA could now be used for restriction digests 
or sequence PCR. 
Sequence PCR: 
The purified plasmid solution was sequenced by the following procedure: 
 
PCR mix: 
1 µl Purified plasmid solution 
1 µl Primer 
2 µl BigDye® Terminator v1.1 Cycle Sequencing RR-100 (AB Applied Biosystems). 
4 µl BigDye buffer (AB Applied Biosystems) 
12 µl H2O 
 
PCR program: 
1. 94°C   4 min 
2. 96°C 30 sec 
3. 50°C 15 sec 
4. 60°C   4 min  Step 2-4 was rep. through 35 cycles. 
 
The sequence PCR product was precipitated with ethanol: 
20 µl PCR product 
50 µl 96% Ethanol (De Danske Spritfabrikker) 
2 µl 3M NaAc (Sodium acetate, Merck) 
 
1. The mixture was incubated in the freezer for 15 minutes. 
2. The vials were centrifuged 10 minutes at maximum speed and 4°C. The supernatant was 
removed. 
3. Pellet was washed with 70% ethanol and centrifuged as before. The supernatant was removed. 
4. The pellet was dried under speed vacuum.  
The sequence PCR product was now ready for sequencing. 
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Maxiprep of plasmid: 
When the correct sequence of the plasmid was confirmed, the remaining part of the overnight culture 
from the plasmid preparation was transferred to a large bottle containing ~300 ml LB medium 
supplemented with 100 mg/L ampicillin. The culture was grown overnight at 37°C with shaking at 220 
rpm. 
 
The plasmid was purified using the Jetstar 2.0 Plasmid Purification MAXI Kit /20 (Genomed). The 
final pellet was dissolved in sterile H2O to a final concentration of 1 µg/µl. The concentration was 
measured photometrically using the Nanodrop ND-1000 Spectrophotometer (Saveen Werner). 
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13.12 Experimental procedures for stable transfection: 
Digestion of plasmid prior to transfection: 
The plasmid had to be linerized in order for it to be incorporated in the genome of the cell. 
 
Digestion mixture: 
26 µl Plasmid DNA (Stock 1 µg/µl) 
3 µl Buffer adequate for the restriction enzyme 
1 µl Restriction enzyme  
 
The mixture was incubated overnight at 37°C. The linerazation was documented on a 1% agarose gel, 
stained with ethidium bromide and run at 120V. The rest of the digested plasmid DNA was purified 
from the digestion mixture using the GFX™ PCR DNA and RNA Band Purification Kit (Amersham 
Biosciences) and eluted in sterile H2O. 
Transfection: 
Day 0: CHO cells were plated in 5 ml culture dishes the day before the experiment in a concentration 
of 60-80% confluence (~800.000 cells/dish).  
 
Day 1: 
Reaction mixture: 
8 µl DNA (Stock 1 µg/µl) 
12 µl FuGENE 6 Transfection Reagent (Roche Diagnostics) 
400 µl OptiMEM 1 (Gibco/Invitrogen Corporation) 
 
1. First OptiMEM was pipetted into the test tube 
2. Then FuGENE was pipetted into the OptiMEM, and the test tube was tabbed gently with the 
finger. 
3. The DNA was added in the same way and the mixture was incubated for 15-45 minutes. 
4. After incubation 5 ml of Dulbecco’s Modified Eagels Medium (DMEM), + 4500mg/L 
Glucose, + GlutaMAXTMI, - Pyruvate (Gibco/Invitrogen Corporation) supplemented with 10% 
FBS (Gibco/Invitrogen Corporation) and 1% P/S (Sigma), was added. 
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5. The incubation medium was aspired from the plated cells and the fresh mixture medium with 
FuGENE/DNA/OptiMEM was added drop wise. The cells were incubated in the incubator 
over night (10% CO2 and 37°C). 
Day 2: The mixture medium was aspirated and fresh DMEM (10%FBS, 1% P/S) was added. 
Day 3: The cells were split into 10 ml culture dishes: The medium was aspirated and the cells are 
harvested using PBS +EDTA (Bie & Berndtsen A-S). Fresh DMEM (10% FBS and 1% P/S) was 
added supplemented with 500 µg/ml Geneticin (G418, Gibco, Invitrogen) as selection reagent. 
Selection continued for at least three weeks. 
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13.13 Experimental procedures for RT-PCR and LightCycler 
RNA extraction: 
Medium was aspired from the culture flask and the cells were harvested using PBS with EDTA. The 
pelleted cells were resuspended in1 ml Trisol and incubated 5 minutes. 
 
1. 200 µl chloroform was added the mix was vortexed vigorously for 10 sec and thereafter 
incubated 2-3 minutes. 
2. The tubes were centrifuged 15 minutes at max. speed at 4°C. 
3. The top water phase (The RNA) was transferred to new tubes. 
4. 500 µl isopropyl alcohol was added and the tubes were incubated 10 minutes. 
5. The tubes were centrifuged 10 min. at max. speed at 4°C. (Results in a gel-like pellet). 
6. The supernatant was aspirated and the pellet was washed with 1 ml 70% ethanol. 
7. The tubes were centrifuged 5 minutes at 7500 rpm at 4°C. 
8. The pellet was air-dried.  
9. 200 µl sterile H2O was added and the tubes were incubated 10 minutes at 60°C. 
10. The RNA was then diluted to a concentration of 1 µg/µl and placed in the freezer (-80°C). 
 
All incubations were performed at room temperature unless otherwise stated.  
RT-PCR: 
The RNA was converted to cDNA by reverse transcriptase PCR. 
2 µl RNA sample (0.5 µg/µl) 
2 µl RT-buffer (Roche) 
0.3 µl RNase inhibitor 
1 µl Reverse Transcriptase M-MuLV (Roche) 
1 µl Random primer (Roche) 
1 µl dNTP (Stock 10 mM) 
2.7 µl H2O 
The mix was incubated over night at 37°C and thereafter stored in the fridge 4°C until use. 
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LightCycler PCR: 
Primers:  
PAC1-RT3-For: 5’-CGGAACTGCACGGAGGATGGC-3’ 
PAC1-RT3-Rev: 5’-GTGGATGAAGTTGCGTGTGCAG-3’ 
mGAPDH-For: 5’-GGTGCTGAGTATGTCGTGGA-3’ 
mGAPDH-Rev: 5’-GTGGTTCACACCCATCACAA-3’ 
For sites of primers see supplement 13.3. 
 
Primers for GAPDH were used determine the amount of cDNA in the samples compared to one 
another, since GAPDH levels should be unaffected by transfection. The amount of GAPDH-cDNA 
found was used as an intern standard from which the PAC1-cDNA levels were corrected. 
The LightCycler reaction was performed using the LC FastStart DNA Master SYBR Green I kit 
(Roche). 
The amounts of RNA were estimated using 3-4 dilutions of the template mixture (x10, x100, x1000 or 
x10000) and plotting these on a graph. 
 
Reaction mix: 
2 µl cDNA template 
1 µl Forward primer (stock conc. 10 µM) 
1 µl Reverse primer (stock conc. 10 µM) 
1.6 µl MgCl2 (final conc. 3 mM) 
2 µl SYBR (Roche) 
12.4 µl H2O 
 
All except template were mixed and pippeted into the LightCycler® Capillaries (20 µl, Roche). The 
template was added and the capillaries were centrifuged at max. 2000 rpm for 1-2 minutes in 
LightCycler Centrifuge Adaptors (Roche). 
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LightCycler PCR program:   
1. Denature  95°C 10 min 20°C/s 
2. Cycles (x45) 95°C   0 sec 20°C/s Denature 
  60°C   8 sec 20°C/s Anneal  
  72°C 11 sec 20°C/s Elongation 
  86°C   0 sec 20°C/s Melt/measure 
3. Melt  95°C   0 sec 20°C/s 
  70°C   0 sec 20°C/s 
95°C   0 sec 0.2 °C/s 
4. Cool  30°C   5 min  20°C/s 
 
The PCR were performed on the LightCycler (Roche) and the data were analyzed using the LightCycler 
Software version 3.5 (Roche).  
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13.14 Experimental procedures for the binding assay: 
The stably transfected CHO cells expressing the PAC1 and the mutPAC1 receptor were used for the 
binding assay. The whole experiment was performed at room temperature. 
1. Cells were harvested, washed once in Tris-buffer (50mM Trizma Base adjusted to pH 7.4 with 
HCl, 0.5 mM MgCl2, 0.9 mM CaCl2, 1% Bovine Serum Albumin (BSA, Sigma) and resuspended 
in the same Tris-buffer.  
2. 350 µl of the desired concentration of cells (Should give a binding efficiency of ~10% of total 
amount of tracer, to avoid ligand depletion) were transferred to LoBind tubes (Eppendorf). 
3. Cold peptide: The concentrations 10-5 to 1011 M (10-6 to 1012 M) were made in the Tris-buffer 
described above. 
4. Tracer: [125I]-PACAP27-NH2 (PerkinElmer) was dissolved in 1 ml sterile H2O. 2 µl tracer + 98 
µl Tris-buffer (50x dilution) and measured for 60 sec. on a γ-counter. The reference date and 
the isotope decay scheme were used to calculate the specific activity of the day. The tracer was 
then diluted in Tris-buffer according to the following equation: The specific activity (Ci/mmol) 
of the day was multiplied with the desired concentration (40 pM = 2x10-11 mmol in 500 µl) and 
this result was again multiplied with the factor 2.2x1012 counts/min.*Ci. This result was the 
desired count/min. in 100 µl of tracer, i.e. amount of tracer pr. vial. The count/min. measured 
was divided by the calculated count/min. and multiplied by 50 to establish times of dilution 
necessary. The tracer was then diluted and ca. 1 ml extra were made. 100 µl of the tracer 
solution was counted 5 minutes on the γ-counter (The longer you count, the more accurate the 
result, but be aware of a maximum readout of the γ-counter). The result was saved. 
5. Now the tracer solution was added to the various concentrations of cold peptide. 100 µl tracer 
to 50 µl cold peptide, and 150 µl of the mix of hot and cold peptide was added to each vial of 
cells, so the final reaction volume reached 500 µl. Duplicates or triplicates were made. 
6. Remember the controls:  1) Tracer without cold peptide (Background on cells) 
2) No tracer, no cold peptide, just buffer (Background) 
3) No cells, no cold peptide, just tracer (Background on vials) 
7. The vials were incubated at room temperature for 2 hours, with occasional invertions of the 
vials.  
8. The cells were pelleted by centrifugation at 5000 rpm for 5 minutes The supernatant was 
decanted. 
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9. The cells were washed once in the Tris-buffer and centrifuged as before. The supernatant was 
pipetted of to ensure that most of the buffer was removed. 
10. 500 µl 0.2 M NaOH was added to lyze the cells and incubated 15 minutes on a rocking table. 
11. The lyzed cell solution was transferred to polystyrene tubes and the counts were measured for 5 
minutes in the γ-counter. 
 
When maximum binding assays were done, no cold peptide was needed, only increasing concentrations 
of tracer. Otherwise, the experiment was performed as described above. 
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13.15 Experimental procedures Hpc4 tagged plasmid construction: 
The construct below was used to direct the expressed protein through the secretory pathway 
(Preprogastrin signal peptide) and attached an epitope (Hpc4 – Protein C) that would allow detection. 
 
 
   >NheI              >HindIII 
   |  |Signal peptide – Preprogastrin          | | 
AATGCTAGCGAGATGCAGCGACTATGTGTGTATGTGCTGATCTTTGCACTGGCTCTGGCCGCCTTCTCTGAAGCT 
      M  Q  R  L  C  V  Y  V  L  I  F  A  L  A  L  A  A  F  S  E  A   
 
 >BamHI   >XhoI         >XbaI 
   |        |     |Epitope – Hpc4                |   | 
TCTGGATCCTCTCTCGAGATGGAGGATCAAGTCGACCCAAGGCTGATCGATGGAAAGGACCCTTAGTCTAGATAA 
 S  G  S  S  L  E  M  E  D  Q  V  D  P  R  L  I  D  G  K  D  P St. 
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PCR: 
PAC1 fragment PCR mix:   Signal/Hpc4 tag PCR mix: 
2 µl DNA template (stock conc. 100 ng/µl) 1 µl DNA template (stock conc. 0.1 µM) 
0.5 µl For. primer (stock conc. 20 µM)  2.5 µl For. primer (stock conc. 20 µM)  
0.5 µl Rev. primer (stock conc. 20 µM)  3 µl Rev. primer (stock conc. 20 µM) 
5 µl Elongase buffer A   10 µl PCR buffer (10x) 
5 µl Elongase buffer B   10 µl MgCl2 (stock conc. 25 mM)  
1 µl Elongase polymerase (Roche)  0.5 µl Taq DNA polymerase 
1 µl dNTP’s (stock conc. 10 mM, Invitrogen) 1 µl dNTP’s 
35 µl H2O    72 µl H2O 
 
Primers: 
Signal/Hpc4 construct:  
Forward primer: 5’-AATGCTAGCGAGATGCAGCGACTA-3’  
Reverse primer: 5’-TTATCTAGACTAAGGGTCCTTTCCATCGATCAGCCTTGGGTCGAC-3’. 
 
The N-terminal PAC1 fragment was PCR amplified using the primers carrying an XhoI site: 
Forward: PAC1-F-XhoI: 5’-CGTGCTTCTCTCGAGATGCATTCTGACTGCATCTTCAAG-3’  
Reverse: PAC1-R-XhoI: 5’-CGTGCTAGACTCGAGGGCCTTCACTGACAGGTAG-3’. 
For sites of primers see supplement 13.3. 
 
PCR program:   PCR program: 
1. 94°C 30 sec  1. 94°C   1 min 
2. 94°C 30 sec   2. 94°C 30 sec 
3. 58°C 30 sec  3. 58°C 30 sec 
4. 68°C 45 sec  4. 72°C   1 min 
5.  Step 2-4 was rep. 35 cycles 5.   Step 2-4 was rep. 30 cycles 
6.  Hold 4°C   6. Hold 4°C  
 
The PCR products were verified on a 1.5% agarose gel, stained with ethidium bromide, and run at 
120V. The remaining PCR products were column purified using the GFXTM PCR DNA and Gel Band 
Purification Kit (Amersham Biosciences), procedure according to protocol. 
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Cloning: 
The cloning kit: pcDNA3.1/V5-His-TOPO TA Expression Kit (Invitrogen). The two PCR fragments 
were cloned into the vector separately. 
 
Cloning mix: 
3 µl PCR product 
1 µl Salt solution 
1 µl Vector 
The mixture was incubated 5 minutes at room temperature to complete ligation. The ligation mixture 
was then transformed into TOP10 chemically competent cells as described in supplement 13.11. 
Minipreparation, maxipreparation and sequencing were also performed as described in supplement 
13.11. 
 
Digestion and ligation of the PAC1 fragment into the Hpc4 plasmid construct: 
The purified short-PAC1 fragment containing plasmid and the Hpc4 plasmid construct were digested 
with the XhoI restriction enzyme (Roche). 
 
Digestion:    Digestion: 
16 µl Miniprep of PAC1 plasmid  5 µl Miniprep of PAC1 plasmid 
2 µl SuRe/Cut Buffer H (Beohringer Mannheim) 2 µl Buffer H 
2 µl XhoI    2 µl XhoI  
    11 µl H2O 
The digestion mixture was incubated 1 hour at 37°C. The digestion was verified on a 1.5% agarose gel. 
The desired bands were cut from the gel and purified again using the GFXTM columns.  
 
Ligation mix: 
20 µl Digested PAC1 fragment  
5 µl Digested Hpc4-plasmid 
3 µl T4 Ligase (Roche) 
2 µl Ligase buffer (Roche) 
The ligation mixture was incubated overnight at 16°C. 5 µl of the ligation mixture was transformed into 
TOP10 chemically competent cells as described in supplement 13.11. Minipreparation, maxipreparation 
and sequencing were again performed as described in supplement 13.11. 
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13.16 Experimental procedures V5-plasmid construction: 
 
 
PCR: 
PCR mix:     PCR program: 
1 µl DNA template (stock conc. 1ng/µl)  1. 95°C   2 min 
6 µl Forward primer (stock conc. 20 µM)  2. 95°C 30 sec 
6 µl Reverse primer (stock conc. 20 µM)  3. 58°C   1 min 
10 µl Pwo PCR buffer (10x , Roche)  4. 72°C 30 sec 
10 µl MgSO4 (stock conc. 25 mM, Roche)  5.  Step 2-4 is rep. through 30 cycles 
0.5 µl Pwo polymerase (Roche)   6. 72°C 10 min 
2 µl dNTP’s (stock conc. 10 mM, Invitrogen) 7.  Hold 4°C 
64.5 µl H2O     
The PCR product was verified on a 1% agarose gel and purified on a GFXTM column. 
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Primers: 
PAC1-V5-forward: 5’-CACCATGGCTGGTGTCGTGC-3’ 
PAC1-V5-half-rev: 5’-GGCCTTCACTGACAGGTAGTA-3’  
PAC1-V5-full-rev: 5’-GGCCAGATTGTCAGCAGGGAG-3’ 
For sites of primers see supplement 13.3. 
Cloning: 
The Gateway cloning kit: pcDNA3.2/GW/D-TOPO Expression Kit (Invitrogen). 
 
Cloning mix: 
2 µl PCR product 
1 µl Salt solution 
1 µl Vector 
2 µl H2O 
 
The mixture was incubated 15 minutes at room temperature to complete ligation and thereafter 15 
minutes on ice. The ligation mixture was then transformed into TOP10 chemically competent cells as 
described in supplement 13.11. Minipreparation, maxipreparation and sequencing of the plasmid were 
performed as described in supplement 13.11. 
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13.17 Experimental procedures for expression by transient 
transfection: 
The purified plasmid constructs were expressed in different cell lines by transient transfection. The 
plasmid DNA needed not to be linearized prior to transient transfection, since the DNA would not be 
incorporated into the genome. 
Transient transfection was performed as described in supplement 13.12, the only difference being the 
samples for visualization. These were plated in glass bottom dishes only containing 2 ml medium. 
The list below shows the different combinations for the transfections, identification and purifications 
performed: 
 
Exp. Plasmid Cell line Inkub. post transf. (h) Medium Serum Experiments 
short-PAC1-Hpc4 HeLa 18, 26, 42, 46, 54, and 66 DMEM 10% FBS WB 
short-PAC1-Hpc4 CHO 18, 26, 42, 46, 54, and 66 DMEM 10% FBS WB 1 
short-PAC1-Hpc4 PC12 50 and 66 DMEM 10% FBS WB 
short-PAC1-Hpc4 CHO 24 and 48 DMEM 1% FBS WB + Column 2 short-PAC1-Hpc4 CHO 24 and 48 F12 (Ham) 1% FBS WB 
3 short-PAC1-Hpc4 CHO 48 DMEM 1% FBS Column 
short-PAC1-Hpc4 CHO 48 DMEM 10% FBS Column 4 short-PAC1-Hpc4 CHO 48 DMEM 10% Rabbit serum Column 
short-PAC1-V5 CHO 24 DMEM 10% FBS WB  
full-PAC1-V5 CHO 24 DMEM 10% FBS WB + 
visualization 
short-PAC1-V5 Hit 24 DMEM 10% FBS WB 
5 
full-PAC1-V5 Hit 24 DMEM 10% FBS WB + Column 
+ visualization 
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13.18 Experimental procedures for western blot: 
Gel electrophoresis:  
The samples were loaded on prefabricated 4-20% SDS-PAGE gels (either 4-20% NOVEX-Tris-
Glycine Gel 1.0 x 10 well (Invitrogen), or PAGEr® Duramide® Precast Gels 4-20% 10 wells 
(Cambrex)), which were submerged in Novex Tris-Gly SDS Running Buffer (Invitrogen) diluted 10 
times. A biotinylated Protein ladder (Cell Signalling) and a Precision Plus Protein™ Dual Color 
Standard (BioRad) were also loaded on the gel. The gel was run at 130V for approx. 90 minutes until 
the blue color reached the bottom of the gel.  
Blotting of the gel: 
After electrophoresis the gel was placed in the Novex Tris-Gly SDS Running Buffer diluted 100 times 
and containing 20% Ethanol. 
12 pieces of filter paper were also soaked in the Novex Tris-Gly SDS Running Buffer diluted 100 times 
and containing 20% Ethanol. 
A piece of Hybond™-P PVDF membrane (Amersham Biosciences) were cut in the same proportions 
as the gel, and soaked in 96% ethanol. The ethanol increases the transfer of proteins to the membrane. 
Assembly: From the bottom, six layers of filter paper, the Hybond membrane, the gel, and finally 
another six layers of filter paper. The gel was then blotted at 175 mA for 2 hours, making sure the 
layers did not dry out. 
Hpc4 detection:  
The short-PAC1-Hpc4 cell and media samples were collected after transfection. The cells were washed 
once in PBS and then lysed in sample buffer (10 mM Trizma Base adjusted with HCl to pH~8, 8% 
SDS, 40% Glycerol, 40 mM DTT and bromephenol blue). A sample of the medium was also mixed 
with sample buffer (amount 3 sample to 1 buffer). Samples in buffer were heated at 96oC for 5 minutes 
and the cell lysates were homogenized using a 1 ml Syringe with needle (BD Plastipak). The samples 
were now ready to load on the prefabricated gel.  
1. After gel-separation and blotting, the membrane was then incubated in 20 ml blocking buffer 
(10 mM Trizma Base adjusted with HCl to  pH 7.5, 150 mM NaCl, 1 mM CaCl2 and 5% skim 
milk powder) for 1 hour.  
2. The blocking buffer was decantated. 
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3. Antibody dilution: The Anti-[Protein C]-peroxidase conjugate and HRP-conjugated Anti-Biotin 
Antibody (Cell Signalling Technologies). Both were diluted 1:1000 in half blocking buffer half 
TBS-Ca solution (10 mM Trizma Base adjusted with HCl to pH 7.5, 150 mM NaCl, 1 mM 
CaCl2), 10 ml of each, and the membrane were incubated in the mixture for 1 hour.  
4. The antibody mixture was decantated and the membrane was then washed four times in the 
TBS-Ca solution supplemented with 0.05% Tween 20. 
5. Detection was performed using 5 ml SuperSignal® West Pico Chemiluminescent Substrate 
solutions (Pierce), mixed 1:1.  
6. All washing and incubation steps were performed at room temperature with gentle shaking. 
V5 detection:  
The short-PAC1-V5-CHO, full-PAC1-V5-CHO, short-PAC1-V5-CHO, and full-PAC1-V5-CHO cell 
samples were harvested 24 hours after transfection. Both the medium and cell lysates were collected. 
The cells were washed once in PBS and then lysed in either sample buffer (10 mM Trizma Base 
adjusted with HCl to pH~8, 8% SDS, 40% Glycerol, 40 mM DTT and bromephenol blue), Cymal 5 
lysis buffer (50 mM Trizma Base adjusted with HCl to pH 7.5, 150 mM NaCl, 1 mM CaCl2, 0.5% 
Cymal 5 (Anatrace), 0.05% Deoxycholate, and Complete® Tablets (Roche)) or NP40 lysis buffer 
(Buffer suggested by Invitrogen: 50 mM Trizma Base adjusted with HCl to pH 7.8, 150 mM NaCl, 1% 
Nonidet P40 and Complete® Tablets). Complete® tablets were also added to the aspirated medium 
samples to avoid proteolysis). Fractions of the medium samples were mixed with sample buffer 
(amount 3 sample to 1 buffer). All samples in buffer were heated at 96oC for 5 minutes and the cell 
lysates homogenized using a 1 ml Syringe with needle.  
1. After gel-separation and blotting, the membrane was then incubated in blocking buffer (Wash 
buffer from Bie & Berndtsen A-S supplemented with 0.05% Tween 20 and 5% Skim milk 
powder) over night.  
2. The blocking buffer was decanted. 
3. Antibody dilution: The Anti-V5-HRP Antibody (Invitrogen), the HRP-conjugated Anti-Biotin 
Antibody (Cell Signaling), 1:1000 dilution, and Mouse Monoclonal [mAbcam 9484] to 
GAPDH-loading control (HRP) (Abcam), 1:10.000 dilution, were made in the blocking buffer. 
The membrane was incubated in the antibody mixture for 1 hour.  
4. The membrane was washed 3 times 5 minutes in wash buffer. 
5. Detection was performed using 5 ml SuperSignal® West Pico Chemiluminescent Substrate 
solutions, mixed 1:1.  
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All washing and incubation steps were performed at room temperature with gentle shaking.  
After antibody binding and detection the blots were scanned with Fujifilm LAS-1000, Fujifilm 
Intelligent Dark Box II and software Fujifilm Image Reader LAS-1000 Pro V2.5 and Image Gauge 
V4.0. 
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13.19 Experimental procedures for visualization by immunostaining: 
Immunostaining with the Anti-V5-FITC-conjugated antibody (Invitrogen) (FITC – Fluorescein 
Isothiocyanate). The transiently transfected CHO and Hit cells were incubated 24 hours after 
transfection to allow the expression of the receptor. It was important that the transfection was 
performed in glass bottom dishes, because of autofluorescence from various plastic dishes, and that 
some UV wavelengths have problems penetrating plastic dishes. The whole experiment was performed 
at room temperature. 
1. The cells were washed with PBS three times 
2. The cells were fixated with 2 ml Methanol (99.8%, Merck) for 5 minutes. 
3. 5 times 2 minutes wash in PBS (2 ml). 
4. The cells were then fixated by incubated in PBS containing 0.1% Triton X-100 and 10% FBS, 
for 3 minutes. 
5. 3 times 2 minutes wash in 2 ml blocking buffer (PBS with 10% FBS) followed by incubation in 
2 ml of the same buffer for 20 minutes. 
6. The blocking buffer was aspirated 
7. The Anti-V5-FITC-conjugated antibody was diluted 1:500 times in 1 ml fresh blocking buffer 
and added to the cells. Incubation with antibody continued for 60 minutes. 
8. Finally 2 times 5 minutes wash in PBS. 
9. The cells were observed with a fluorescence microscope equipped with a FITC filter. 
The cells could be stored at 4°C for weeks, while maintained in PBS. 
 
  
 
  
  
